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Abstract 
Infectious diseases are a persistent problem throughout the world, potentially 
threatening everyone who comes in contact with them. This thesis attempts 
to improve our understanding of infectious diseases by developing mathemat-
ical models of the cellular dynamics of human infectious diseases. This has 
been carried out through the investigation of the interaction between infectious 
agents and cells of the humoral and cell-mediated immune response. Addition-
ally, dynamics of the infectious agent in an infected cell are described through 
the development of descriptive mathematical models. The modelling has been 
specifically applied to the study of two important causes of sexually transmitted 
disease, Chlamydia and human immunodeficiency virus (HIV), although much 
of the work may be more generally applicable to other infectious agents. 
In this thesis, theory is developed for simplifying the estimation of the ag-
gregate size distribution for ligand binding over a cell surface. The thesis also 
presents theoretical predictions for the expression of the valence, the number 
of ligand sites available for binding, in the neutralization of Chlamydia tra-
chomatis based on antibody and host cell receptor aggregation on the surface of 
an extracellular Chlamydia particle. The expression for the valence is in good 
agreement with Monte Carlo simulations and is used in a model of population 
dynamics describing infection with Chlamydia. The first mathematical model of 
chlamydia! infection at a cellular level is presented, which, amongst other things, 
investigates the change in the cell-mediated immune response over a Chlamydia-
infected cell's life-time, and the important persistent phase of Chlamydia. The 
specificity of the cell-mediated immune response is also investigated with a model 
for evolutionary drift in HIV antigenic diversity, based on theory of the antigen 
diversity threshold, but extended to consider mutant strains on a continuum of 
viral fitness. 
Using a mathematical model, predictions for the doubling time of Chlamy-
dia trachomatis strain 12 are given, based on measured gene transcript lev-
els. Potentially this modelling also provides the foundation for the application 
of emerging micro-array technology to identify the gene signals that trigger a 
chlamydia! body to start replicating or transform to its infectious form. Finally, 
to contribute to the study of intracellular signalling, a mathematical model is 
developed to investigate a hypothesis that contact-dependent activation of Type 
Three Secretion is a trigger for chlamydia! replication. 
Key words: 
Infectious diseases, Mathematical modelling, Chlamydia, HIV /AIDS, Cell-mediated 
immunity, Humoral immunity, Within-host modelling, Antibodies, Neutraliza-
tion, Receptor-aggregation, Mutation, Gene-expression analysis, Doubling time, 
Type three secretion system. 
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Chapter 1 
Introduction 
1.1 Description of Research Problem Investi-
gated: Infectious Diseases 
Infectious diseases present a global threat to human populations. The numerous 
species of viruses, bacteria, and higher organisms that are able to infect humans 
have changed the course of history. In the 14th century, 25 million people out of 
an estimated population of 100 million people in Europe died from a bacterial 
infection, the bubonic plague (Mee [6]). In 1520, approximately half of the three 
and a half million Aztec population died from smallpox, a virus introduced by the 
Spanish during their conquest of the New World (McNeill [5]; Nowak [7]). More 
than 68 thousand people are thought to have died in the 1665 plague in London 
(Brayley [3]), and in 1918-1919, the influenza virus was the cause of a world-
wide epidemic resulting in the death of at least 20 million people (Crosby [4]; 
van Hartesveldt [8]). The world-wide eradication of smallpox in the late 1970s 
and the decline in the incidence of other infectious diseases such as diphtheria 
and paralytic poliomyelitis are testimony to the effectiveness of the development 
and widespread use of vaccines to immunize susceptible populations against a 
variety of directly transmitted viral and bacterial infections (Anderson & May 
[1]). However, approximately one million children die each year from malaria 
(WHO [16]). Additionally, other communicable diseases, such as tuberculosis 
and influenza, are a fact of modern life. This is despite the availability of a vac-
cine against tuberculosis. The pandemic of the human immunodeficiency virus 
1 
(HIV), the aetiological agent of acquired immunodeficiency syndrome (AIDS), 
has resulted in millions of deaths and will continue to cause many more millions 
of deaths. It has produced global concern and a greater awareness of infectious 
diseases in the affluent west. The prevalence and effects of many diseases in 
developing countries are less well-known but may be of even more importance. 
Diseases such as malaria, typhus, cholera, and schistosomiasis are endemic in 
many parts of the world, and every year millions of people die of measles, res-
piratory infections, diarrhea and other diseases that are easily treated and not 
considered dangerous in the Western world (Brauer & Castilla-Chavez [2]). Ad-
ditionally, one of the most common infectious agents in the world is Chlamydia 
and while it does not usually cause death it is of major importance as a cause 
of blindness, infertility and pneumonia. Most recently, in 2003, Severe Acute 
Respiratory Syndrome (SARS) caused by a member of the coronavirus family 
never previously seen in humans has resulted in death and fear worldwide. 
In response to the adverse effects of infectious diseases, humans are equipped 
with intricate biological defence mechanisms. The human immune system con-
sists of approximately 1012 cells (Nowak [7]) functioning together in comple-
mentarity to make up two arms of attack, namely humoral immunity and cell-
mediated immunity. Humoral immunity refers to the component of the immune 
system involving antibodies, that are secreted by B cells and which circulate 
as soluble proteins in blood plasma and lymph. Antibodies bind to the sur-
face of extracellular infectious particles. Other cells (macrophages) are signalled 
and activated to engulf and process antibody-bound infectious particles. In ad-
dition, binding of antibodies to the surface of infectious particles prevents the 
attachment and infection of a healthy cell by the infectious particle. In contrast, 
cell-mediated immunity refers to the branch of the immune system in which the 
reaction to foreign material is performed by specific defence cells rather than 
antibodies. Here, cytotoxic immune T cells and natural killer immune cells at-
tack infection by destroying infected cells. However, the immune system is not 
capable of controlling and clearing many infections as is evidenced by the sig-
nificant statistics of disease and death caused by infectious diseases. 
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The last few decades have seen significant advances in our understanding of 
molecular biology of the immune system and how it fights infection, including 
many of the fine details of the immune system. However, many biologically im-
portant questions are not primarily concerned with the molecular mechanisms of 
immune recognition but with the population dynamics of the immune response. 
Many questions arising from the cellular dynamics of human infectious diseases 
are quantitative in nature. To investigate these processes and the complex dy-
namics of infectious diseases, one requires the insight gained through the use of 
accurate mathematical models. Mathematical modelling is one way to formulate 
hypotheses in a framework that allows their full implications to be identified. 
Mathematical equations are merely the language by which the hypotheses are 
described and their implications communicated. In this thesis mathematical 
models of the cellular dynamics of human infectious diseases are developed in 
order to contribute to the understanding of the underlying mechanisms that 
influence the spread of infection. The mechanisms include the interaction of 
infectious agents with the immune system and the interaction between infected 
cells and the pathogen. During the modelling process we investigate micro-
biological questions that are of a quantitative nature and suggest targets and 
strategies for disease control. In this thesis special emphasis in application of 
our theoretical models is placed on Chlamydia and HIV, although much of the 
theory is generally applicable to many infectious agents. 
1.2 Overall Objectives of the Study 
The natural mechanisms involved in determining disease pathogenesis at a cel-
lular level upon introduction of an infectious agent can be broadly separated 
into three categories, namely, 
1. the humoral immune system, 
2. the cell-mediated immune system, and 
3. the intracellular developmental properties of the pathogen. 
In this thesis the overall objective is to explore certain aspects within each of 
these categories in-depth, through the development of mathematical models and 
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mathematical analysis to elucidate the behavior of the solutions of the model 
equations. 
1.3 Specific Aims of the Study 
The specific aims of this study are as follows: 
• To investigate humoral immunity 
- primarily through the development of a theoretical approach for the 
expression of the aggregate size distribution of antibody Fab (frag-
ment antigen binding) receptors binding to a pathogen with a large 
number of antigen binding sites. Additionally, extend the investiga-
tion to consider steric effects of antibody attachment to more accu-
rately model the aggregate size distribution. 
- by determining whether the concentration of antibodies, or the strength 
that antibodies bind to an infectious particle, is more important in 
neutralizing an extracellular infectious particle from infecting a cell. 
• To investigate cell-mediated immunity through the development of 
- the first mathematical model of Chlamydia's development, indicating 
how chlamydial development influences the effectiveness of the cell-
mediated immune response. Here, the aim is to elucidate how the 
cell-mediated immune response changes over the developmental cycle 
of an infected cell. 
- a mathematical model of HIV mutations, to describe how the speci-
ficity of the cell-mediated immune response changes with the progres-
sion of disease. 
• To investigate intracellular developmental properties of pathogens (using 
Chlamydia as an example for application) by 
- analyzing gene expression data in order to estimate the doubling time 
of a strain of Chlamydia. 
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- presenting and investigating a hypothesis for the triggering mecha-
nism inducing chlamydia! development intracellularly. 
1.4 Account of Research Progress Linking the 
Research Papers 
In this thesis, a series of seven papers are presented relating to the mathematical 
modelling of the cellular dynamics of human infectious diseases. Each paper is 
presented in a separate chapter and contributes to the investigation of an aim 
of the project in order to meet the objectives of increasing the understanding of 
each of the three categorized natural mechanisms of infectious diseases. Chapter 
2 contains a review of the literature relevant to the aims and objectives of this 
study and develops a framework for the proceeding chapters. Chapters 3, 4 and 
5 investigate case (i), namely humoral immunity, Chapters 6 and 7 investigate 
different aspects of case (ii), cell-mediated immunity, and Chapters 8 and 9 in-
vestigate case (iii), intracellular dynamics. Chapters 3 and 4 remain generally 
applicable to any infectious agent, whilst Chapters 5, 6, 8 and 9 specifically 
emphasize application to chlamydia! infection and Chapter 7 specifically em-
phasizes HIV infection. 
As an introduction to the investigation of humoral immunity in this thesis, 
the paper Wilson [9] given in Chapter 3, addresses the question of whether the 
concentration of antibodies or the strength of the antibody in attaching to an 
infectious particle, is more important in neutralization. 
There are many pathogens that express many antigen binding sites. There-
fore, to neutralize such a pathogen, antibodies must bind many of the antigen 
sites. The central problem associated with the theoretical investigation of mul-
tivalent binding is to predict the aggregate size distribution, referring to the 
distribution of the number of sites bound at a particular time, from which many 
quantities of interest can be estimated. A complete description requires a large 
system of coupled differential equations (each equation is of the form investi-
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gated in Chapter 3). This system may well be of the order of tens of thousands 
of coupled ordinary differential equations. In the paper Wilson & McElwain [10] 
given in Chapter 4, theory is developed to improve current techniques in obtain-
ing the aggregate size distribution. It is shown that the complete description 
of the aggregate size distribution can be determined by the solution of a single 
equation. 
Because of its physical size, a receptor that binds a single site may exclude 
receptor binding at neighboring sites by covering or excluding the neighboring 
sites because they are too close in proximity to be physically bound by another 
receptor. Steric hindrance greatly influences the number of available sites that 
may be bound. In the previous study (presented in Chapter 4) it was assumed 
that the set of sites available to be bound consists of the set of all sites on the 
ligand minus the set of sites that are bound by a receptor, and steric hindrance 
was not taken into consideration. This is reasonable if the receptors are small, 
relative to the size of the ligand sites. In the paper Wilson & McElwain [11] 
given in Chapter 5, steric effects of antibody attachment is modelled. It is indi-
cated that steric effects must be taken into consideration to accurately model the 
aggregate size distribution. A continuous model is developed and steric effects 
are considered in describing the size distribution of aggregates of two receptor 
species, antibody Fabs and host epithelial cell receptors, attaching to the sur-
face of a chlamydia! particle. Although the chapter is specifically applied to 
chlamydia! infection the theory is applicable to other multivalent ligands where 
the receptors are larger than the ligand binding sites. 
The chapters discussed above investigated the humoral immune response. 
The other arm of the immune system is the cell-mediated response. Chlamydia 
is susceptible to cell-mediated immunity. In the paper Wilson, Timms & McEl-
wain [12] given in chapter 6, the cell-mediated immune response (Th1 response) 
against chlamydia! infection is analyzed. Chlamydia trachomatis, a human strain 
of Chlamydia, replicates intracellularly and is characterized by a complex devel-
opmental cycle. Additionally, the number of cytotoxic T effector cells for the 
response changes with time due to clonal expansion. Here, a form for the im-
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murre response over one developmental cycle is predicted by modelling the change 
in the number of intracellular chlamydia! particles and assuming peptides are 
presented in proportion to the number of replicating forms of chlamydia! parti-
cles. External to the infected cell, the inter-cellular dynamics of immune cells, 
chlamydia! particles and infected cells is modelled. Additionally, the persistent 
phase of chlamydia! infection is also considered. Persistent chlamydiae refers 
to an abnormal latent chlamydia! form induced by the immune response or an-
tibiotics. A closed form expression for the basic reproduction ratio is obtained 
and predictions made about the processes within the chlamydia! developmental 
cycle. Numerical simulations are also presented for different scenarios: active 
disease progression, control and clearance for varying levels of Th1 effectiveness. 
To conclude our investigation of the immune system we investigate one of 
the most complex interactions between pathogen and immune system. Some 
pathogens evolve via mutation to elude immune defense. This is seen most 
clearly in the human immunodeficiency virus (HIV). In the paper Wilson & 
McElwain [13] given in Chapter 7, HIV mutations based upon a continuum rep-
resentation of the fitness of the virus is investigated, including the interaction 
of the virus with the specific cell-mediated response to show immune system 
collapse when a diversity threshold is exceeded. 
Although the innate immune system is effective in clearing many infections, 
active infection causes productive disease in many cases. Many microbiologists 
are concerned with the study of development of intracellular pathogens within 
host cells in order to develop strategies for interrupting the onset of disease. It is 
at this point of the thesis that our focus turns to intracellular dynamics. In the 
paper Wilson, Mathews, Wan & McElwain [14] given in Chapter 8, the intracel-
lular dynamics of the chlamydia! developmental cycle are modelled. Because the 
unique chlamydia! developmental cycle is complex it is neither easy to track the 
progression of chlamydia! particles, nor the rate of replication. Real-time PCR 
methodology was used to quantitatively measure gene transcript levels in C. 
trachomatis 12 strain, to obtain 168 rRNA eDNA data for more developmental 
time-points than previously reported. The gene, 168, is a constitutive gene as 
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it is expressed over the full developmental cycle. A mathematical model and 
the gene transcript levels are used to standardize for the number of chlamydial 
particles. The model is used to predict the number of each type of chlamydia! 
particle within a host cell. The modelling presented in this chapter is a founda-
tion for extension in the application of the large data emerging from micro-array 
technology, which has the potential to provide developmental expression for ev-
ery chlamydial gene. 
One of the most important questions to microbiologists studying chlamydiae 
is "What is the mechanism that triggers the replicative form of Chlamydia, the 
reticulate body (RB), to convert to the infectious form, the elementary body 
(EB)?". In the paper Wilson et al. [15] given in Chapter 9, a hypothesis is 
proposed for the triggering mechanism inducing chlamydia! development. The 
hypothesis assumes contact between Chlamydia and the host cell vacuole for 
replication, and contact is restricted via two mechanisms. Firstly, contact is re-
stricted due to limitations of the size of the infected cell and, secondly, contact 
is restricted due to decreased attachment strength associated with injectisomes 
of a complex system known as the type III secretion system. Injectisomes pro-
trude from the surface of chlamydia! particles to interact with the host cell. In 
Chapter 9, data is presented and a mathematical model developed to investigate 
this hypothesis. If the mechanism were known it would reveal clearly defined 
targets for microbiologists in drug and vaccine development. 
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Chapter 2 
literature Review 
2.1 Brief History of Epidemiology 
The application of mathematics to the study of infectious disease was initiated 
by Daniel Bernoulli in 1760. Aiming to influence public health policy, he used 
mathematical techniques to evaluate effectiveness of the procedures of variola-
tion against smallpox (Bernoulli [12]; Dietz & Heesterbeek [30]). In 1840 William 
Farr fitted a normal curve to smoothed quarterly data on deaths from smallpox 
in England and Wales over the period 1837-1839 (Farr [35]). In 1906 Hammer 
postulated that the course of an epidemic depends on the rate of contact be-
tween susceptible and infectious individuals (Hammer [48]). This notion has 
become one of the most important concepts in mathematical epidemiology; it is 
the mass-action principle in which the net rate of spread of infection is assumed 
to be proportional to the product of the density of susceptible people multiplied 
by the density of infectious individuals *. This concept was used by Kermack 
and McKendrick in 1927 who began to provide a firm theoretical framework for 
the investigation of observed patterns of the course of an epidemic (Kermack 
& McKendrick [61]). Kermack and McKendrick's framework has evolved to be-
come the classic SIR model for studying population biology. We present an SIR 
model to provide motivation for a similar model at a micro-epidemiological level 
in the next section that will provide a framework for the studies in this thesis. 
*This is sometimes called pseudo-mass action, as opposed to true mass action where the 
product of the number of susceptible and infectious populations is divided by the number of 
individuals in the total population 
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A simple early version of the SIR model may be constructed as follows. For 
infectious agents, the host population is divided into 3 classes of individuals, 
namely, susceptible, infected, and recovered-and-immune. We let S(t) denote 
the number of individuals who are susceptible to the disease at timet, I(t) de-
note the number of infected individuals, assumed to be infectious and able to 
spread the disease by contact with susceptibles, and R(t) denote the number 
of individuals who have been infected and then removed from the possibility 
of being infected again or of spreading infection. The SIR model with pseudo 
mass action assumes an average infective makes contact sufficient to transmit 
infection with f]N others per unit time, where N represents the total population 
size. It also assumes a fraction, a, of infectives leave the infective compartment 
per unit time and that the system is closed. Then, the change in the population 
in the compartments is described by 
dS 
dt 
dJ 
dt 
dR 
dt 
= 
= 
-f]SI 
f]SI- ai 
ai. 
(2.1) 
(2.2) 
(2.3) 
An SIR model incorporating births and deaths was formulated in 1929 by Soper 
[136] and extended in 1932 by Kermack and McKendrick [62]. A more general 
SIR model with births and deaths for a disease that may be fatal to some infec-
tives is shown in Figure 2.1 and may be described with the following equations, 
namely, 
dS p,K + rJR- f]SI- p,S (2.4) dt 
dJ f]SI- ai- p,I- 11 (2.5) dt 
dR 
ai- rJR- p,R, (2.6) 
dt 
where p, is the natural rate of death in each compartment, p,K is a constant 
rate of birth per unit time ( K is the maximum population size), 1 is the rate 
that infectives die from the infection, and rJ is the rate recovered individuals 
become susceptible to infection again. This model and variations of the model 
have been studied extensively (for example, Murray [90] and Brauer & Castilla-
Chavez [16]). The development of the epidemiological models described above 
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is carried out in order to lead in to closely related equations that also describe 
population dynamics, but at the micro-epidemiological level. 
!l !l 
Susceptible ~ Infected a Recovered (Uninfected) (Immune) 
S(t) R(t) 
I 0~•:1 
1l 
Figure 2.1: Schematic representation of the flow of hosts between susceptible (S(t)), infected 
(J(t)) and recovered (R(t)) classes in a population in which an infection has been introduced. 
2.2 Framework and Literature Review for Micro-
epidemiological Studies in this Thesis 
Traditional epidemiology describes the spread of infectious agents within popu-
lations of individuals. Consider the population dynamics of infection at a smaller 
scale, the dynamics within the body of an infected individual; the description of 
how infectious agents, such as viruses and bacteria, spread from cell to cell. This 
micro-epidemiology offers a new approach to understanding infectious diseases. 
The aim of this relatively new discipline is to reveal the basic laws that gov-
ern the spread of infectious agents within individuals, their interaction with the 
immune system and their response to treatment. In this thesis we investigate 
the spread of infectious agents within individuals and their interaction with the 
immune system. Our purpose in this chapter is not to review in detail all of the 
important literature of micro-epidemiology. Instead, we formulate a version of 
the simplest model of infectious agent dynamics to serve as a departure point 
for our investigations, to provide a governing structure to the topics of interest 
in this thesis. Then, in the following sections we review specific areas within 
micro-epidemiology that are identified by our simple model of infectious agent 
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dynamics and are associated with the project aims of this thesis. In addition, 
we will provide a brief review of specific pathogens of application used in this 
thesis, namely Chlamydia and HIV. 
Nowak and May have written what is becoming a classic text for modelling 
cellular dynamics of infectious diseases in which they also review modelling of 
HIV (Nowak & May [98]). The candidate has published a review of this book 
(Wilson [157]). Nowak and May present what they state to be the basic model 
of virus dynamics. Here, an extension of this model is presented. For further 
description, with application to mathematical modelling of Chlamydia, see Wil-
son [158]. A caricature model is presented in order to establish a framework 
to govern the specific studies of investigation in this thesis and show how the 
chapters fit together. 
Similar to the susceptible and infected compartments of the population dy-
namics model at an epidemic scale presented above, cellular dynamics involve 
susceptible and infected populations, namely, population of cells that are sus-
ceptible to infection by an infectious agent and the population of cells that 
have become infected by an infectious agent. However, in micro-epidemiology 
of cellular dynamics a population of recovered cells is not included. Instead, the 
population of infectious particles causing the infection is considered. In order to 
establish a toy model of the dynamics of an intracellular pathogen three time-
dependent variables are included: uninfectedjsusceptible cells, E(t); infected 
cells, I(t); and infectious particles, P(t). Infectious particles invade uninfected 
cells and transform them into infected cells. Infected cells produce and release 
new infectious particles which allow subsequent rounds of pathogen replication. 
The immune response acts against infected cells and infectious particles. If the 
cellular dynamics are simplified by modelling interactive processes by parame-
ters, then a simple mathematical description of the change in the interacting 
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'species' may be given by 
dP 
dt 
dE 
dt 
di 
dt 
Pi'\,2I(t)- J-LP(t)- i'\,1P(t)E(t) 
O"E- JEE(t)- i'\,1P(t)E(t) 
i'\,1P(t)E(t)- ryi(t)- i'\,2I(t) . 
(2.7) 
(2.8) 
(2.9) 
Here, p is the number of infectious particles released from infected cells at a 
generation rate of /'\,2 and /'\,1 is a parameter denoting the rate of infection of 
uninfected cells. The number of infectious particles released from one infected 
cell, p, is referred to as the burst size. The parameter, J-L, models clearance of 
extracellular infectious particles by humoral immunity (effected through engulf-
ment by macrophages). Uninfected cells are produced at a rate O"E and we let 
JE be the rate of uninfected cell natural death. We let 'Y be the rate of clearance 
of infected cells due to cell-mediated immunity. A schematic diagram depicting 
the model is presented in Figure 2.2. It is clear from the setup of the caricature 
model and the simple description of cell interactions presented that there are a 
number of factors influencing the pathogenesis of infection. This can be seen 
more clearly by examining steady states and the basic reproduction ratio. 
Our model system of equations has two possible steady states: a trivial 
steady state, 
- O"E E=-
JE' 
f=O 
' 
and a non-trivial steady state, 
p O"E [(p- 1)/'\,2- 'Y] JE 
f-t(/'\,2 + ry) /'\,1 
E f-t(i'\,2+'Y) = 
/'\,1 [(p- 1)/'\,2- 'Y] ' 
l O"E bEJ-L 
/'\,2 + 'Y /'\,1 [(p- 1)/'\,2- 'Y] 
(2.10) 
(2.11) 
(2.12) 
(2.13) 
The basic reproduction ratio is a fundamental concept in epidemiology and 
micro-epidemiology (Anderson & May [1]; Diekmann & Heesterbeek [28]; Diek-
mann et al. [29]). It is defined for a population as the expected number of sec-
ondary cases produced, in a completely susceptible population, by one typical 
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Infectious 
agent 
P(t) 
Infected 
cells 
l(t) 
Susceptible 
cells 
E(t) 
Figure 2.2: Schematic representation of a version of the basic model of an infectious agent 
dynamics where E(t) represents susceptible cells, I(t) represents infected cells and P(t) rep-
resents the infectious agent. 
infected pathogen during its entire period of infectiousness. The basic reproduc-
tion ratio is evaluated when an abundance of uninfected cells are at pre-infection 
level. Clearly if the basic reproductive ratio is greater than one, then a "chain 
reaction" will lead to a rampant increase in abundance of infectious particles. 
There are several ways to calculate the basic reproductive ratio, R0 . One way is 
to consider the invariant solution set in the sense that any solution which starts 
in it remains there for all time. For instance, in our system, 
dPI (2.14) > 0, 
dt P=O 
dEl 0 and dEl < 0 (2.15) > 
dt E=O dt - ' E=aE/8E 
dJI 0. (2.16) > 
dt l=O 
(2.17) 
Then, determining constraints on the steady states such that they remain in 
the invariant solution set gives rise to an expression for the basic reproduction 
ratio. Whilst there are an infinite number of combinations of parameters at the 
bifurcation point to construct such a constraint, the combination is chosen such 
that the expression is always positive. The constraint will result by examining 
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any of the non-trivial steady state variables. For example, for the non-trivial 
steady state value, P, to remain in the invariant set, 
(2.18) 
Rearranging this inequality in terms of unity, and ensuring it remains positive 
leads to the basic reproduction ratio, R0 , for our system of equations (2.7)-(2.9) 
of 
Ro = (p- 1)~1~2{)E 
!OEf-L + ~20Ef-L + /{)E~l (2.19) 
The trivial steady state is stable if R0 < 1 and the non-trivial steady state is 
stable if R0 > 1. Some infections that result in active disease (where R0 is 
greater than one) are not controlled by the natural defences of the immune sys-
tem. However, drug therapy has proved to be effective in clearing or somewhat 
inhibiting infection. In the following paragraph we simplify our expression for 
R0 and interpret R0 in terms of the natural targets for clearance of infection. 
We simplify our modelling of the dynamics by assuming that within the 
time-frame of investigation (very early post infection) the number of host cells 
is approximately constant and we let E(t) = E0 . Then, we obtain the following 
simplified expression for the basic reproductive ratio, namely, 
(2.20) 
We note that increased ability to clear infection will be obtained if 
(i) macrophage engulfment of infectious particles occurs prior to host cell in-
fection, represented by an increase in (t-L/~1 ), 
(ii) the cytotoxic immune response clears infected cells prior to lysis of the 
infected cell, represented by an increase in (J / ~2 ), or 
(iii) the number of infectious particles released by an infected cell is reduced, 
represented by a decrease in (p). 
Case (i) refers to the effectiveness of humoral immunity, case (ii) refers to the 
effectiveness of cell-mediated immunity, and case (iii) refers to the intracellular 
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development of the pathogen. In this thesis we explore each of these cases in-
depth and in the following sections we review the literature applicable to the 
projects of study in this thesis within each of these cases. 
2.2.1 Literature Review Associated with Case (i): Effec-
tiveness of Humoral Immunity 
As mentioned earlier, humoral immunity refers to the component of the immune 
system involving antibodies. Antibodies are secreted by B cells and circulate 
as soluble proteins in blood plasma and lymph. Antibodies bind to the surface 
of extracellular infectious particles in order to effect, amongst other functions, 
signalling and activation of macrophages to engulf and process antibody-bound 
infectious particles. 
There is evidence to substantiate the necessity of humoral immunity in vari-
ous situations. For example, antibody neutralization is both necessary and suf-
ficient for protection against the rhabdovirus vesicular stomatitis virus (VSV) 
(Bachmann et al. [4, 5]). It has been shown that humoral immunity boosted 
by peptide immunization has provided protection against infection of a strain 
of Chlamydia in guinea pigs (Volp et al. [146]). A recent review describes the 
importance of neutralizing antibodies in some other infectious agents (Parren & 
Burton [105]). Antibody coating of infectious particles often results in a block 
of pathogen attachment to target cells, an effect that is sufficient (but not nec-
essary) for neutralization. 
Because of the importance of multivalent ligand-receptor binding, not only 
associated with humoral immunity but also in general signal transduction [83], 
significant experimental and theoretical effort has been directed at understand-
ing receptor-ligand interactions. The theoretical problems associated with the 
binding of multivalent ligands have been well studied. The central problem is 
to predict the receptor aggregate size distribution over a ligand with time, from 
which many quantities of interest can be calculated (Posner et al. [117]). When 
comparing theoretical predictions with experiment it is often important to know 
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this distribution because some types of cells respond differently to different size 
aggregates. Some examples are stated in Chapter 4 of this thesis. 
Theoretical work by Dembo & Goldstein [26] and Perelson & DeLisi [108] 
has been particularly influential. They contribute two approaches that have 
been used to calculate the aggregate size distribution. The first approach, the 
obvious one, is to write down equations for the concentrations of all possible 
ligand-receptor aggregates. Using this method, Dembo & Goldstein showed 
how to calculate the equilibrium size distribution for the binding of a symmet-
ric bivalent ligand to a homogeneous symmetric bivalent receptor population, 
provided all necessary equilibrium constants were known. This approach has 
been extended to other problems involving bivalent ligands binding to biva-
lent receptors at equilibrium (Goldstein & Wofsy [42]; Wofsy [159]; Wofsy & 
Goldstein [160]). To describe the time development of the concentration of an 
aggregate one must write down a differential equation (a chemical rate equa-
tion) for that aggregate. A complete description requires a large set of coupled 
differential equations (for example, for chlamydial elementary bodies there are 
approximately 2.86 x 104 receptors per cell). Therefore, if one wishes to use this 
approach to numerically calculate a time dependent aggregate distribution size 
one must truncate the set of equations to some tractable number (Dembo et al. 
[26]; Schweitzer-Stenner et al. [130]). The second approach is less general, but 
can be used to obtain the complete time dependent aggregate size distribution 
by solving just two coupled nonlinear differential equations (Perelson & DeLisi 
[108]). In Chapter 4 of this thesis, another approach is developed to obtain 
the complete time dependent aggregate size distribution for multivalent ligands 
(cell surfaces with many receptors) bound by monovalent binding molecules (Fab 
fragments of antibodies) by solving one diffusion equation. 
The most widely used kinetic equation for modelling adsorption of ligands 
is that due to Langmuir [66]. However, the Langmuir equation does not include 
steric hindrance effects. Research has been undertaken into the effects of steric 
hindrance on adsorption of large ligands onto the surface of a pathogen with a 
large number of potential binding sites. We also investigate this phenomenon in 
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chapter 5 of this thesis. 
When the valence of a ligand is greater than two, models for ligand-receptor 
binding are complicated by a number of factors (Perelson [107]; Macken & Perel-
son [76]; Lauffenburger & Linderman [69]). One complication arises when a 
bound receptor, because of its physical size, excludes binding at neighboring 
sites. Steric exclusion of ligand sites will be of significance in many receptor-
ligand interactions, particularly interactions between antibodies and various 
types of antigens (Hlavacek et al. [50]). Steric effects can also be important 
in antibody binding to protein antigens, because the whole surface of a pro-
tein is potentially antigenic (Davies & Cohen [24]) and domains important for 
protein-protein binding are smaller than protein-protein interfaces (Wells [152]). 
Stankowski discusses steric effects on ligand adsorption and suggests an ap-
proach for modelling these effects (Stankowski [137]). Scatchard plots have been 
the most popular method of analyzing binding data, by linearizing and then 
analyzing the data using linear regression. Stankowski showed that ordinary 
Scatchard-type analysis yields erroneous results when applied to the binding of 
large molecules to membranes or cells. Ligands of any shape, with emphasis on 
large ligands covering more than one binding contact upon adsorption was con-
sidered in Stankowski's model. Mathematical complexity was minimized and the 
accuracy of the theoretical predictions was demonstrated by comparison with 
Monte Carlo simulations. 
A number of theoretical techniques and methods are available for modelling 
steric effects on adsorption reactions. For example, McGhee & von Rippel [74], 
Schwarz [129], Epstein [34], Reiter & Epstein [121], and Di Cera & Kong [27] have 
developed theories and methods for modelling the binding of large ligands (that 
cover more than one site) to one-dimensional lattices of binding sites. McGhee & 
von Rippel developed one of the first theoretical models of adsorption reactions 
[74]. Their theory was developed through lengthy combinatorial arguments, and 
has been widely used to analyze the binding of proteins to DNA. Schwarz devel-
oped a mathematical model for the case of equivalent binding sites on a linear 
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lattice and shows overlapping of potential sites may occur with larger ligands 
[129]. Schwarz also uses a simple approach to extend the model to consider dif-
ferent mutually exclusive classes of binding sites. Epstein uses a combinatorial 
approach to calculate the exact expressions for the extent of binding a finite 
one dimensional lattice of ligands which cover more than one lattice site [34]. 
Whilst the Monte Carlo method is probably the most versatile tool to model 
cooperative binding systems and validate theoretical predictions, the method 
is computationally expensive. Reiter & Epstein developed a significantly faster 
and more versatile version of the Monte Carlo algorithm for use in exploring 
cooperative binding of ligands of arbitrary length to a one-dimensional lattice 
[121]. Di Cera & Kong use theory of contracted partition functions to investi-
gate a linear lattice, under general conditions with binding of large ligands [27]. 
They provide an analytical solution in various cases of interest. The derivation 
is straightforward and involves no combinatorial arguments. Di Cera & Kong 
derive the McGhee-von Rippel model as a special case of their model in the 
limit as the number of binding sites approaches infinity. They also extend their 
one-dimensional lattice model to a simple two-dimensional lattice version. 
Theoretical work has been extended to the development of methods for mod-
elling the binding of large ligands to two-dimensional lattices of binding sites by 
various people including Cowan & Underwood [23], Chatelier & Minton [20], 
and Sild et al. [134]. Cowan & Underwood developed a theory which accounts 
for steric hindrance when monovalent ligands (antibodies) of general shapes re-
act reversibly with multivalent molecules (antigens) [23]. The surfaces of the 
multivalent molecules are modelled with general two-dimensional lattices. They 
use their theory to demonstrate that curvature of Scatchard plots can arise 
from steric effects alone. Their results further generalize the conclusions of the 
McGhee - von Rippel model. They also discuss inaccuracies in the estimation 
of the intrinsic association constant and antigen valency when using the tradi-
tional approach of fitting straight lines to Scatchard plots. Interactions between 
proteins and surfaces may be classified in terms of the specificity of the inter-
action. Antibodies are very specific and selective whereas other protein-surface 
interactions are relatively weak and non-specific. Chatelier & Minton directed 
21 
their attention to the general study of adsorption of relatively weak and non-
specific electrostatic or hydrophobic interactions [20]. They extend the work 
of Stankowski and present new models of adsorption of large ligands of various 
shapes, competition between two nonassociating large ligands, binding of a large 
ligand that can also undergo self-association on the surface, and the exclusion of 
volume in the supernatant solution. The modelling prior to this study assumed 
that the affinity of the ligand for the adsorbent surface is high. Chatelier & 
Minton consider the various situations mentioned and the case of weak affinity 
between the ligand and the adsorbent surface. Their results are qualitatively 
similar to those obtained by previous investigators and their formulations are 
more rigorous and more accurate. Sild et al. developed a computer simula-
tion model for the binding of ligands to a totally anisotropic surface (infinite 
two-dimensional square lattice for which each point on the surface has differ-
ent properties and distribution of binding sites for different directions from the 
given point) with overlapping binding sites [134]. They estimate the amount 
of bound ligands as a function of the amount of free ligands. They not only 
contribute towards the development of a universal analytical expression describ-
ing the binding of large ligands to a two-dimensional lattice with overlapping 
potential binding sites, but also to the application of binding with ligands of 
complicated shapes like cellulases. 
Hlavacek et al. [50] included a steric hindrance factor in a standard mathe-
matical model for ligand-receptor interactions. They derive expressions for the 
steric hindrance factor for various cases in which the receptor covers a compact 
region on the ligand surface and the ligand expresses sites randomly in one or 
two dimensions. They have also accounted for a wide array of site distribution 
arrangements with a single general approach. The study of Hlavacek et al. pro-
vided the initial motivation for investigation of steric effects in this project. In 
this thesis, a new approach to steric effects in describing the size distribution of 
aggregates and the corresponding valency where the two-dimensional ligand has 
a large number of binding sites and binds to two mutually exclusive groups of 
receptors is presented. Our theoretical description of the valence is deterministic 
in nature and is applied to a model for the in-host population dynamics of a 
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chlamydia! infection. 
Although not directly related to specific applications in this thesis, mention 
must be made of a book by Lauffenburger and Linderman [69]. It is becoming 
a classic text, introducing important problems in receptor biology. The intent 
of the book is to build a bridge between cell biologists and engineers towards 
the emerging interdisciplinary field of quantitative cell biology. Lauffenburger 
and Linderman demonstrate how insights can be gained into the relationship 
between receptor /ligand molecular properties and the cell functions they govern, 
by a combination of cell biology experimentation and quantitative engineering 
models. 
2.2.2 Literature Review Associated with Case (ii): Ef-
fectiveness of Cell-Mediated Immunity 
Cell-mediated immunity is an immune response that does not involve antibodies 
but rather involves the activation of NK-cells, the production of antigen-specific 
cytotoxic T-lymphocytes, and the release of various cytokines in response to an 
antigen. Cell-mediated immunity protects the body by: 
(i) activating antigen-specific cytotoxic T-lymphocytes (CTLs) that are able to 
lyse body cells displaying epitopes of foreign antigen on their surface, such 
as virus-infected cells, cells with intracellular bacteria, and cancer cells 
displaying tumor antigens; 
(ii) activating NK cells, enabling them to destroy intracellular pathogens; and 
(iii) stimulating cells to secrete a variety of cytokines that influence the function 
of other cells involved in adaptive immune responses and innate immune 
responses. 
Cell-mediated immunity is directed primarily against antigens embedded in 
the membranes of cells. It is most effective in removing virus-infected cells, but 
also participates in defending against fungi, protozoans, cancers, and intracellu-
lar bacteria. There is considerable literature associated with the mathematical 
23 
modelling of immunological processes. Here, we select a paper by Nowak & 
Bangham [94] to review briefly, before narrowing our focus to aspects of the 
cell-mediated response of interest in this project. Whilst there have been other 
papers of significance in the field, most early papers on the mathematical mod-
elling of immunological processes involved the investigation of the humoral im-
mune system (See, for example, Bell [10] and Perelson et al. [109, 110, 111], 
and the papers reviewed in the above section specific to topics of interest in this 
thesis). 
Nowak & Bangham develop models to explore the relation between immune 
responses, virus load, and virus diversity (Nowak & Bangham [94]). A simple, 
but general mathematical framework is presented for viral replication and im-
mune responses. They explore the basic dynamics of virus-host cell interaction 
and consequences of immune responses on virus and antigenic diversity. Their 
strategy was to consider the simplest possible models and explore their impli-
cations thoroughly. The model results are compared to data on cytotoxic T 
cell responses and viral diversity in infections with human T cell leukemia virus 
(HTLV-1) and the human immunodeficiency virus (HIV-1). The simple models 
developed by Nowak and Bangham are general and are a good starting place 
for any investigation of the population dynamics of infectious agents and the 
cell-mediated immune system. The basis of these model equations have been 
used extensively in answering many questions that are quantitative in nature, 
particularly with application to HIV infection. 
In this thesis two aspects of cell-mediated immunity, namely, how the cell-
mediated immune response changes over the life-cycle of an infected cell, and 
how the specificity of the cell-mediated immune response changes with the pro-
gression of an evolving disease, is chosen for investigation. Infectious agents 
that demonstrate these phenomena well are Chlamydia and HIV and thus, these 
infectious agents are used for application in this thesis. 
• Changing Th1 Response (as applied to Chlamydia) 
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The immune response to an invading chlamydia! inoculum is critical to the 
outcome of an infection. The roles of humoral and cell mediated immunity has 
received attention in determining the pattern of effective protective response to 
C. trachomatis and the mechanisms by which chronic infection and pathogene-
sis occur. Although humoral immunity provides a preventive role against early 
infection (Batteiger et al. [9]; Knight et al. [63]; Peeling & Brunham [106]), 
the antibody response is considered ineffective at clearing established infection 
because Chlamydia is mainly intracellular. Cell-mediated immunity is necessary 
for the clearance of infection once chlamydiae become intracellular (Holland et 
al. [52]; Knight et al. [63]; Perry et al. [114]). The role of CDS T cells in antich-
lamydial immunity has been reported by Igietseme et al. [53], where specificity 
and reactivity of CDS T cell clones was investigated and shown to be important. 
The ability to resolve infection in individuals appears to depend upon their abil-
ity to mount an effective cell mediated immune response (Debattista [25]). 
The importance of cell mediated immunity (Th1 response) to chlamydia! in-
fection has been emphasized by a number of studies which observe an increase 
in lymphoproliferation at the site of infection (Holland et al. [52]; Cain & Rank 
[17]; Kelly et al. [60]; Van Voorhis & Barrett [145]), accumulation of protective 
lymphocytes at the infection site (Anderton et al. [2]; Igietseme et al. [53]), 
as well as CD4 depletion (Magee et al. [7S]) and B-cell depletion (Ramsey et 
al. [11S]). Studies have also shown the significance of cytokines as markers of 
cell-mediated and humoral immunity (Yang et al. [165]; Johansson et al. [54]; 
Perry et al. [115]). Studies indicate that efficient Th1 responses are sufficient 
to clear all infection (Malinerni [79]). However, obviously not all Th1 responses 
are successful. 
Chlamydia is an obligate intracellular pathogen with a unique and complex 
developmental cycle. Consequently, the effect of the cell-mediated response 
against Chlamydia-infected cells is unique. The mathematical modelling of the 
micro-epidemiology of Chlamydia has not been performed prior to this study. 
Additionally, we are not aware of any study that considers the dependence of 
the Th1 response on intracellular pathogen dynamics. Thus, the mathematical 
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model developed in this study is novel and foundational for further modelling 
in chlamydia! research and the approach may be used in the study of other 
pathogens. 
• Evolution of Thl Specificity with Disease (As applied to HIV) 
In HIV patients it is observed that there is great genetic diversity within the 
virus throughout the disease progression. As a retrovirus, HIV does not have 
the required mechanisms to prevent error during the replication process. HIV 
generates a large number of copying errors as it replicates in a host cell. The 
outcome is that each viral genome must be viewed as being different from any 
other but at the same time, each viral strain needs to be thought of as popula-
tions of closely related genomes. Different mutant strains of virus are produced 
that can be thought of as closely related, yet distinct. The continual mutation 
of immunodominant epitopes during the time of an infection is advantageous to 
the progression of HIV disease because it enables the virus to escape immuno-
logical surveillance. The immune system is then persistently confronted with 
new antigen targets before it has built up a defence to antigen already present. 
Additionally, antigenic variation enables HIV to resist inhibiting drugs. In 
1987 AZT (zidovudine, Retrovir) became the first anti-HIV drug approved by 
the Food and Drug Administration, U.S. Department of Health and Human 
Services (FDA), but drug resistance was soon observed and first characterized 
by Larder et al. [67, 68] where mutation was suggested as the cause. Despite 
its failings, continued treatment with the drug was endorsed. The mathemati-
cal modelling of AZT resistance has been carried out by McLean and Nowak [77]. 
Nowak et al. was the first to develop models for the population dynamics of 
virus infections that investigated an evolutionary mechanism for HIV progres-
sion (Nowak et al. [96, 93]). They suggest the existence of an antigen diversity 
threshold, below which the immune system is able to regulate viral production 
growth but above which the virus population induces the collapse of the CD4+ 
lymphocyte population. Their model suggested that antigenic diversity is the 
cause, not the consequence, of immunodeficiency disease. Nowak and May ex-
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tend this work further and give some insight to why the viral diversity falls once 
the diversity threshold is exceeded (Nowak & May [95]). The model tracks the 
population densities of the various viral strains and different kinds of CD4+ cells. 
There are three distinctive features of the model. They are 
(i) the continual appearance of new antigenic variants, or new viral strains, 
(ii) direct immune responses against the virus involving specific response to 
antigenic HIV strains along with cross-reactive responses that act against 
all strains, 
(iii) the assumption that each viral strain can infect and kill any CD4+ cells 
regardless of their strain specificity. 
The model was compared with available data, and used to assess how the tim-
ing of the application of chemotherapy or immunotherapy influences the rate of 
progress to disease. 
The model put forward by Nowak et al. has a maximum of fifty strains of 
virus (Nowak et al. [93]). Their model is extended in this thesis to the case 
where antigenic diversity and the immune response specificity is considered on 
a continuum representative of the viral fitness. Since mutation occurs at a very 
high rate and these mutations result in only small changes in the viral genome, 
we consider it reasonable to investigate evolution of antigenic variation with 
a variable denoting strain identification and a strain's competitive advantage 
as a continuous variable. This deterministic model allows a straight forward 
measure of the diversity of the viral population and reproduces the observed 
increase in diversity as the disease progresses in an untreated patient. We use 
the diversity threshold theory, extending the modelling to track mutations on a 
continuum. When the diversity threshold is exceeded, the host immune system 
collapses. Chapter 7 of this thesis allows a detailed mathematical analysis which 
is not possible with the Nowak and May model. The concept of the selective 
advantage of a virus resulting from mutation is still a very active area of research 
since HIV continues to resist newly-developed drugs. 
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2.2.3 Literature Review Associated with Case (iii): Ef-
fectiveness of Intracellular Pathogen Development 
Bioinformatics is a newly emerging interdisciplinary research area and is an inte-
gration of mathematical, statistical and computer methods to analyze biological, 
biochemical and biophysical data. As a consequence of the large amount of data 
produced in the field of molecular biology, most of the current bioinformat-
ics projects deal with structural and functional aspects of genes and proteins. 
Although mathematical modelling is not considered as a technique at the fore-
front of current bioinformatics, in chapter 8 of this thesis we use mathematical 
modelling to present a new approach in the analysis of biological gene expres-
sion data. We suggest that mathematical modelling is particularly applicable in 
the analysis of gene expression data associated with Chlamydia because of the 
uniqueness and complexity of the chlamydial developmental cycle. 
The mathematical modelling of processes within an infected cell has not been 
explored extensively. We suggest that for the special case of chlamydial infection, 
tracking the dynamics within an infected cell is particularly important. Outside 
of the work in this project, modelling of this type has not been attempted. In 
Chapter 9 of this thesis, we present a mathematical model of the dynamics within 
an infected cell to investigate a new hypothesis for chlamydial development 
within an infected cell. 
2.3 Brief Introduction and History of Pathogens 
to which Models have been Applied in this 
Thesis 
2.3.1 Chlamydia 
Chlamydia is an obligate intracellular parasite of humans, birds and many mam-
mals. In humans Chlamydia trachomatis is recognized as one of the most com-
mon sexually transmissible diseases throughout the world, particularly amongst 
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persons less than 25 years of age (Pimenta et al. [116]; Westrom & Mardh 
[155]). In the case of urogenital tract infection, C. trachomatis is a cause of 
Pelvic Inflammatory Disease (PID) and salpingitis (Westrom & Mardh [155]), 
ectopic pregnancies (Wolner-Hanssen et al. [162]) and tubal infertility (Moore 
& Cates [86]) in females and epididymitis in males (Berger [11]). In the case 
of conjunctival infection, it is the primary aetiological factor for blinding tra-
choma (Mabey [72]; Peeling & Brunham [106]; Stocks et al. [139]; Tabbara 
[140]; Thylefors et al. [144]). Whilst the majority of infections are self-limiting, 
acute infections can progress to the chronic conditions characterized by severe 
inflammation, the pathogenesis of which remains unknown. The other major 
human strain, Chlamydia pneumoniae, has been implicated as the etiological 
agent in pneumonia, chronic obstructive pulmonary disease (COPD), asthma, 
Reiter's syndrome, Guillain Barre syndrome, atherosclerosis and Alzheimer's 
disease (Balin et al. [6]; Grayston et al. [45]; Grayston [43]; Kuo et al. [65]; 
Saario & Toivanen [125]). As over half of the world's population are seropositive, 
C. pneumoniae is becoming a significant burden on public health systems (Kuo 
et al. [65]). 
In Australia, C. trachomatis infections are widespread (Asche et al. [3]; Gar-
land et al. [40]). The level of STD due to C. trachomatis is comparable to that 
in other developed nations. However, in the Australian aboriginal population 
trachoma occurs at levels more identifiable with infection levels of developing 
countries (Rasmussen [119]) and Australia is the only developed country in the 
world where blinding trachoma still exists (Taylor [143]). 
Chlamydia! infections have been recognized for over 2000 years (Rasmussen 
[119]). C. trachomatis is a causative agent of trachoma, which was described 
as far back as the Egyptian Ebers papyrus in 1900 BC and was well known to 
Hippocrates (Mabey & Bailey [73]). However, it was not until early in the twen-
tieth century that the causative agent was identified (Mardh et al. [81]). It was 
in 1907 that Halberstaedter and von Prowazek [47] first named and described 
chlamydia! inclusions. However, chlamydiae were initially believed to be proto-
zoa and they were then classified as viruses because of their inability to grow 
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and multiply outside a host cell and also because of their small size (300-700 
nm) (Miyagawa et al. [84]. They were known as viruses until the late 1960's 
when they were officially recognized to be bacteria (Moulder [87]). 
An early summary of species and classification was published by Page (Page 
[102]). At that time, there were various names for this group of bacteria. 
Widespread use of the term psittacosis-lymphogranuloma-venereum-trachoma 
(PLT) group was suggested (Fraser et al. [37]; Eddie et al. [32]). However, in 
1966 this group was classified into the one genus Chlamydia. The species type 
was known as C. trachomatis (Page [102]). Two years later, the genus Chlamydia 
was subdivided into two species, C. trachomatis and C. psittaci (Page [103]). C. 
trachomatis and C. psittaci remained the only species in the chlamydial genus 
until 1989, when a third species, C. pneumoniae, was designated as a separate 
species to C. psittaci, with which it had been grouped until that time ( Grayston 
et al. [44]). In 1992, a fourth species, C. pecorum was proposed, consisting of 
the ovine and bovine strains of C. psittaci (Fukushi & Hirai [38]). Of the four 
chlamydial species, C. trachomatis and C. pneumoniae are almost exclusively 
human pathogens. The other two, C. psittaci and C. pecorum cause infections 
in animals and can also cause opportunistic infections in humans. 
C. trachomatis, which is the main species of focus in this thesis, has been 
divided into three biovars; trachoma, lymphogranuloma venereum and mouse 
(Moulder et al. [88]; Stephens [142]) and further divided into eighteen serovars 
(Wang & Grayston [147]). Of the three biovars, trachoma and lymphogranu-
loma venereum are human biovars. C. trachomatis infections result in various 
diseases and complications including urethritis and urethral syndrome (Oriel & 
Ridgway [100]; Cates & Wasserheit [18]), mucopurulent cervicitis (Westrom & 
Mardh [154]), PID (Paavonen & Wolner-Hanssen [101]; Kalogeropoulos et al. 
[58]; Moore & Gates [86]), postabortal and postpartum infection (McGregor & 
French [75]), perinatal infection (McGregor & French [75]), lymphogranuloma 
venereum (Schachter & Osoba [127]), Reiter's syndrome and reactive arthritis 
(Keat et al. [59]), trachoma (West et al. [153]) and myocarditis and endocardi-
tis (Odeh & Oliven [99]). Studies have also linked chlamydial infection with an 
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increased risk of HIV infection (Wasserheit [148]). 
It was not until 1957 that the isolation of C. trachomatis (Tang et al. [141]) 
enabled detailed microbial analysis to proceed. Prior to the development of ad-
vanced biotechnical methods, the epidemiology of Chlamydia was the principle 
area of study. The advent of molecular biological techniques has allowed a fuller 
understanding of the biology of the pathogen, diagnosis and disease preven-
tion. However, investigators have had difficulties in understanding the pathogen 
because of its unusual life cycle. The chlamydia! life cycle, known as a devel-
opmental cycle because the Chlamydia do not die between cycles of infection, is 
described in detail in various sources (Schachter & Caldwell [126]; Mardh et al. 
[81]; Moulder [89]) and is also described in detail later in this thesis (Chapters 
6, 8 and 9). 
Good summaries of historical and current Chlamydia research can be found 
in Barron [8] and Tanner et al. [142]. In 1988, Barron covered the field of knowl-
edge at that time of Chlamydia comprehensively. Since that time, the field has 
increased considerably. Tanner et al. give a good summary of the major ad-
vances from 1989 until1999 (Tanner et al. [142]). Significant advances occurred 
in the 1990's, including knowledge of the fundamental biology of Chlamydia, the 
identification of host immuno- and cytogenetic markers, the understanding of the 
mechanism for gene transcription and regulation (Engel & Ganem [33]; Hatch 
[49]), and the development of single-dose oral therapy. Excitingly, the genome 
sequence has recently been completed for various chlamydia! strains (Stephens 
et al. [138]). According to Tanner et al., 
This is an exciting time for chlamydial research, as horizons of un-
derstanding are expanding and researchers are drawn into the field 
... In addition, with the genome sequences now revealed for these 
organisms, an explosion of research activity on Chlamydiae is antic-
ipated. 
Chlamydia! infections have been referred to as the "silent epidemic" be-
cause the majority of infected persons are often unaware of their infection as no 
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symptoms are evident. Often, therefore, the infection remains undiagnosed and 
consequently is left untreated (Rasmussen [119]). Repeated or long term infec-
tion results in an immunological response and long-term inflammatory damage, 
leading to irreversible scarring of infected tissue. However, Chlamydia is sus-
ceptible to antibiotic treatment. If it is diagnosed and successfully treated with 
antibiotics, a chlamydia! infection can be effectively cleared. There are currently 
three diagnostic testing strategies; direct fluorescent antibody test, enzyme im-
munoassays and tests that detect the DNA of C. trachomatis in samples such 
as urine (Nordenberg [92]). There are many approved diagnostic tests. A rel-
atively new antibiotic drug, azithromycin, may be cost effective as it requires 
only one oral dose whereas another common drug, doxycycline, requires a seven 
day course (Woodward & Fisher [163]; Lauharanta et al. [70]). There have been 
numerous studies of antichlamydial drugs (Segretti et al. [131]; Somani et al. 
[135]; Moola et al. [85]; Wolf & Malinverni [161]) that have demonstrated, for 
example, that combinations of antibiotic drugs show enhanced antichlamydial 
activity when compared to single drug treatment alone and could possibly favor 
eradication of the pathogen. 
In the absence of a preventative vaccine for Chlamydia, early identification 
and treatment remains the most effective strategy for controlling transmission 
of the organism and the later development of pathological sequelae. Given the 
significant consequences to female reproductive health, screening and education 
programs for women have been heavily promoted over recent years (Risser et al. 
[123]). Primary prevention has been facilitated by the development of nucleic 
acid amplification assays for the diagnosis of C. trachomatis. Diagnosis can be 
made from a urine specimen, replacing the need for swabbing of the male or 
female urethra. The potential economic and social burden consequent to C. tra-
chomatis infection and PID (infertility, ectopic pregnancy, miscarriage) provides 
considerable impetus for the development of formalized screening programs and 
research into the microbiology and the cellular dynamics of chlamydia! infection. 
While there has been some limited modelling of Chlamydia at an epidemi-
ological level (see, the studies of Kretzschmar [64] and Lietman et al. [71]), 
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to date the growth and development of chlamydia! infections at a cellular level 
has not been the subject of mathematical modelling. Kretzschmar's model dis-
cussed specific problems that one faces when developing a model for a sexually-
transmitted disease, and used Chlamydia trachomatis as an example. A network 
simulation model was specifically designed to describe the transmission dynam-
ics of Chlamydia trachomatis and the model took into account the heterogeneity 
within a population in sexual behavior, the influence of partnership duration on 
the dynamics of a STD, and the impact of contact tracing on the effectiveness 
of STD prevention. The model was used to investigate the effects of various 
screening strategies on the prevalence of asymptomatic chlamydia! infections in 
women. Lietman et al. [71] used data from a variety of countries to explore 
requirements for meeting the World Health Organization's goal of eliminating 
blinding trachoma by the year 2020. They developed an age-structured mathe-
matical model of the transmission dynamics of trachoma. Since they modelled a 
large treatment program, migration was not included. Partial immunity against 
infection was assumed to be acquired through ageing, and modelled with decreas-
ing susceptibility and faster clearance of infection. The model incorporated the 
immediate removal of infective individuals upon antibiotic treatment. Their rec-
ommendations, based on analysis of their difference equations, is that in areas 
where trachoma is moderately prevalent ( < 35% in children), mass drugs should 
be administered annually, but in hyperendemic areas (> 50% in children), it 
should be treated biannually. 
The molecular structure of Chlamydia is becoming better understood but 
the mechanisms of pathogenesis are not well known and can be explored with 
mathematical modelling. This research project pioneers the mathematical mod-
elling of the cellular dynamics of Chlamydia, and its intracellular developmental 
cycle. 
2.3.2 HIV 
The human immunodeficiency virus (HIV) is the primary agent of a world-wide 
epidemic causing disease and death. Infection with HIV causes changes in the 
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immune system that can result in the acquired immunodeficiency syndrome, 
commonly known as AIDS. Since the early 1980s, AIDS cases have been diag-
nosed in most regions of the world (WH 0 [ 164]), and the spread of HIV infection 
to some of the most populous areas of the world threatens future numbers of 
AIDS cases far greater than the totals reported to date. There is very strong ev-
idence that the trend in HIV infection will have an overwhelming impact on life 
expectancy in many regions of the world and on economic growth in the future 
(UNAIDS [57]). This, along with the intense suffering by millions of individuals 
means that AIDS is unique in its devastating impact on the social, economic 
and demographic foundations of much of the world's development. According 
to UNAIDS, an ever-growing AIDS epidemic is not inevitable. Yet, unless ac-
tions against the epidemic are scaled up significantly, the damage already done 
will seem minor compared with what lies ahead. 
According to 2002 estimates of the global HIV I AIDS situation from the Joint 
United Nations Programme on HIV I AIDS and the World Health Organization 
(WHO), HIV has infected almost 58 million men, women and children and AIDS 
has cost the lives of nearly 22 million people (WHO-UNAIDS [156]). Despite 
the intense international response to the HIV I AIDS pandemic, HIV continues 
to spread, causing more than 15 thousand new infections each day with approx-
imately 95% of these in the developing world (UN AIDS [55, 56]). HIV is a virus 
residing in bodily fluids such as blood and semen. It spreads through sexual 
intercourse and through the exchange of infected blood. The vast majority of 
all infections globally are acquired through unprotected sexual intercourse, with 
over 70% resulting from heterosexual intercourse. Transmission of HIV from 
an infected mother can occur during pregnancy, during labour or after delivery 
through breast milk. HIV transmission in China and Vietnam is mostly due 
to the continuing spread of HIV among intravenous drug users (IDUs). About 
two-thirds of all reported HIV infections in each country are among IDUs, the 
majority of which are localized to specific geographical areas. AIDS is the lead-
ing cause of death in Africa, and the fourth worldwide. 
By the end of 2000 it was estimated by the Australian National Centre in 
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HIV Epidemiology and Clinical Research [91] that the number of cumulative 
HIV infections in Australia was just over 20 thousand. The rate of transmis-
sion of HIV in Australia peaked in the mid 1980's, and there was a secondary 
peak in AIDS incidences in 1994 (Guthrie et al. [46]). Despite the fall of HIV 
transmission in Australia, HIV infection continues to be transmitted at a rate of 
approximately 450 cases per year (Fearchem [36]). HIV infections in Queensland 
rose by 20% in 2002. Thus, Australian health authorities are required to remain 
vigilant with active programs aimed at specific communities at risk. 
Over the last 25 years or so, as HIV I AIDS has become a significant health 
and social problem in the world, enormous amounts of research have been con-
ducted to learn about the virus itself and how the epidemic is growing with the 
aim of preventing individual death and further infection. This scientific research 
has determined some of the finest details about the human immunodeficiency 
virus including its molecular structure. Although scientists know more about 
HIV than any other virus, many challenges exist in designing a vaccine to prevent 
AIDS. There has been no agreement about the entire pathology of the disease 
and this has impeded progress towards development of long-term therapies. In 
addition, there has been a focus on forecasting the devastating problem of the 
pandemic and evaluating behavioral intervention programs, as well as societal 
costs and benefits of different policy decisions. 
It should be noted that HIV I AIDS research is an extremely large field and 
thus it is not possible to review all the literature or even keep abreast of all 
the directions taken in the field. However, here a few representative areas and 
important papers within those areas are discussed to show some of the aspects 
of the problem that have been investigated. There is still a lot of work to be 
carried out to fill the void of knowledge about HIV I AIDS and there is a need 
to build upon work performed to date. 
Here, a brief history of the origins and development of HIV I AIDS knowl-
edge is given. In the early 1980's the acquired immune deficiency syndrome 
was recognized in several countries and reported by the Center for Disease Con-
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trol (CDC) Task Force on Kaposi's Sarcoma and Opportunistic Infections [19]. 
In 1983, Barre-Sinoussi et al. [7] identified a new distinct virus in the group 
of retroviruses, with which AIDS patients are often infected, and they deduced 
that the virus is horizontally transmitted in humans. At that time, the virus was 
known as the human T-cellleukemia virus (HTLV). There were suspicions that 
HTLV caused AIDS. Gallo et al. [39] conducted a project that linked HTLV 
with AIDS patients. They also suspected that the target cell of AIDS is the 
mature T cell and developed methods for a basis of identifying antigens used 
by the AIDS disease. Gelman et al. [41] tested this in vitro and it became 
apparent that HTLV infects CD4+ T cells and the conclusion from this early 
work was that this virus was the chief cause of AIDS. Others continued to show 
that HTLV was the cause of AIDS including Shaw et al. [133] and Weiss et al. 
[151], even though this was hotly disputed amongst scientists as late as 1988 
(Blattner et al. [13]; Dues berg [31]). 
In 1984 Shaw et al. presented findings with important implications about the 
biological properties of HTLV-III, the virus within the HTLV family of retro-
viruses associated with AIDS (Shaw et al. [132]). They demonstrated that 
HTLV-III shares many biological and physicochemical properties with the prop-
erties known about the AIDS virus in vivo. Knowledge that the virus transmits 
through human T-cells, making it largely resistant to cytotoxicity, enabled fur-
ther study of HTLV-III. Shaw et al. analyzed the HTLV-III genome in cell lines 
and fresh tissues from patients with AIDS or AIDS-related complex (ARC). 
Two full-length integrated proviral DNA forms of HTLV-III were cloned and 
analyzed, and DNA sequences of the virus in cell lines and fresh tissues were 
characterized. They were able to determine, amongst other things, that HTLV-
III is approximately 10 kilobases in length and that the virus shows substantial 
diversity in its genomic restriction enzyme cleavage pattern, which they sus-
pected was probably due to a high replication rate. 
In March 1984, CDC and the National Institutes of Health (NIH), in con-
sultation with scientists, physicians, and public health workers in academia, 
industry, and government, published a manual entitled 'Biosafety in Micro-
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biological and Biomedical Laboratories' [122]. The manual contained a sum-
mary statement for human T-lymphotropic virus type III/lymphadenopathy-
associated virus (HTLV-III/LAV). The Human Retrovirus Subcommittee of the 
International Committee on the Taxonomy of Viruses proposed the name human 
immunodeficiency virus (HIV) for these viruses (Coffin et al. [21]). This was 
contested by some (see Marx [82]). However, the AIDS virus from this point in 
time became known as HIV. 
In 1986 Cooper [22] was one of the first to develop a mathematical model of 
HIV infection. Cooper contrasts the growth of a "normal" virus with a retro-
virus (such as HIV), that attacks CD4+ T cells of the immune system. This 
early model, although relatively simple when compared with more recent work, 
showed that remarkable interactions with other infections as well as strong virus 
concentration dependence are general properties of immune system retroviruses. 
Some of the consequences of these ideas were compared with observations. 
In 1987 Reibnegger et al. developed a model that investigated the hypothesis 
that the breakdown of the immune system was due to the active immune de-
struction of infected T cells (Reibnegger et al. [120]). This model incorporated 
the interactions between HIV, cytotoxic T cells specific for the viral particles, 
debris from viral particles, resting macrophages, cytotoxic macrophages, helper 
T cells specific for the viral particles and helper T cells specific for other anti-
gens. This paper was quite advanced for this era of HIV j AIDS research. 
Since that era, the same basic constructs of virus dynamics have been em-
ployed but different aspects and time periods of the disease progression have 
been scrutinized more thoroughly and built upon to obtain more knowledge of 
the virus and its interaction with the immune system. Mathematical modelling 
has been used since then to describe many aspects of the HIV j AIDS disease 
progression and make deductions that are non-intuitive that add to the under-
standing of the virus or confirm suspicions. 
One of the ultimate goals is to have a HIV vaccine to prevent infection 
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of HIV and prevent AIDS. The short-term prospects for a vaccine are fairly 
poor and many scientists are concentrating on improving therapy to care for 
those who have contracted the virus. Recent advances in the treatment of HIV 
with highly active antiretroviral therapy (HAART) have significantly reduced 
morbidity (Palella et al. [104]). HAART has gained acceptance in the Western 
world as the best care for HIV patients. The immediate goal of therapy is to 
suppress HIV replication, and its desired effect is to prolong life and decrease 
transmission (Weidle et al. [150]). However, treatment is burdensome and costly 
and is out of reach of the majority of the people in the world that suffer from the 
disease. Current drugs work by disrupting replication of the virus long enough 
for the body to replace its crucial supply of CD4 T cells. There are three main 
classes of anti-HIV drugs: 
1. Nucleoside Reverse Transcriptase Inhibitors (NRTI) 
2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
3. Protease Inhibitors (PI). 
The reverse transcriptase inhibitors target an enzyme used by the virus to in-
tegrate itself into the human chromosome. Protease inhibitors target another 
enzyme involved in HIV replication. They are used in what is called combina-
tion therapy; therapeutic guidelines recommend combinations of three or four 
anti-HIV drugs as treatment for HIV. However, it has been shown that although 
therapy can suppress HIV plasma virus levels (viremia) to undetectable levels 
for more than 3 years, there is a prompt rebound in viral levels in the majority 
of patients following withdrawal from treatment, indicating that HAART is un-
able to completely eradicate the virus (Saag [124]). Mathematical modelling has 
aimed to explain why this is the case and suggest new avenues and predict how 
effective these drugs need to be to eliminate local epidemics (See, for example, 
Blower et al. [14]). An example of some general mathematical modelling of 
virus dynamics and drug therapy is given in the paper by Bonhoeffer et al. [15]. 
Although much effort has been concentrated on understanding HIV infec-
tion, very fundamental information about the dynamics of HIV infection has 
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been lacking because of the difficulties in performing experiments in humans. 
However, one of the biggest breakthroughs was achieved in the understanding 
of HIV dynamics in 1995, with the use of mathematical modelling. The time 
of initial infection to full-blown AIDS is approximately 10 years. Thus, in some 
sense, HIV infection is a slow process. Due to the slowness of the process it 
was not clear in the early 1990s whether HIV should be treated aggressively, 
when first discovered, or if treatment should be withheld until symptoms be-
came apparent. It was also thought by some that HIV replication itself is slow 
and thus drug resistance would be slow to develop. In 1995, this view changed 
dramatically with the simultaneous publications by Wei et al. [149] and Ho et 
al. [51]. Shaw's group and Ho's group each showed by analysis of the kinetics 
of HIV-1 RNA decline following initiation of potent antiretroviral theory that 
HIV must be replicating rapidly and being cleared rapidly. If clearance was 
blocked, then the amount of HIV in the body doubled every two days. Further 
theoretical analysis of similar experiments with more frequent sampling of pa-
tient's blood after initiation of therapy showed that productively infected T-cells 
were rapidly being lost, with a half-life in blood of slightly more than a day and 
that free virus was being cleared from the blood with a half-life of 6 hours or 
less. Many other results followed rapidly from the newly invented paradigm of 
combining mathematical modelling with frequent quantitative measurements of 
plasma HIV-1 RNA, and changes in the level of infected cells from quantitative 
cultures. Perelson and Ho, working in collaboration, have made a substantial 
impact in the modelling of HIV-1 infection. Developing models of drug therapies 
with protease inhibitors and reverse transcriptase inhibitors, they have been able 
to predict behaviours of the HIV-1 virus interaction with the immune system 
such as virion clearance rate, infected cell life-span, and viral generation time 
(see, for example Perelson et al. [113]). 
In the Appendix of this thesis a simple illustration is given of the cause of 
death of patients with HIV infection, namely opportunistic infections (such as 
Chlamydia), when the state of HIV disease pathogenesis is the period defined 
as AIDS. The illustration uses a mathematical modelling framework based on 
a version of the caricature model of infectious agent dynamics presented earlier 
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in this chapter. Although much progress has been made in understanding the 
dynamics of this disease, there is still a lot of work to be done if the ultimate 
goal of a cure is to eventuate in order to save millions of lives worldwide. 
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Chapter 3 
Concentration of cell receptors is more important 
in effecting binding reactions than cell receptor 
affinity 
Published in Australian Mathematical Society Gazette, 30/2 pp.82-85. 2003. 
Abstract: Antibodies are crucial to the human immune system for the removal 
of viruses, bacteria and other foreign particles (antigens) that are potentially 
damaging to the body. The concentration of antibodies and the antibodies' 
ability to bind a foreign particle are both important aspects of the antibody 
response's impact in clearing an invading antigen. We look at the common 
reaction binding equation to determine whether the affinity (strength of binding) 
of an antibody to an antigen, or the concentration of antibodies in a system is 
more important in binding antigen receptor sites towards eliminating infection. 
Our model investigates a system in which the antigens (target cell receptors) 
are in very large supply. We conclude that increasing the concentration is more 
effective than increasing affinity. This theory can easily be extended to other 
cell receptor interactions. 
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3.1 Introduction and Background 
The immune system is one of the defence mechanisms that the body uses to pro-
tect itself from potentially injurious agents. When a foreign substance (antigen) 
is introduced to the body, the body evokes a response from the immune system 
in an endeavour to remove the antigen from the body as quickly as possible. 
Lymphocytes are cells of the immune system that recognise a particular molec-
ular configuration on what is to be attacked. There are two types of lymphocyte 
cells: T lymphocytes and B lymphocytes. 
T lymphocytes produce CD4+ T cells and CDS+ T cells. The CD4+ T and 
CDS+ T cells perform the respective roles in the immune system of orchestrat-
ing the immune response and suppressing an antigen that has infected a cell. 
When an immune response is necessary against an antigen then a primary im-
mune response is sent by the CD4 + T cell. CD4 + T cells express (present) a 
unique antigen-binding molecule on its surface, called the T cell receptor. T 
cell receptors can recognise antigen molecules and subsequently stimulate the 
cell to release signals to other immune cells including CDS+ T cells which can 
eliminate antigen-infected cells. Only intracellular antigen is attacked by this 
immune response. This is known as cell-mediated immunity. 
A second type of immunity is known as humoral immunity. The humoral 
component of the immune system is crucial in eliminating many infectious agents 
that enter the body. It functions against antigen outside a cell. B cells are the 
major contributors to humoral immunity. The humoral response, also known as 
the antibody response, occurs when the CD4+ T cells signal B lymphocytes to 
produce plasma cells whose function is to manufacture and discharge antibJd-
ies. Antibodies are Y-shaped proteins that are specifically designed to attach to 
the binding sites of the antigen at hand. Other cells such as macrophages are 
signalled and activated to engulf and process an antibody-bound antigen and 
hence assist in direct antigen clearance. In addition, antigen receptors (binding 
sites) that are bound by antibodies are consequently unable to attach to and 
infect a healthy cell and so cell entry is inhibited. 
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Obviously, if antibodies have a strong adhesiveness to an antigen then it will 
be advantageous in removing the antigen. The adhesiveness of an antibody is 
known as the antibody's affinity. Also, it will be useful if there is a very high 
concentration of antibodies able to attach to an antigen. During conversation 
with a microbiologist the question was raised, 'Is the strength of antibody bind-
ing or the concentration of antibodies more important in effecting bound sites 
on an infectious particle?' Here, we develop a simple mathematical model to 
answer this question for the case in which a large number of antigens are present 
and we predict that antibody concentration is of greater importance than anti-
body affinity in the humoral immune defence. 
3.2 Model 
When an antibody (receptor) binds with an antigen binding site (more generally 
a receptor binds with a ligand), or when a substrate interacts with an enzyme, 
we assume that binding follows the common law of mass action and we write 
the reaction as 
al 
T+A1 ~ C1. 
dl 
(3.1) 
In this reaction, we let T be the concentration of antigen binding sites, A1 
the concentration of antibodies and C1 the concentration of antibody-bound-
antigen complexes. Association and dissociation rate constants are represented 
by a1 and d1 respectively. Then, the rate of change of the complex, antibody 
and antigen concentrations are 
dC1 
dt 
dA1 
dt 
dT 
dt 
(3.2) 
(3.3) 
(3.4) 
The association rate, a1 , is related to the adhesiveness of the attractive forces 
for binding, known as the affinity. In many models of receptor-antigen kinetics, 
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affinity and concentration have been indistinguishable in relative importance 
because they are multiplicative factors of each other, a1A1 . In this chapter we 
refer to the antigens that antibodies seek to attach to as target cells. There are 
numerous ways we can deal with the number of target cells. However, here we 
make the assumption that their concentration can be treated as approximately 
constant. This assumption is only valid in a system where antigen populations 
are large relative to antibody concentrations (and the associated antibody affin-
ity constant) which are not significantly large. We assume that the antigen is 
in very large supply, so much so that at least during early dynamics the anti-
gen population is seemingly unaffected. This is sometimes referred to as the 
pool chemical approximation. This case is of particular interest to us because 
humoral immunity is of the essence when the body is under considerable im-
munological stress from a large supply of antigen. In later stages of infection 
this approximation can no longer be assumed because the immune system will 
stimulate the proliferation of more antibodies, decreasing the antigen concentra-
tion. Our assumption is to be considered valid during early infection dynamics. 
In our system, equations (3.2) - (3.4), if we assume C1 (0) 
A 10 , T(O) = T0 , the full solution can be expressed as 
C1(t) = A10- A1(t), (3.5) 
T(t) T0 - A10 + A1(t) , (3.6) 
(73 y!i3tanh ( ~ t) + y'al(A10 + !') _I' 
Al(t) V ~ v13 + y'al(A10 +!')tanh ( ~ t) (3.7) 
where f3 and I' are given by 
/' = - To - A10 + - . 1 ( dl) 
2 a1 
(3.8) 
However, we assume that the number of target cells, T, is in great over-supply 
that its concentration is not significantly reduced by the binding process. We 
let the number of target cell binding sites be given by T0 . Here, we consider the 
following thought experiment. Let there be a chamber of two compartments, 1 
and 2, each containing the same concentration of antibodies of the same affin-
ity towards a certain target cell. The dynamics in each compartment should 
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be similar when an equivalent inoculum of target cells is introduced to each 
compartment. However, consider the effect of increasing the concentration of 
antibodies in compartment 1 by a factor of x and increasing the affinity (mea-
sured by the parameter a!) of the antibodies in compartment 2 so they bind with 
an x-fold strength. Then, we will compare the dynamics of each compartment 
as the large target cell inoculum is introduced and evaluate average equilibrium 
levels to determine which compartment contains the more effective antibodies. 
The compartment containing more antibody-target cell complexes on average 
will contain the more effective antibody. 
Assuming T = T0 , we obtain two linear systems, namely, 
dCi 
- = a·T.0 A- - d·G-dt ' ' ' ' ) 
dA 
- = d·G- - a·T.ok dt ' ' ' ' ) 
and assuming there are no complexes initially, 
aiToAiO (1 _ e-(a;To+d;)t) 
aiTo + di 
AiO ( di + aiToe-(a;To+dl)t) 
aiTo + di 
i = 1, 2) 
i = 1, 2) 
(3.9) 
(3.10) 
(3.11) 
where A10 and A20 are the antibody concentrations of antibody type 1 and type 
2 respectively at t = 0. Subscript '1' and '2' refer to concentrations and kinetic 
parameter rates in compartment 1 and compartment 2 respectively. 
3.3 Results and Discussion 
Since T0 is relatively large, Ci ~ C and Ai ~ A for sufficient time post inocu-
lation depending on a 1 , where the bar denotes equilibrium levels. This remains 
valid prior to immune system induced increase of the antibody concentration. 
To compare the number of complexes formed in each compartment we examine 
the following ratio of equilibrium levels, 
a1Aw(a2To + d2) 
a2A2o(a1To + d1) (3.12) 
To compare the effect of affinity versus concentration we assume that the disso-
ciation rates are equal, d1 = d2 = d, and we let there be an x-fold increase in 
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the initial concentration of antibody in compartment 1 and a matching x-fold 
increase in the binding affinity of antibody in compartment 2 and we determine 
which compartment contains the greater number of complexes. If we consider 
the antibodies in each compartment to have the same affinity and concentration 
prior to the x-fold increase (a1 =a, az = xa, A10 = xAo, A20 = Ao), then 
~1 = ( xaTo + d) > 1 , 
Cz (aTo +d) (3.13) 
since x > 1. The antibodies in compartment 1 will form a larger proportion of 
complexes at equilibrium and during the dynamics prior to equilibrium than the 
antibodies in compartment 2. That is, there will be more complexes produced 
by multiplicatively increasing concentration compared with multiplicatively in-
creasing binding strength by the same amount. In practice it is also easier to 
increase the concentration of antibodies than the affinity. 
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Chapter 4 
Diffusion theory can be applied to antibodies 
attaching to ligand sites 
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Abstract: Humoral immunity is that aspect of specific immunity that is me-
diated by B lymphocytes and involves the neutralizing of pathogens by means 
of antibodies attaching to the pathogen's binding sites. Antibodies bind to and 
block ligand sites on the pathogen from attaching to target cell receptors and 
so cell entry is inhibited. We present a master equation in quantum (discrete) 
and classical (continuous) form for a ligand bound at n sites becoming a ligand 
bound at m sites in a given interaction time. To track the kinetics of antibody-
ligand interaction, moving between states towards an equilibrium, it is shown 
that the process is most easily treated classically and that in this case the mas-
ter equation can be reduced to an equivalent one dimensional diffusion equation. 
Thus, the well known diffusion theory can be applied to antibody-ligand interac-
tions. We also present a term for the probability of a ligand changing antibody 
states. Numerical solutions are given for three distinct cases: the probability 
of antibody binding compared to the probability of dissociation relatively high, 
low, or comparable. We also extend this theory, developing a multidimensional 
diffusion equation for studying competing antibodies. 
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4.1 Introduction 
Many biological processes involve the binding of ligands to specific sites on large 
macromolecular complexes. Typical examples include substrate binding to the 
catalytic site of an enzyme, antibodies binding to cell surface receptors, regu-
latory proteins binding to DNA, and hormone binding to membrane receptors. 
Here we investigate antibodies attaching to cell receptors which is the basic 
mechanism of humoral immunity. Humoral immunity refers to immune protec-
tion provided by soluble factors such as antibodies against foreign pathogens 
introduced to the body. Antibodies circulate in fluids or 'humors', primarily 
serum and lymph. Humoral immunity is that aspect of specific immunity which 
is mediated by B lymphocytes and involves the neutralizing of pathogens by 
means of antibodies attaching to the ligand sites of the pathogen. Antibodies 
bind to and block ligand sites on the pathogen from attaching to target cell 
receptors and so cell entry is inhibited. Additionally, antigen-bound antibodies 
signal macrophages to activate and then macrophages may engulf the bound 
pathogen. Since viruses and many bacteria are intracellular in nature for re-
production, elimination of an essential function such as the ability to enter host 
cells would be the terminal event for the pathogen, since it would be prevented 
from entering the one environment in which it is capable of replication. The 
time dependent dissociation and recombination of complexes formed by anti-
bodies attaching to the surface of ligands is a fundamental process in humoral 
immunity and is the topic of investigation in this paper. 
Significant advances continue to be made in our understanding of the im-
mune system. The mechanisms by which humoral immunity is effective has 
been studied experimentally (Slifka, 2002; Slifka et al., 1998; Cogne, 2001) and 
theoretically (Sobottka et al., 2001; Rundell et al., 1998; Smirnova, 1991). In 
this paper we investigate humoral antibody effectiveness by developing a math-
ematical model of multivalent ligands in many states corresponding to the large 
number of antibody Fab fragments that may bind to the ligand. The theoreti-
cal problems associated with the binding of multivalent ligands have been well 
studied. The central problem is to predict the aggregate size distribution, from 
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which all quantities of interest can be calculated (Posner et al. 1995). When 
comparing theory to experiment it is often important to know this distribution 
because some types of cells respond differently to different size aggregates. For 
example, dimers of IgE are relatively ineffective at stimulating degranulation of 
rat basophilic leukemia (RBL) cells, compared with larger aggregates (Fewtrell 
& Metzger, 1980). Aggregates of two IgEs are predominantly mobile on RBL 
cell surfaces while larger aggregates become immobile immediately after for-
mation (Menon et al., 1986). Large aggregates of IgE may turn off RBL cell 
degranulation (Seagrove et al., 1991). Human basophils also display sensitivity 
to aggregate size (MacGlashon, et al., 1986). 
Two approaches have been used to calculate the aggregate size distribution. 
The first approach, the obvious one, is to write down equations for the concen-
trations of all possible ligand-receptor aggregates. Using this method, Dembo 
& Goldstein (1978) showed how to calculate the equilibrium size distribution 
for the binding of a symmetric bivalent ligand to a homogeneous symmetric 
bivalent receptor population, provided all necessary equilibrium constants were 
known. This approach has been extended to other problems involving bivalent 
ligands binding to bivalent receptors at equilibrium (Goldstein & Wofsy, 1980; 
Wofsy, 1980; Wofsy & Goldstein, 1987). To describe the time development of 
the concentration of an aggregate one must write down a differential equation 
(a chemical rate equation) for that aggregate. A complete description requires 
a large set of coupled differential equations (e.g. for RBL cells there are approx-
imately 105 receptors per cell and for chlamydia! elementary bodies there are 
approximately 2.86 x 104). Therefore, if one wishes to use this approach to calcu-
late numerically a time dependent aggregate distribution size one must truncate 
the set of equations to some tractable number (Dembo et al., 1978; Schweitzer-
Stenner et al., 1987). The second approach is less general, but can be used to 
obtain the complete time dependent aggregate size distribution by solving just 
two coupled nonlinear differential equations (Perelson & DeLisi, 1980). Here, we 
develop another approach to obtain the complete time dependent aggregate size 
distribution for multivalent ligands (cell surfaces with many receptors) bound 
by monovalent binding molecules (Fab fragments of antibodies) by solving one 
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diffusion equation. 
We formulate a version of pathogen antibody level dynamics on a continuum 
and convert the governing integra-differential equation to a diffusion equation, 
using theory similar to that used by Keck & Carrier (1965), so that the well-
known results of diffusion theory can be applied. Keck & Carrier investigated 
techniques for solving master equations for the coupled vibration-dissociation-
recombination process for molecules and atoms. We also develop a probability 
distribution based on association/dissociation rates and numerically illustrate 
solution of the diffusion equation, estimating various values for binding on/off 
rates. Additionally, we establish a framework for the investigation of competi-
tion between antibodies with a multidimensional diffusion equation. 
4.2 Modelling Antibody Attachment Numbers 
on a Pathogen 
Consider a pathogen bound at n sites by antibodies. We assume that there 
is a probabilistically inferred rate at which the pathogen bound at n sites can 
become a pathogen bound at m sites. The quantum (discrete) version of any 
such model is of the form 
N 8E(n, t) ~ 
at = L..t [K(m, n)E(m, t)- K(n, m)E(n, t)]- L(n)E(n, t) , 
m=O 
( 4.1) 
where E(n, t) is the concentration of pathogens with n antibodies attached and 
N is the maximum number of antibodies that can be bound to a pathogen si-
multaneously. This equation states that pathogens bound by n antibodies may 
leave this state by making transitions to pathogens bound by m antibodies, 
gaining or losing antibodies, at a rate K(n, m)E(n, t). We expect transitions 
from n antibodies to n - 1 or n + 1 antibodies on a pathogen to dominate the 
rate function, K. Equations such as equation (4.1) are common and have been 
studied extensively (Berg & Purcell, 1977; Shoup & Szabo, 1982; Zwanzig & 
Szabo, 1991; Adam & Delbruck, 1968; Wang et al., 1992; Macken & Perelson, 
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1982; Sulzer & Perelson, 1996). We also model external loss, whereby pathogens 
can be removed from the extracellular environment by immune clearance or in-
fection of host cells at a rate L( n). 
In this paper the antibodies we consider are monovalent antibody Fab arms. 
Not only does this reduce complexity from studying whole bivalent antibodies 
but it is also relevant to various biological systems. For example, the pent-valent 
adenovirus requires full occupancy by antibodies to achieve neutralization, which 
can be achieved by Fabs but not whole IgG molecules (Stewart et al., 1997). As 
another example, Suet al. (1991) found that cells allowed uptake of chlamydia! 
particles with bound antibody expressing Fe receptors, and if they took care 
to use a cell culture which lacked Fe receptors, the chlamydia! particles were 
prevented from being taken into the cells. Moreover, when only the Fab portion 
of the antibody molecule was used, uptake of chlamydia! particles by cells with 
Fe receptors was prevented.We also assume that all binding sites are equivalent 
and we assume that adsorbed particles do not interact. 
In general, to determine the time dependence of the concentration of any par-
ticular aggregate requires solving a very large set of coupled ordinary differential 
equations (Posner et al., 1995). The kinetics of the ligand-receptor complexes 
distribution may be presented in the form of a series (Perelson, 1985; Bentz 
et al., 1988). Although working well for relatively small numbers of binding 
sites (1-100), a simpler mathematical approximation would be very useful for 
a system with the number of binding sites significantly greater (Surovtsev, 2000). 
Since the number of ligand sites on a multivalent pathogen that may be 
bound by antibodies is quite large, and also because there is relatively little 
difference between a pathogen that is bound at n sites and a pathogen bound 
at n + 1 sites, we consider that it is reasonable to model the concentration of 
pathogens bound at x sites on a continuum. Here, we let E(x, t) be the concen-
tration of pathogens at time t that are bound by x antibodies, where 0 s; x < f 
is a real number. 
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We let l ( x) represent the combined rate of loss of pathogens with x antibodies 
attached, due to macrophage clearance and target cell infection. We also let 
k(x, x') be the probabilistically inferred rate of moving from state x to state 
x'. Then the quantum equation for the dynamics of the pathogen-antibody 
concentrations reverts to the analogous continuous version, namely, 
aE~~' t) = 1! k(x', x)E(x', t)- k(x, x')E(x, t)dx' -l(x)E(x, t) , (4.2) 
where f is the maximum number of antibodies on average that can attach to 
the surface of the pathogen simultaneously. 
In the absence of immune clearance and cell infection the pathogen-antibody 
concentrations, E(x, t), have a non-trivial equilibrium distribution, which we 
denote as Ee(x). At equilibrium, aE~~' t) is zero, and the requirement for 
detailed balancing leads to the conditions 
R(x',x) = k(x',x)Ee(x') = k(x,x')Ee(x) = R(x,x'). (4.3) 
Detailed balancing is a strong constraint that ensures that at equilibrium there 
is conservation of concentration not only 'in' and 'out' of every state, x, but also 
between every pair of states (x, x'). Keck and Carrier (1965) have used a similar 
detailed balancing constraint. We use the equilibrium distribution to introduce 
the non-dimensionalised concentration 
X( ) = E(x, t) x, t Ee(x) ' ( 4.4) 
which is the ratio of the concentration of pathogens with x antibodies attached 
to the associated equilibrium concentration. Then, equation ( 4.2) can be written 
in the more symmetrical form 
8X(x, t) {! 
Ee(x) at = Jo R(x, x') [X(x', t)- X(x, t)] dx' -Ee(x)l(x)X(x, t). (4.5) 
4.3 Transformation to the Diffusion Equation 
We now transform the master equation, equation (4.5), to an equivalent diffusion 
equation. The transformation assumes the integrand in equation ( 4.5) can be 
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expanded in a Taylor series about x' = x and we assume that the kernel, R(x, x'), 
is separable and large only for x' >::::J x. We can then anticipate that the solution 
of equation ( 4.5) can be well approximated by the solution of 
Ee(x) oX~x, t) = joo R(x', x) [X(x', t)- X(x, t)] dx', 
t -oo 
(4.6) 
where we ignore the pathogen loss term. 
Expanding X(x', t) about x' = x, we obtain the partial differential equation 
(4.7) 
where 
.6-n(x) = 1: R(x', x)(x'- xtdx' (4.8) 
is the nth moment of the change in antibody level ( x' - x) with respect to 
R(x', x). Observing symmetry of R(x', x) on interchange of x and x' requires 
that 
R(x', x) = S (x, 1.6.1) , (4.9) 
where 
x = (x' + x)/2 (4.10) 
is the mean of the initial and final antibody levels and 
.6. = x'- x ( 4.11) 
is the change in the antibody levels. Assuming S (x, 1.6.1) is sharply peaked at 
.6. = 0 we expand about .6. = 0 and obtain 
and 
so that 
.6-l(x) = fooo ~~~X .6.2d.6.+0(.6.4) 
.6.1 (x) = ~ 8.6.2 + 0(.6. 4) 
2 ox 
and substituting ( 4.14) into ( 4. 7) results in 
E ( )ax=~ (.6.2(x) ax) 
eX ot OX 2 OX ' 
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(4.12) 
(4.13) 
(4.14) 
(4.15) 
a one-dimensional diffusion equation. The boundary conditions necessary to 
determine X(x, t) uniquely are 
exl -o exl ~ - and~ = 0, 
uX x=O uX x=f 
( 4.16) 
since a pathogen cannot have a negative number of antibodies and will not have 
more than the maximum of f antibodies. We also require an initial condition 
which we define as 
X(x,O) = f6(x) ,x ~ 0, ( 4.17) 
where 6(x) is the Dirac delta function. Here, we let there be an initial concen-
tration of magnitude, f, on the boundary at x = 0 and zero concentration for 
x > 0. This specifies that there are no attached antibodies initially. When we 
solve the diffusion equation numerically we let 
{ f, O:S:x<1 X(x, 0) = 0' 1 ::::; x::::; f 
We note that equation (4.15) can be written as 
E ( )aX_ t.z(x) 82X ~ 8.0.2 aX 
e X at - 2 ax2 + 2 OX OX ' 
(4.18) 
(4.19) 
and thus there are two components indicating how the distribution will change 
with time, namely, X will move along a gradient in the direction of least an-
tibodies, and will be balanced by what equilibrium should be according to the 
probability distribution that influences the moment, .0.2 . 
4.4 Probability Distribution for Change in Num-
ber of Antibodies 
To solve the diffusion equation we require a form for R(x, x'). Consider the 
quantum version of antibody-pathogen interactions. In a time characteristic of 
the interaction of an antibody with an antigen, of duration 6t, a bound site may 
dissociate with probability q or remain bound with probability 1 - q. Here, q 
is related to the antibody's dissociation constant, kD. Also, an antibody may 
attach to an unbound site with probability p or an unbound site may remain 
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unbound with probability 1 - p. Here, p is related to the antigen-antibody 
association rate, kA. Then, if v(i) is an integer it is straightforward to show that 
min{n-j, i} . . 
P(' ') = """' ( v(2) ) ( 2 ) k(1 - )i-kn-J-i+k(1 - )v(i)-(j-i+k) 2
' J L...J j- i + k k q q J1 p ) 
k=max{i-j, 0} 
(4.20) 
where P( i, j) denotes the probability that a pathogen bound at i sites becomes 
a pathogen bound at j sites in one interaction time and 
v(i) 
LP(i,j)=1 (4.21) 
j=O 
as required. The function, v(i), represents the valency of the pathogen that has 
i bound sites. Hlavacek et al. (1999) define the valence of the ith state, v(i), to 
be the number of sites that are available for receptor binding on a ligand that is 
bound at i sites averaged over all possible microscopic states of the ligand. Steric 
effects of ligand-receptor binding can decrease the effective number of available 
sites. However, here we neglect steric effects and take the valence of the ith 
state to be given by 
v(i) =n-i. ( 4.22) 
Since r(n + 1) = n!, we take the analogous probability distribution for the 
approximate continuous distribution, namely, 
1min{v(x'), x} P(x,x') = C(x,x') qC::(l- q)x-(px'-x+((1- p)v(x)-(x'-x+() d(' max{x-x', 0} 
(4.23) 
where C(x, x') is the number of ways a pathogen bound at x sites can become 
a pathogen bound at x' sites, and can be expressed as 
C X x' = f(v(x) + 1)f(x + 1) 
( ' ) r(v(x)- (x'- x + () + 1)f(x'- x + ( + 1)f(( + 1)f(x- ( + 1) · 
( 4.24) 
An example of the probability distribution is illustrated in Figure 4.1. 
Then, k(x, x') = k1P(x, x'), where k1 is a rate parameter that incorporates 
the interaction time 6t. The equilibrium distribution, Ee(x), can now be deter-
mined by ensuring P(x', x)Ee(x') = P(x, x')Ee(x). Because we are not consid-
ering any source or loss, the number of pathogens will remain at a fixed level, 
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Figure 4.1: A typical probability distribution for moving from one antibody level to an-
other. Here, we illustrate the probability of a pathogen bound with 18 antibodies becoming a 
pathogen bound by x antibodies in one interaction time. Here, p = 0.005 and q = 0.003. 
E0 . Then, 
E ( ) = E [1! P(x, x') d '] -1 
e X 0 P( I ) X ' 0 x,x ( 4.25) 
which is illustrated in Figure 4.2 for various probabilities, p and q. 
In the limiting case as p -+ 0 (that is, antibodies do not attach to unbound 
sites because the antibody and epitope are not complementary), 
Ee(x) =Eo 6(x) . ( 4.26) 
Although the reaction of ligand-receptor binding is reversible, in particular cases 
of specific binding the dissociation reaction can be neglected (Surovtsev et al., 
2000). Then in the limiting case as q-+ 0 (that is, irreversible binding), 
Ee(x) =Eo 6(x- f) , ( 4.27) 
where 6(x) is the Dirac delta function. 
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Figure 4.2: Plots of the equilibrium distribution, Ee(x). We take f = 100. (a) Binding proba-
bility low relative to dissociation probability (p = 0.00005, q = 0.03). (b) Binding probability 
comparable to dissociation probability (p = 0.005, q = 0.003). (c) Binding probability high 
relative to dissociation probability (p = 0.05, q = 0.0003). 
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4.5 Numerical Solution 
The kernel of our non-linear diffusion equation, equation ( 4.15), can be expressed 
as 
- 1min{2x,2(f-x)} - - [1! P(x + f::::./2, ~) ] -1 2 
!::::.2 (x) = 2k1E 0 
0 
P(x+f::::./2, x-f::::./2) 
0 
P(~, x _ f::::./ 2) d~ !::::. d!::::.. 
( 4.28) 
which is illustrated in Figure 4.3 for various choices of binding and dissociation 
probabilities. We note that the magnitude of the kernel function varies consider-
ably with the probabilities for binding and dissociation. This greatly influences 
the time for diffusion. 
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Figure 4.3: Plots of the kernel function, D.2 (x). We take f = 100. (a) Binding probability 
low relative to dissociation probability (p = 0.00005, q = 0.03). (b) Binding probability 
comparable to dissociation probability (p = 0.005, q = 0.003). (c) Binding probability high 
relative to dissociation probability (p = 0.05, q = 0.0003). 
We employ a fully implicit vertex-centred finite volume method to obtain 
numerical solutions to the one-dimensional diffusion equation, Eqn. (4.15), and 
then use Eqn. (4.4) to revert to the solution for E(x, t), the concentration of 
pathogens with x antibodies attached at time t. Figures 4.4, 4.5 and 4.6 il-
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lustrate the diffusion solutions for the non-dimensional variable, X, for three 
different expression of the kernel, Ll2 (x), corresponding to relative low, medium 
and high probabilities of antibody attachment. Accordingly, Figures 4. 7 and 4.8 
illustrate the solutions for E at various points in time. We do not display the 
solution for E when the probability of antibody attachment is low because there 
is little change from the initial distribution and distinguishing between plots in 
this case is rather futile. Finally, Figure 4.9 displays a sequence of solutions for 
E(x, t) when the loss term is taken into consideration. 
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Figure 4.4: Sequence of plots of diffusion in our non-dimensional variable. Here, p 
0.00005, q = 0.03. The ti's are 0.0125, 0.025, 0.05 and 0.075 in scaled time units. The 
tj's are 0.1, 0.15, 0.25 and 0.5 in scaled time units. 
4.6 Extension 
The study of the response of different antibodies to protect against infection 
is highly publicized and is crucial in the pursuit of vaccine development (for 
example, Gonzales et al., 2002). Thus, modelling and analyzing competition 
between two or more antibodies is an area for investigation. Here, we extend 
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Figure 4.8: Sequence of numerical solutions for E(x), the pathogen concentration of antibody 
distribution, for various points in time. Here, p = 0.05, q = 0.0003. 
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Figure 4.9: Sequence of numerical solutions for E(x), the pathogen concentration of antibody 
distribution, for various points in time when loss from the extracellular environment is con-
sidered. We assume, for simplicity, that the loss rate is directly proportional to the number of 
attached antibodies, l(x) = hx, and we tale lt = 0.000001 time- 1 . Here, p = 0.005, q = 0.003. 
The distribution is displayed for time = 0.025, 0.05, 0.075, 0.1 scaled time units. 
our governing equations to the competition of Nx different antibodies binding to 
the surface of a pathogen. Generally, to determine the time dependence of the 
concentration of any particular aggregate containing combinations of different 
numbers of each antibody would require solving NNx coupled ordinary differen-
tial equations. However, analogous to the development of our diffusion equation, 
if we let 
E(x, t) 
X(x, t) = Ee(x) ' ( 4.29) 
where x = [x1 , x2, ... , XNxf is a vector containing a list of competing antibodies, 
then 
Ee(x) aX = ~ ~ (6n(x) aX) . 
at ~ax· 2 OX· i=l t t 
(4.30) 
Here, ii is an ordered list of Nx elements ( nj, j = 1, ... , Nx) such that if j = i 
the element is 2 but if j -=f. i the element is 0, and the nth moment is expressed 
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as 
( 4.31) 
where A is the set of all real numbers in the hyperspace, x~ x x~ x ... x xk, 
and dS = dx~ dx~ ... dxk. The function, R, is defined as 
R(x', x) = k(x', x)Ee(x') = k(x, x')Ee(x) = R(x, x') . ( 4.32) 
4. 7 Discussion 
The humoral arm of the immune system is crucial in neutralizing many infectious 
agents that enter the body. It is mediated by B lymphocytes through the release 
of antibodies specific for attaching to a pathogen's binding sites. Increasing the 
level of antibodies attached to a pathogen's surface binding sites inhibits cell in-
fection and increases pathogen clearance. The central problem is to predict the 
aggregate size distribution, from which all quantities of interest can be calculated 
(Posner et al. 1995). When comparing theory to experiment it is often impor-
tant to know this distribution because some types of cells respond differently 
to different size aggregates. However, predicting the aggregate size distribution 
requires the solution of a very large number of coupled ordinary differential equa-
tions. We have presented the master equation for pathogen-antibody levels in 
quantum and classical forms and shown how the classical master equation can be 
transformed to an equivalent diffusion equation in a non-dimensional variable. 
Thus, we have reduced a system of N (N usually very large) coupled ordinary 
differential equations to a diffusion equation. We also developed a framework 
to reduce NNx coupled ordinary differential equations to one multidimensional 
diffusion equation for investigating competition between antibodies. The diffu-
sion equation is much easier to work with and the theory of such an equation is 
well-known. We developed a probabilistically inferred rate of transition between 
antibody levels for the pathogen which influenced the non-constant coefficient 
of the diffusion equation. We determined equilibrium distributions and solved 
the one dimensional diffusion equation numerically for solutions tending towards 
the equilibrium distributions. The theory may be generally applicable to any 
extracellular infectious agent with a large number of binding sites. 
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Abstract: Humoral immunity is that aspect of specific immunity that is me-
diated by B lymphocytes and involves the neutralizing of pathogens by means 
of antibodies attaching to the pathogen's binding sites. Antibodies bind to and 
block ligand sites on the pathogen which prevents these sites from attaching to 
target cell receptors and so cell entry is inhibited. Many studies investigate the 
role of humoral immunity for protection against chlamydia! challenge and they 
have shown that neutralization of the chlamydia! body requires a large number 
of attached antibodies. Steric hindrance greatly influences the number of avail-
able sites that may be bound, reducing relative occupancy well below 100%. We 
model steric effects of antibody Fab fragment attachment indicating that they 
must be taken into consideration to accurately model valency, the number of 
available binding sites. We derive a partial differential equation for the number 
of antibody Fabs and host cell receptors that are aggregated to extracellular 
chlamydia! elementary bodies. We consider steric effects in describing the size 
distribution of aggregates. Our theory is in good agreement with Monte Carlo 
simulations of binding. We use our theoretical prediction for the valency in a 
model for the in-host population dynamics of a chlamydia! infection and we fit 
our model to experimental data. 
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5.1 Introduction 
The humoral arm of the immune system is crucial in neutralizing many infec-
tious agents that enter the body. It unleashes its power as antibodies attach to 
the ligand sites on the pathogen. Antibodies bind to (and block) ligand sites 
on the pathogen which prevents the ligand sites attaching to target cell recep-
tors and so cell entry by the pathogen is inhibited. This is the essence of the 
coating theory (Klasse & Sattentau, 2002). For example, the obligate intracel-
lular nature of Chlamydia means that elimination of an essential step such as 
the ability to enter susceptible cells would be the terminal event for Chlamy-
dia, since the bacteria would be prevented from entering the one environment 
in which they are capable of replication. Additionally, antigen-bound antibod-
ies provide signals to macrophages to become activated and engulf the bound 
pathogen. Humoral immunity and, in particular, pre-existing Major Outer Mem-
brane Protein (MOMP) antibody, appear to provide a preventative role against 
initial chlamydia! infection, whilst cell-mediated immunity is necessary for the 
removal of established infection once the organisms become intracellular within 
the mucosa (Batteiger et al., 1993; Knight et al., 1995; Peeling & Brunham, 
1996). The first observation that antibody could neutralize or prevent infec-
tivity of Chlamydia trachomatis in HeLa cells in tissue culture was reported by 
Reeve & Graham (1962). Philip et al. (1974) first reported the requirement for 
high concentrations of antibody for neutralization of C. trachomatis. Although 
high concentrations of antibody do neutralize infection, the exact mechanism of 
chlamydia! neutralization is not clear (Rank, 1999). 
Burnet et al. (1937) stated "That the 'survival' or 'inactivation' of a given 
virus particle is determined by the amount of antibody combined with it at 
the moment of effective contact with the susceptible cell". Thus, we model the 
tracking of antibody Fab receptor aggregation over the surface of the chlamydia! 
extracellular pathogen, termed the elementary body (EB). Tracking the distri-
bution of antibodies aggregating on chlamydia! particles is more important than 
for many other pathogens because of the large number of binding sites and the 
high antibody concentration required for neutralization. 
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There is a major difference between the requirements for neutralization of 
Chlamydia and a virus. A major difference relates to the size of chlamydiae 
and viruses. The diameter of a chlamydial elementary body (EB) is over 10 
times that of a poliovirus, implying, perhaps, a greater than 2000-fold difference 
in volume and hence a corresponding difference in mass. In addition, Peeling 
and Brunham (1991) calculated that between 103 and 104 species-specific mon-
oclonal antibodies (mAbs) per EB are required for 50% neutralization. Suet al. 
(1990) estimated that there are 2.86 x 104 MOMP epitopes (binding sites) on the 
surface of each EB. For most viruses, not all binding sites on the virion need be 
bound to render the virus noninfective (neutralized). However, generally virions 
have significantly less binding sites. Poliovirus was shown to require an average 
of nine mAb molecules per virion for 90% of the infectivity to be neutralized 
(Icenogle et al., 1983) while it has been shown that a minimum of four or five 
molecules per virion are required for some degree of neutralization (Klasse & 
Moore, 1996). Rhinovirus requires 5-6 antibody molecules per virion for 50% 
and 10-20 antibody molecules for 90% neutralization (Smith et al., 1993). How-
ever, neutralization of adenovirus by antibodies requires full occupancy (on all 
of its five sites), and this can be achieved by Fab receptors but not by whole 
IgG molecules (Stewart et al., 1997). 
The importance of multivalent ligand-receptor binding has led to significant 
theoretical and experimental effort in an attempt to understand the general in-
teractions of multivalent ligands with cell surface receptors and the theory has 
been applied to a wide variety of problems. For example, Hlavacek, Posner & 
Perelson (1999) have extended models of ligand-receptor interactions by intro-
ducing a steric hindrance factor, and others, such as Dembo & Goldstein (1978) 
and Perelson & DeLisi (1980) have been particularly influential in developing 
theory for bivalent ligands. In considering steric impact on valency, we suggest a 
two-dimensional geometrical argument, based on physical areas on the pathogen 
surface. The effects of steric hindrance form the main contribution to the coating 
theory of pathogen neutralization whereby a proportion of a pathogen surface 
is blocked from cell membrane-pathogen interaction due to spatial interference 
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(Klasse & Sattentau, 2002). The coating theory explains why antibodies to 
non-viral molecules on the virion surface can neutralize infectivity (Zebedee & 
Lamb, 1988; Rizzuto & Sodroski, 1997). Here, we develop a theory for binding 
of two receptors to a ligand with a large number of binding sites and use it to 
demonstrates the coating theory of humoral protection against chlamydial in-
fection. In the following section we develop our expression for the valence (the 
number of sites available for binding) given the aggregation of antibody Fabs 
and cell-surface molecules to Chlamydia's infectious extracellular particle, the 
elementary body (EB). We then develop a model for the in-host dynamics of 
infection with Chlamydia, and fit our model to experimental data. 
5.2 Valency 
Each pathogen needs a certain number of unimpeded functional surface antigen 
molecules in order to infect a potential host cell (Klasse & Sattentau, 2002). 
When antibody Fab binding leaves fewer antigens unobstructed than required 
to bind to a host cell receptor for entry, then it is neutralized (Klasse & Moore, 
1996). In this section we present an overview of how such obstruction is caused 
by Fabs and develop an expression for the valence. 
Perelson (1981) defines the general concept of valence as the number of sites 
on a ligand at which a receptor can bind, and the effective valence as the maxi-
mum number of sites on a ligand that can be bound simultaneously by receptors. 
Here, we let n be the total number of epitopes (ligand sites) on a chlamydial EB 
that may bind with target cell receptors or be bound by antibody Fab fragments. 
However, due to steric effects, this maximum cannot be achieved. We denote 
the maximum number of sites that can be bound simultaneously by antibody 
Fab fragments, by fx (:::; n). Similarly, }y (:::; n) denotes the maximum number 
of sites that can be bound simultaneously by host cell receptors. Hlavacek et al. 
(1999) define the valence of the ith state, v(i), to be the number of sites that 
are available for receptor binding on a ligand that is bound at i sites averaged 
over all possible microscopic states of the ligand. Of course, v( i) :::; n - i and 
the valence when fx Fabs are bound, or when }y host cell receptors are bound, 
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is zero as no further binding can take place. When steric effects of binding are 
considered (see below), fx < n, jy <nand v(i) < n-i. We define the x,y-state 
valence, v(x, y), to be the average number of sites remaining that may be bound 
on a ligand that is bound at an average of x sites by Fabs and y sites by host 
cell receptors. 
In this paper the antibodies we consider are monovalent antibody Fab frag-
ments although a more general approach would be to consider the multivalency 
of antibodies. However, Suet al. (1991) have shown that cells allowed uptake of 
EBs with bound antibody expressed Fe receptors, and if they took care to use a 
cell culture which lacked Fe receptors, the EBs were prevented from being taken 
into the cells. Moreover, when only the Fab portion of the antibody molecule 
was used, uptake of EBs by cells with Fe receptors was prevented. This has 
influenced standard neutralization assays (Byrne et al., 1993). We also assume 
that all binding sites are equivalent and that adsorbed particles do not interact. 
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Figure 5.1: The surface of a ligand on which two receptors are bound. Sites may be bound, 
covered, excluded, or available, as indicated. The dashed circle indicates the size of a receptor 
at minimum distance to an already bound receptor (the receptors are touching). This indicates 
the exclusion region. 
Because of its physical size, a bound receptor may exclude receptor binding 
at neighboring sites (see Figure 5.1). A receptor may bind a single site but phys-
ically may cover an area that encompasses more than one site on the ligand. A 
ligand may be bound or unbound and unbound sites may be covered, excluded 
or available. A site that is covered is not available for receptor binding because 
it is physically covered by a bound receptor. An excluded site is one which is 
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not covered, but unavailable for receptor binding because it lies near a bound 
receptor and an overlap of receptors would occur if binding was attempted. An 
available site is one that is not bound, covered, or excluded. A receptor that 
covers an area a will exclude any site in an area of 7Ja containing the covered 
area a, where 7J is a parameter characterizing the specific receptor-pathogen in-
teraction. Pellequer and Van Regenmortel use data from experiments with the 
tobacco mosaic virus (TMV) to suggest that an antibody Fab arm covers the 
surface of approximately three viral subunits (Pellequer & Van Regenmortel, 
1993). Hlavacek et al. (1991) also assume an annular exclusion region of 3a. 
However, 7J is ligand-receptor dependent. Here, we use a simple two-dimensional 
geometrical argument to show that taking TJ = 4 (that is, an exclusion area of 
3a) is an appropriate choice for most ligand-receptor systems whilst data is not 
available. But we also model overlap of exclusion regions which has the effect of 
decreasing TJ. 
Steric hindrance factors are closely related to insertion probabilities (Widom, 
1963). Andrews (1975, 1976) approximated insertion probabilities by using a 
physical interpretation of the statistical mechanical expression for the reciprocal 
of the activity of a classical fluid, obtaining greater accuracy than commonly 
used virial expansion coefficients. Andrews (1976) investigated two-dimensional 
insertion probabilities, evaluating covered areas and excluded areas. We also 
evaluate covered and excluded areas, extending the theoretical expression of ex-
cluded areas. 
We are aware that receptor turnover and clustering both occur on the sur-
face of the pathogen. However, here we assume that the spatial distribution of 
sites on the pathogen surface is uniform (Axelrod & Wang, 1994) and thus we 
also assume that each target receptor sees the same free antibody concentration 
as any other on average. When determining the valence, we must determine 
separately the valence for an antibody Fab fragment to attach to an EB and 
the valence for a host cell receptor to attach to an EB because of their different 
contact areas. Generally, if x antibody Fab fragments and y host cell receptors 
are bound to the pathogen then the x, y-state valencies for the number of avail-
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able EB receptor sites for binding with free Fabs and free host cell receptors are 
given by 
Vx(x, y) = n- X- y- Cx(x)- Cy(Y)- Xx(x, y) , (5.1) 
and 
vy(x, y) = n- x- y- cx(x)- cy(y)- Xy(x, y) , (5.2) 
respectively. Here, n is the total number of binding sites on the surface of an 
EB of surface area A, Cx represents the average number of sites on the EB sur-
face covered by antibody Fab fragments, cy represents the average number of 
sites covered by host cell receptors, Xx represents the number of sites excluded 
from binding with Fabs and Xy represents the number of sites excluded from 
binding with epithelial cell receptors (generally epithelial cells are the host cells 
of chlamydia! infection). There are also other complications of steric hindrance 
by coating: the angle of the antibody Fab binding and the bulkiness of the Fe 
portion, if considering whole antibodies, which can also cause an increase in the 
area of the pathogen surface that is blocked. However, we do not consider these 
effects here. 
To determine an expression for the valence, we let a0 be the area of a ligand 
site, a1 be the area that an antibody Fab receptor covers, and a2 be the area 
that a host cell receptor covers. We assume a2 > a1 . An Fab fragment binds 
to an epitope by weak non-covalent interactions, which operate only over short 
distances. For a strong bond, the Fab's binding site and the epitope must have 
complimentary shapes. This requirement poses a restriction on the epitope in 
that its size can be no larger than the size of the Fab's binding site (Klasse & Sat-
tentau, 2002) so that a0 < a1 . The shape of the epitope that can be recognized 
by the Fab is determined by the shape assumed by the sequence of amino acids 
in the binding site and the chemical environment that they produce. For these 
globular protein antigens, the shape of the epitope is entirely determined by the 
tertiary conformation of the native protein. Fabs make contact with antigen 
across an undulating surface in which protrusions on the epitope (or Fab bind-
ing region) are matched by corresponding depressions on the Fab binding region 
(or epitope) (Amit et al., 1986). We assume complimentary Fabs-epitopes and 
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assume that receptors, and epitopes are circular (Berg, 1985; Axelrod & Wang, 
1994; Saterbak, et al., 1993; Lauffenburger & Linderman, 1993). 
If a Fab receptor has a contact area of a1 and binds to a site of area a0 , the 
area containing covered sites by the Fab is a1 - a0 and the average number of 
sites in this covered area is (a1 - a0 ) :;I, where we are assuming, as above, that 
a0 is the area of a ligand site, a1 is the area that a Fab receptor covers, and n 
is the total number of binding sites on the surface of an EB of surface area A. 
Then, 
(5.3) 
Similarly, the number of sites covered by epithelial cell receptors bound to EB 
surface receptors is given by 
(5.4) 
A site is excluded if it is not covered but if when a receptor attempts to bind to 
the site, an overlap of receptor areas would result. We model exclusion of binding 
sites with continuous analogs of discrete difference equations. The equations 
are defined such that the number of sites excluded is given by the number of 
sites excluded prior to the last binding interaction, plus the average number 
of sites excluded due to the most recent binding event, whilst also considering 
average overlap of exclusion regions. If we let r 1 = ~and r2 = ~' 
then the exclusion region for Fabs (that is, the region on the surface of the EB 
surface excluded from binding with Fabs) caused by the binding of one Fab to an 
available EB site will be the area of the circle of radius 2r1 minus the receptor 
contact area, a1 , which can be expressed as 3a1 . Based on our assumptions, 
there are 3~ n sites in this exclusion area. The exclusion region for Fabs caused 
by the binding of an epithelial cell receptor will be the area of the circle of 
radius (r2 + ri) less the receptor area, a2 , and this is given by (a1 + 2ylal(i2). If 
two available sites that are near each other each become bound by a receptor, 
then although the two receptors may not interfere, the exclusion regions formed 
by the receptors may overlap and care must be taken to ensure that a given 
site is not excluded more than once. Then, we determine the probability that 
the last binding event was effected by an antibody Fab arm or by a epithelial 
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cell receptor and estimate the proportion of the additional exclusion region that 
consists of available sites as opposed to sites that are already excluded. This 
proportion is given by v / ( v + x). We express the exclusion of sites by 
Xx(x, y) xxx(x- 1, y) YXx(x, y- 1) ----'--'------'-+---'---'-----'-
x+y x+y 
+ x (3a1n) ( Vx(x- 1, y) ) 
x+y A vx(x-1,y)+xx(x-1,y) 
+ _Y_ ( (a1 + 2J(iia2)n) ( vx(x, y- 1) ) (5.5) 
x+y A vx(x,y-1)+Xx(x,y-1) 
and 
xxy(x- 1, y) YXy(x, y- 1) 
--"-'------'-+.;..._.o:....;_--'-----'-
x+y x+y 
+-x- ((az + 2J(iia2)n) ( vy(x -1,y) ) 
x + y A vy(x- 1, y) + Xy(x- 1, y) 
y (3a2n) ( vy(x, y- 1) ) 
+x+y A vy(x,y-1)+xy(x,y-1) · (5.6) 
Here, _x_ is the probability that the last binding reaction was by an Fab and 
x+y 
_Y_ is the probability that the last binding reaction was by a epithelial cell 
x+y 
receptor, assuming independence. The exclusion area for epithelial cells caused 
by the binding of an antibody Fab arm is the area, ( a1 + 2J(iia2), and the 
exclusion area for epithelial cell receptors caused by the binding of another cell 
receptor is 3a2 . Of course Xx(O, 0) = Xy(O, 0) = 0. Our estimates for the values 
of our model parameters are shown in Table 5.1. We note that the area of cell 
contact is ambiguous because of difficulties in distinguishing between areas in 
true contact and those not in the presence of numerous membrane invaginations 
and protrusions (Lauffenburger & Linderman, 1993). However, we estimate the 
contact area from assumptions of Hammer & Lauffenburger (1987). 
To determine the maximum number of sites that can be bound simultane-
ously by Fabs, fx, we consider the case of no host cell receptor attachment to 
the EB surface. Then, fx is the solution of vxUx, 0) = 0. Similarly, jy, the max-
imum number of sites that can be bound simultaneously by host cell receptors, 
is the solution of vy(O, jy) = 0. 
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Parameters 
n = number of epitopes per EB 
A = surface area of EB 
a0 = epitope area 
a 1 = area covered by antibody 
a2 = area covered by cell receptor 
PN = source of epithelial cells 
oN = death rate of epithelial cells 
kb = rate infected cells burst releasing infectious progeny 
P = number of infectious EBs released by infected cells 
Values 
2.86 X 104 
2.8 x 105 nm2 
6.5 nm2 
7.6 nm2 
500 nm2 
40 cells/mm3 /day 
2 day-1 
0.6 day-1 
200 
Table 5.1: Parameter estimates for Chlamydia neutralization model 
We assume that in the continuous case, Xx(x, 0), can be derived from the 
discrete analog. In the continuous version, we assume a continuum of binding 
and thus the last binding interaction involves the binding of ox sites. Upon 
binding one site, the exclusion area is 3a1 n/ A, and thus upon binding ox sites 
the exclusion area is 3a1noxjA. We multiply this area by the proportion of this 
region consisting of available sites, v / ( v + x), to determine the new number of 
sites excluded from the binding of ox sites. We obtain 
Xx(x--+ X+ Ox, 0) = Xx(x- Ox--+ x, 0) (5.7) 
3a1nOx ( vx(x- ox--+ x, 0) ) 
+ A Vx(x- OX--+ x, 0) + Xx(x- OX--+ x, 0) 
Taking the limit as ox--+ 0 results in 
dxx 
dx 
3a1n Vx(x, 0) 
A Vx(x, 0) + Xx(x, 0) 
3a1n n- X- Cx(x)- Xx(x, 0) 
A n-x-cx(x) (5.8) 
From the solution of Eqn. 5.8, we obtain the following expression for the x, 0-
state valence, namely, 
Vx(x, 0) = n- X- Cx(x) (5.9) 
3a1n ( (n- X- Cx(x)) A+(!:1nao)n) 
- n-x-cx(x)-n (2a1 + a0 )n - A n 
Figure 5.2 shows the plot vx(x, 0). Amit et al. (1986) studied the three-
dimensional structure of antigen-antibody complexes. Based on their study, 
we take a0 = 6.5nm2 , we also let a 1 = 7.6 nm2 (Aaskov, 2002), and let the sur-
face area of an EB to be given by A= 2.8 x 105 nm2 as estimated by Matsumoto 
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(1988). Figure 5.2 also compares the valence without steric hindrance and the 
valence when considering only covered sites with the valence when considering 
covered sites and excluded sites. Obviously, it is essential to consider excluded 
sites when studying valency. It is also essential to consider overlap of exclusion 
sites as evidenced by the non-linearity in the valence curve. Using our parameter 
values from Table 5.1, we obtain fx ~ 12628.54, less than 50% of all sites. Thus, 
less than 50% of all sites need to be bound by Fabs to render the EB 100% 
neutralized. Similarly, jy is the root of 
Hammer & Lauffenburger (1987) presented a dynamical model for cell receptor-
mediated adhesion in which they suggested estimates for various parameters. 
We use this study as a source for estimating the area covered by a cell receptor 
to be a2 = 500nm2 . Then, with our parameters, jy ~ 235.82 which is less than 
1% of all sites. That is, no more sites on the chlamydia! EB are available to be 
bound if jy sites are bound by host cell receptors. 
To demonstrate how well our theoretical model works we compare our model 
predictions with the results of Monte Carlo simulations. In each simulation 
2.86 x 104 epitopes (Su et al., 1990) were randomly distributed over a region 
with area A = 2.8 x 105 nm2 . This region had periodic boundaries to repre-
sent the surface of a sphere. Then a process of randomly selecting a site to be 
bound was performed and any sites within the covered or exclusion region of the 
bound site was recorded and removed from the set of available sites. A site was 
recorded as covered if it was located within the circular region of area (a1 - a0 ) 
nm2 centered at the bound site and any site not in the covered region but within 
the circular region of area 3a1 nm2 centered at the bound site was recorded as 
an excluded site. The process was repeated until the number of available sites 
was zero. The number of available sites versus the number of sites bound was 
recorded and the entire simulation, including the random spatial distribution of 
binding sites, was performed 450 times. The results are illustrated in Figure 5.3 
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Figure 5.2: Plot of the antibody state-x, 0 valence, vx(x, 0), that is, the number of sites 
available for antibodies to bind to given that a chlamydia! EB is already bound by x antibodies. 
Here, we present the state-x, 0 valence for the cases of (i) no steric hindrance (thin solid curve), 
(ii) the valence when considering bound sites and covered sites (dashed curve), (iii) the valence 
when considering bound sites, covered sites and excluded sites (thick solid curve). Obviously, 
it is essential to consider excluded sites when studying valency. It is essential to consider 
overlap of exclusion sites as evidenced by the non-linearity in the valence curve. Parameter 
values used are those from Table 5.1. Here, fx :::::: 12628.54 < 0.45n. 
from which we can see that our theoretical prediction (dotted curve in Figure 
5.3) is in good agreement with the simulations. The simulations had a mean 
value for fx of 12626 with a range of 12119 to 12859, compared with our theo-
retical prediction of fx = 12628.54. 
5.3 Mathematical Model of Population Dynam-
. 
ICS 
In this section we develop a model for the in-host population dynamics of a 
pathogen, Chlamydia, which is the ligand of focus in the previous section. We 
specifically apply our theory of valence and our population dynamics model to 
the chlamydia! EB pathogen. A pathogen is neutralized by the abrogation of 
infectivity through the binding of antibodies (Fabs) to the pathogen. We adopt 
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Figure 5.3: The valence (sites available), v(x, 0), versus x, the number of sites bound. The set 
of solid curves represent 450 Monte Carlo simulations of binding causing complete neutraliza-
tion and the dotted curve is our theoretical prediction. 
a continuum approach where the population of chlamydial EBs bound at x sites 
by antibody Fab fragments is regarded as a continuum, x 2: 0. It is reasonable 
to also add the criterion that antibodies (Fabs) act before the major biosynthetic 
event in the replicative cycle has taken place (Dimmock, 1984). Then, we also 
consider EBs bound with y host cell receptors, y 2: 0. Epithelial cells are the 
primary host cells infected with Chlamydia. 
Let E(x, y, t) be the concentration of extracellular chlamydial particles (EBs) 
at time t that are bound by x Fabs and bound to y host cell receptors. We use 
a conservation law to derive the following governing equation for the change in 
the distribution of EBs, namely, 
8E 8 (kx(x, y, t)E) 8 (ky(x, y, t)E) L( )E _ O 
ot + ox + oy + x,y,t - ' (5.11) 
where 
kx(X, y, t) = Kxj(X, y, t) - Kxr(X, y, t) (5.12) 
is the rate of change in the aggregation of antibodies on the EB, considering 
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average antibody-EB association (Kxf) and dissociation (Kxr) rates, and 
ky(x, y, t) = Kyf(X, y, t) - Kyr(X, y, t) (5.13) 
is the rate of change in the aggregate of host cell receptors on the EB, consider-
ing host cell receptor-EB association ( Kyf) and dissociation ( Kyr) rates. Here, 
L(x, y, t) represents loss of extracellular chlamydia! particles, incorporating loss 
of extracellular particles as they become internalized by host cells, and loss from 
the system due to antibody-induced clearance of EBs by macrophages. 
The average global rate of Fab attachment over an EB per unit time de-
pends on the number of binding sites and Fabs that are available (Brendel & 
Perelson, 1987). The reaction-limited process is generally assumed for ligand-
receptor binding (Lauffenburger & Linderman, 1993). Based on the assumption 
that all receptors act independently, and binding is reaction-limited (as distinct 
from diffusion limited), we take Kxf = kxtF(t)vx(x, y), where kxf is the associ-
ation rate constant for a single ligand-receptor complex interaction, F(t) is the 
concentration of available Fabs at timet and vx(x, y) represents the number of 
sites available to which Fabs can bind. We let Kxr = kxrX, where kxr is the dis-
sociation rate constant for the complex, assuming dissociation of an Fab-epitope 
complex is independent of other complexes. Because there is always some dis-
sociation of Fabs from EBs, on average an EB will never be entirely packed 
with Fabs. Using a model similar to that for receptor association/dissociation 
kinetics, we let ky(x, y, t) = kyJN(t)vy(x, y) - kyrY , where N(t) is the number 
of epithelial cells which EBs may bind to and infect, vy(x, y) is the valence, 
that is, the number of sites available to bind with host cell receptors and kyf is 
the forward association rate constant for binding and incorporates the average 
number of receptors per host cell. The constant, kyr, is the dissociation rate for 
a EB site/host cell receptor complex. 
We track the time evolution of the concentration of Fabs and epithelial cells, 
F(t) and N(t) respectively. We also model the concentration of infected ep-
ithelial cells, I(t), and the production of new generations of infectious EBs. 
Volp et al. (2001) studied guinea pig infection with Chlamydia caviae (formerly 
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Figure 5.4: (a) Volp et al.'s time course of antibody levels in vaginal secretions of guinea pigs 
post infection using enzyme-linked immunosorbant assay (ELISA), and cubic spline interpo-
lation of data. The dashed curve indicates to pre-challenge time-course and the solid line 
indicates the post-challenge time-course. 
Chlamydia psittaci) and obtained a time course of antibody Fabs over the time 
of infection (Figure 5.4). In addition, they determined the percentage of vaginal 
mucosal cells infected with C. caviae over the time of infection. They used the 
C. caviae strain because it closely parallels C. trachomatis infection in humans. 
We fit our mathematical model to the data obtained by Volp et al. Based on 
these experiments, we have a time course for F(t) at certain times which we 
interpolate to obtain an approximate continuous time course. This time course 
will incorporate any natural source and decay of antibodies, the clonal expansion 
that occurs during a humoral immune response as B-cells that express the ap-
propriate antigen receptors are clonally expanded, and will incorporate change 
in antibody Fab concentration due to attachment/detachment with EB binding 
sites. Although we have a time course available, we assume a description of the 
Fab dynamics can be represented by 
dF = So_ JpF(t) + SlF(t)Er(t) _ f1x f1y a (kx(x, y, t)E) dydx . (5_14) 
dt Ec + Er(t) }0 } 0 ax 
Here, S0 is a natural production term, and 6p is the rate of natural decay. We 
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model the process of clonal expansion with the term, S1F(t):rr;, where Ec is 
Ec+ r t 
the half saturation constant of the proliferation process and Er(t) = 1fx 1/y E(x, y, t)dydx 
is the total number of EBs in the system. We also incorporate change in anti-
body Fab concentration due to attachment/detachment with EB binding sites, 
at a rate kx as defined earlier. 
We assume that the changes in epithelial cell concentration at timet, N(t), 
are associated with a source, PN, a natural death, 6 N, and depletion as cells are 
infected by EBs. We let oN = 2 days-1 implying a half life of approximately 
0.5 days (Collier, 2002), and as an order of magnitude estimate, we let PN = 40 
cellsjmm3 j day. This gives rise to the equation, 
dN {fy {fx 
dt = PN- 6NN(t)- Jo Jo kE(y)E(x, y, t) dx dy, (5.15) 
where we recall that fx and JY refer to the maximum number of sites that can be 
bound simultaneously by antibody Fab fragments, and the maximum number 
of sites that can be bound simultaneously by host cell receptors, respectively. 
The factor, kE, denotes the rate epithelial cells become infected with chlamydia! 
EBs. We note that kE = kE(Y) denoting dependence on the number of epithelial 
cell receptors bound to chlamydia! EBs. The change in the infected epithelial 
cell population, J(t), at time t is given by 
di rfy rfx 
dt = Jo Jo kE(y)E(x, y, t) dx dy- kbi(t) , (5.16) 
where kb is the rate infected cells lyse. Beagley & Timms (2000) state that the 
average time of host cell infection is 40 hours leading to our estimate for kb of 
0.6 day-1 . As infected cells lyse, they release a new generation of EBs able to 
infect epithelial cells. Subsequently, we let the boundary condition for equation 
(5.11) be 
dE(~~ 0, t) = Pkbi(t) ' (5.17) 
where P is the number of EBs released upon lysis of an infected cell ( approx-
imately 200 (Wilson et al., 2003)). We assume that prior to inoculation of 
chlamydia! EBs the epithelial cell concentration is at steady state and that 
there are no infected cells. Then, the initial conditions for our system upon an 
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inoculation of EBs, E0 , are given by E(x, y, 0) = Eo o(x)o(y) , N(O) = N0 = 
PN /oN , I ( 0) = 0 , where o is the Dirac delta function. 
5.4 Solution of governing model equation 
Since Fabs that have bound to an antigen produce signals to activate immune 
effector cells called macrophages, we assume that clearance by macrophages is 
a monotonically increasing function of the number of bound sites, x, and we 
k 
assume generally can be taken of the form m( x) = :'"ox k, where m 0 is the 
x5o +x 
maximal clearance rate, x50 is the number of Fabs bound to an EB for which the 
clearance rate is half-maximal and k is a shape fitting parameter. This term is to 
be incorporated into L(x, y, t), governing loss of EBs from the system. A com-
plete model description would incorporate the concentration of macrophages, 
but we take this concentration as constant. If we assume that xg0 > > xk then 
the term becomes m 1x, if we take k = 1 and m 1 as a constant. Fabs attached 
to EBs inhibit EB entry into target cells by blocking sites on the ligand surface 
from binding to host cell receptors. However, once an EB-host cell receptor 
complex is formed, we assume that internalization is simply proportional to the 
number of complexes. Here, we let L(x, y, t) = m(x) + kiy, where ki is a param-
eter representing the rate of internalization. 
We use a finite difference algorithm to numerically solve the system of dif-
ferential equations (5.11), (5.15) and (5.16) within a method of steepest decent 
algorithm to fit model predictions to data published by Volp et al. As stated 
previously, Volp et al. infected guinea pigs with a chlamydia! strain and pub-
lished a detailed time course for antibody levels and the percentage of vaginal 
cells that were infected. We use cubic spline interpolation to obtain a continuous 
time course for the concentration of antibodies, using the data of Volp et al., 
and fit our model to the data of the percentage of vaginal cells infected. The 
steepest decent algorithm was used to minimize the error function, 
g(x) = [%rnf(t)- %fuf(x, t)r , (5.18) 
experiment time pts. 
where xis a vector containing the list of parameters to be determined, %Inf(t) 
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is the experimental data for the percentage of infected cells, and <iofuf(x, t) is 
the predicted percentage of infected cells from our mathematical model. 
It is reasonable to assume that once a single EB receptor binds to a host 
cell receptor, the host cell begins the process of internalizing the EB. Then, we 
simplify our model, no longer modelling aggregation of host cell receptors, but 
only antibodies accumulating on the EB surface, assuming that once the first 
major biosynthetic event occurs, internalization will result. Subsequently, the 
host cell infection can be modelled as a decreasing function of antibody coverage 
on the EB surface, Ke(x, t), replacing the previous infection term, kE(Y) = kiY· 
We note that Ke and kE represent the same process of epithelial cell infection, 
but in our simplified model, we model the process differently to in our full model 
system. We let Ke(x, t) = kev(x)N(t) to model that fact that as available sites 
decrease then there is a decreased probability of host cell receptor binding and 
internalization occurring. The term also incorporates the concept that host 
cell infection depends on the concentration of host cells available. Then, the 
governing equation reduces to 
8E 8 (K(x, t)E) L( )E = O 
at + ax + x, t ' 
where K(x, t) = kxtv(x)A(t) - kxrX, v(x) = Vx(x, 0) and L(x, t) 
Ke(x, t). The domain of E is {(x, t): 0::; x < fx, t > 0}. 
5.4.1 Simplified Model 
(5.19) 
m(x) + 
Clearance of chlamydia! infection occurs over the timescale of weeks. Antibody 
Fab fragments attach to EB sites in a time which is of the order of minutes so 
we make the approximation that this occurs instantaneously. If we assume that 
EB-Fab equilibrium level aggregates form instantaneously, then K(x, t) = 0. We 
let x(t) denote the equilibrium number of Fabs aggregated on the surface of an 
EB at time t. The concentration of Fabs generates the time dependence of the 
system. Then, xis the root of kaffv(x)F(t)- x, where kaff = kxf. Of course, 
kxr 
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x < fx· Then, our model equations become 
dE 
dt 
dN 
dt 
di 
dt 
(5.20) 
(5.21) 
(5.22) 
We solve the reduced model system of equations (Equations 5.20- 5.22) nu-
merically and fit the unknown parameters, x = [Eo, kaff, ke, m1f, to the data 
of Volp et al. Figure 5.5 illustrates the numerical solution for the percentage of 
infected cells with time post infection. Here, the parameters of best fit (to 4 sig-
nificant digits) are E0 = 4152 cells/mm3 , kaff = 9.547 x 10-3 , ke = 1.897 x 10-s 
mm3/day/cell, and m 1 = 9.220 x 10-4 hrs-1 . 
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Figure 5.5: Experimental and best-fitting simulated percentage of guinea pig vaginal cells 
infected as a result of chlamydia! challenge. Error bars indicate one SD from the mean. We 
simulate chlamydia! infection from the time of chlamydia! challenge (t = 0). This occurs 38 
days after immunization by intraperitoneal priming and intravaginal boosting. 
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5.5 Discussion 
The most widely used kinetic equation for modelling adsorption is that due to 
Langmuir (1918). However, the Langmuir equation does not consider steric hin-
drance effects. Most current adsorption models do not properly consider steric 
hindrance effects of preadsorbed molecules either. As a consequence, the mod-
els often fail to represent the adsorption kinetics accurately. Steric exclusion 
of ligand sites is likely to play a role in many ligand-receptor interactions. Oc-
cupancy of antibody /Fab fragments on a ligand surface is central to theories 
of neutralization. We have presented an expression describing effects of steric 
hindrance of Fab binding to a pathogen. The steric hindrance can greatly in-
fluence dynamics. We have developed and analyzed a mass-action model for 
the adsorption of particles onto the surfaces of chlamydial EBs. In applying the 
model to cells, we can predict the distribution of the number of cells with 'x' 
particles adsorbed. A model of this type was proposed by Yassky (1962) for 
the adsorption of phages to bacteria and has been studied extensively by Gani 
(1965, 1967, 1971), Macken & Perelson (1982), Brendel & Perelson (1987) and 
others. We develop a governing equation for the distribution of aggregates of 
both antibody Fab molecules and host cell receptors adsorbed on the surfaces 
of chlamydial EBs. If we neglect loss terms, steric effects, and the aggregation 
of host cell receptors binding to EBs, our governing equation reverts to a form 
equivalent to the classical Langmuir kinetics. Our formulation of the valence is 
unique in its approach as is the development of tracking aggregates of both an-
tibody Fab fragments and host cell receptors. We fit our model to experimental 
data and obtain estimates for unknown parameter values. In addition to provid-
ing deeper understanding of neutralization of chlamydial extracellular particles 
by Fabs, this work contributes to the approaches in theoretical modelling of 
adsorption of neutralizing particles. Our theoretical framework of antibody ag-
gregation on the surface of pathogens with a large number of binding sites can 
also be used in deepening the understanding of many aspects of cellular biology. 
For instance, when immunoreceptors are aggregated through interactions with 
an antigen, signals are generated that lead to cellular activation (Metzger, 1992). 
This includes opsonization, the process of making bacteria more susceptible to 
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the attraction and activation of phagocytes to remove the bacteria, and is de-
pendent on the number of antigen-antibody complexes (Rakita et al., 2000). We 
have developed a new method for increasing realism of models of receptor-ligand 
binding. Our continuum approach for the expression of valency enables greater 
accuracy in continuous models of in-host pathogen dynamics. This theory will 
have importance in a variety of studies examining cellular responses to complex 
antigens. Theoretical and experimental efforts to understand such systems are 
of increasing interest (Hlavacek et al., 1999). 
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Abstract: Chlamydia are bacterial pathogens of humans and animals causing 
the important human diseases trachoma, sexually transmitted chlamydia! dis-
ease and pneumonia. Of the human chlamydia! diseases, sexually transmitted 
disease caused by C. trachomatis is a major public health concern. C. trachoma-
tis replicates intracellularly and is characterised by a complex developmental cy-
cle. Chlamydia is susceptible to humoral and cell-mediated immunity. Here we 
investigate the Thl cell-mediated immune response against Chlamydia-infected 
cells as the response changes over the chlamydia! developmental cycle. We sug-
gest a form for the immune response over one developmental cycle by modelling 
the change in the number of intracellular chlamydia! particles and assume pep-
tides are presented in proportion to the number of replicating forms of chlamydia! 
particles. We predict, perhaps nonintuitively, that persistent Chlamydia should 
be induced and forced not to return to the lytic cycle. We also suggest that 
extending the length of the time of the lytic cycle will effectively decrease the 
required efficacy of the Thl response to eliminate the pathogen. We produce 
plots of active disease progression, control and clearance for varying levels of 
Thl effectiveness. 
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6.1 Introduction 
Chlamydiae are obligate intracellular parasites that develop and multiply within 
a host cell's vacuole (termed an inclusion). They are bacterial pathogens of hu-
mans and animals and cause the important human diseases trachoma, sexually 
transmitted chlamydia! disease and pneumonia. Of the four chlamydia! species, 
C. trachomatis and C. pneumoniae are primarily human pathogens, while all 
species, but particularly C. caviae (previously named C. psittaci [1]) and C. 
pecorum are found in animals. 
Infection with the chlamydia! species, C. trachomatis results in the most com-
mon sexually transmitted disease worldwide [2]. It can lead to serious outcomes 
such as infertility and ectopic pregnancy if left untreated. C. trachomatis is 
also the major cause of preventable blindness in the world with over 500 million 
people blinded as a result of trachoma due to this pathogen. There are currently 
no vaccines available for either of these major diseases. Chlamydia infections 
can be effectively treated with a course of antibiotics although the majority of 
people that are infected do not show evidence of symptoms and many infections 
go undetected, undiagnosed, and consequently, untreated. Untreated Chlamydia 
infections are able to persist and establish a long lasting, chronic infection, that 
can increase the risk of acquiring or transmitting HIV, the virus that causes 
AIDS, and in women can also spread into the pelvic area and infect the uterus, 
fallopian tubes, and ovaries leading to pelvic inflammatory disease. 
All chlamydiae share a common biology [3]. Chlamydia has a unique biphasic 
life cycle which is initiated when an infectious, relatively durable, extracellular 
transmission cell, termed the elementary body (EB), attaches to a suscepti-
ble host cell, promoting entry into a host cell-derived phagocytic vesicle. The 
Chlamydia lytic developmental cycle begins when extracellular Chlamydia EBs 
attach to host cells (Figure 6.1). This attachment may be blocked by antibod-
ies. The host cells internalize the EBs, where, once inside the host cell, the 
EBs are no longer accessible to antibodies. The metabolically inert EB under-
goes morphological changes, reorganizing inside cellular vacuoles to the larger 
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reticulate body (RB). At this stage, they lose their infectivity and change their 
physical attributes, becoming a replicative form so that after reorganisation the 
RBs multiply 200-500 fold. Lymphokines such as IFN-')' from CD4 and CD8 
cells, attracted to the infection site can destroy intracellular Chlamydia at the 
RB stage [4]. 
Although most RB multiplication occurs within 10-20 hours after infection, it 
can occur throughout the entire developmental cycle, resulting in asynchronous 
growth. At 20-25 hours after infection, infectious elementary bodies appear as 
the EB to RB conversion process is reversed. RBs continue to divide and reor-
ganise into EBs until the host cell cannot support the Chlamydia multiplication 
any longer. The host cell bursts, releasing infectious EBs, thereby initiating new 
cycles of infection. Depending on the Chlamydia strain, the developmental cycle 
takes between 40 and 72 hours. 
• EB 
• RB 
Nucleus 
A chlamydia! elementary 
body (EB) begins the cycle 
by attaching via specific 
receptors to the surface of 
an I ceiL 
The chlamydia! particle is 
engulfed, DNA and RNA 
protein synthesis starts, the 
EB converts to the chlamydia! 
replicative form, the reticulate 
body (RB), inside the 
developing chlamydia! 
The RBs multiply 200-500 
fold by binary fission. 
Figure 6.1: The life cycle of Chlamydia trachomatis 
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6.2 Cellular Immune Response to the invading 
chlamydia! pathogen 
It has been suggested that Th1 Cn4 T cell-mediated, not humoral, immune 
responses, play the dominant role in protective immunity [5]. It is known that 
efficient Th1 responses will often successfully clear infection [6, 7]. Humoral im-
munity, and in particular pre-existing Major Outer Membrane Protein (MOMP) 
antibody, appear to provide a preventative role against initial infection, whilst 
cell-mediated immunity is necesary for the removal of established infection once 
the organisms become intracellular within the mucosa. More than 90% of in-
fected men and 99% of infected women have serum antibodies, so it is clear that 
the presence of antibody alone is not protective, even though antibodies can 
be shown to neutralise infectivity in vitro [S]. The importance of cell mediated 
immunity, that is, T helper-1 (Th1) response, to chlamydia! infection has been 
emphasised in a number of studies [9, 10, 11, 12, 13, 14, 15, 16]. 
Cytotoxic T cells play an important role in protecting the host against 
chlamydia! infection. Chlamydiae are confined within an endosomal vacuole, and 
consequently it cannot be assumed that their antigens from infected cells are pro-
cessed via the class I MHC pathway. Alternatively, MHC class II might present 
chlamydia! peptides to CD4+ T cells. Then, once inflammation is induced, ex-
pression of MHC antigens will be upregulated by IFN-1 predominantly. It has 
been shown that ens+ T cells (CTLs) can cause lysis of Chlamydia-infected 
epithelial cells [S]. Thus, we assume that most ens+ T cells are activated by 
MH C class I expression through macrophage engulfment and processing along 
with the appropriate cytokine signalling (IL-2) from Cn4+ T cells. 
A mechanistic understanding of chlamydia! disease pathogenesis is not well 
developed at present. Because the Th1 response appears to be so important 
for immunity to Chlamydia, here we investigate the cell-mediated arm of the 
immune system against a Chlamydia-infected cell to understand its impact on 
overall pathogenesis and required effectiveness to control or clear an infection. 
This paper aims to help build an introductory link between chlamydia! cell 
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biology and the mechanistic components of pathogenesis, by means of a math-
ematical model, with emphasis on examining how the cellular immune system 
responds over the chlamydial developmental cycle. 
6.3 Modelling cell-mediated immunity to Chlamy-
dia 
As the developmental cycle progresses, the parasite presents more antigens to 
the host, making itself more of a target for the immune system. Presumably 
this is reflected in the immune response to the host. We assume that when 
a RB begins to replicate an immune response is initiated and this response is 
most effective when the number of intracellular RBs is largest. We assume that 
chlamydial peptides presented to immune cells are in proportion to the number 
of intracellular RBs [4]. Therefore, we model the number of EBs and RBs inside 
the infected cell's vacuole, over the developmental cycle. 
6.3.1 Dynamics of Intracellular Chlamydia 
During one developmental cycle we denote the maturity (or time) through the 
cycle by the parameter r, where r0 :::; r :::; r3 . We aim to track the number of 
RBs and EBs inside one inclusion. The first process that occurs once an in-
clusion develops is the transformation of the EB to a RB and assume that this 
occurs during the time/maturity from r = r0 to r = r 1. The second phase is 
RB replication where we assume that for r 1 :::; r :::; r 2 an original RB triggers 
successive waves of pure binary replication. The third process, from r = r 2 to 
r = r3 , involves the transformation of RBs back into the infectious form, the EB, 
whilst some RBs are still replicating. We assume that the rate of RB replication 
is fixed but a certain proportion slowly begin to commence transformation to 
the EB form at r = r 2 . We assume that by the end of the developmental cycle, 
when lysis of the host cell occurs, all RBs have commenced transformation to 
the EB although a considerable number may still be in the process of transfor-
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mation. We model this by assuming that the rate of conversion from a RB to 
a transforming body, l(r), will become increasingly large as the cell approaches 
lysis. We focus our attention on the cycle post EB to RB transformation. Figure 
6.2 outlines our concept of the intracellular component of a single developmental 
cycle. 
Host Cell 
Inclusion 
Notation 
Maturity of (r) 1 
Inclusion r 0 
EBO 
transforms 
to RB. Process 
1 
RB 
replication 
2 
RBs transform to EBs whilst 
some RBs still replicate 
(Intermediate forms 0 ) 
I 
I 
r. 
Figure 6.2: The unique developmental cycle of chlamydiae. Chlamydia enters a host via the 
infectious EB and differentiate into the RB. Then the RB replicates by division. Finally RBs 
reorganise back into EBs before cell lysis. 
Accordingly, we develop the following model equation to describe the change 
in the RB population within an inclusion: 
r1 :::; r :::; r2 
r2 :::; r :::; r3 
(a) 
(b) (6.1) 
where RB(r) is the number of RBs within a single inclusion at a progression r 
through the developmental cycle maturation. Here, k is a constant denoting the 
rate of division and the parameter l ( r) indicates the rate that a RB commences 
transformation to an EB. We take the RB sink rate function, l(r), to be of the 
a(r- r2) form l(r) = , to demonstrate the increasing rate of EB production as 
r 3 - r 
the host approaches lysis. Since we assume that initially only one EB enters a 
cell and converts to a RB we set the initial condition 
(6.2) 
Then, the solution for the number of RBs inside an inclusion at progression r 
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through the cycle is given by 
r1 ::; r ::; r2 
, r2 ::; r ::; r3 
(a) 
(b) (6.3) 
Once a RB commences its transformation into an EB, it matures through 
a spectrum of forms until the complete infectious form is produced [8]. We 
assume that the transformation follows an age-structured representation. That 
is, the body progresses through the spectrum of chlamydia! forms with time. 
We let T(X, r) be the number of transforming bodies that have progressed a 
maturity x, 0 ::; X ::; r*, from an RB to an EB at time/progression r through 
the developmental cycle, where r 2 ::; r ::; r3 . Here, a transforming particle at 
x = 0 represents a RB commencing transformation and a transforming particle 
at x = r* refers to a chlamydia! particle that is a fully matured EB. For 0 < 
x < r*, the body is still in the process of transforming, between the two forms. 
Then the RB-EB transforming particles are maturing according to the equation 
(6.4) 
with the boundary condition 
dT(X = 0, r) 
dr = l(r)RB(r)- k7 T(X = 0, r) , (6.5) 
supplied by RBs that are no longer replicating. Here, kr = 1 hours-1 . Equation 
(6.4) states simply that the species time rate of change is given by the rate at 
which the population gets older (matures). 
Once chlamydia! particles have been transformed to maturity r* (typically 
r* = r 1 -r0 , the same time period as EB to RB transformation), T(r*) represents 
a fully matured EB. Therefore, the total number of EBs that exist at some time, 
r, through the developmental cycle is given by 
EB(r) = 1r T(X = r*,() d(, 
T2 
(6.6) 
and the total number of EBs that are released upon bursting, EBr, is given by 
(6.7) 
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We now use equations (6.1)- (6.7) to determine the number of RBs and EBs 
inside an inclusion during the Chlamydia developmental cycle. We seek values 
for the parameters k and a, representing the rate of fission and rate RBs stop 
replicating and start transforming to EBs respectively. To determine k we ap-
proximate the average time that it takes for a RB to divide and ensure that the 
number of RBs within an inclusion remains realistic. If a RB takes an average 
of T hours to divide, then k = ~ ln 2. We let r1 = 10 hours, r 2 = 16 hours 
and r3 = 32 hours, based on the known description of the lytic cycle [2]. We 
evaluate the integral, equation (6.7), and use the Newton-Raphson method to 
find the value of a that will make the total number of EBs in an inclusion equal 
to 200 upon bursting [2]. Taking T = 0.986 hours implies that k ~ 0.7 hours-1 
and a ~ 0.17 hours - 1. Then, the number of RBs and EBs throughout one 
developmental cycle is illustrated in Figure 6.3. Similar results are obtained if 
we set the number of EBs released equal to typical burst sizes of 500 or 1000. 
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Figure 6.3: Numerical solution displaying the number of RBs and EBs separately that are 
inside a C. trachomatis infected cell inclusion based on our mathematical model. The effec-
tiveness of the immune system over the distribution of cells at a particular infection maturity 
is related to the number of RBs inside the inclusion at that instant (plot on left side). 
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6.4 Modelling the chlamydia! developmental 
cycle 
The mathematical model we present uses a deterministic approach to understand 
the cell-mediated response to chlamydia! inclusions for controlling the disease 
by investigating its responsiveness over Chlamydia's developmental cycle. We 
assume that the immune cytotoxic response rate is directly proportional to the 
number of RBs inside the infected cell. It seems reasonable to track the number 
of cells of varying maturation levels in the developmental cycle with a continu-
ous variable, r. 
The developmental cycle can be arbitrarily divided into several compart-
ments. The first compartment represents free extracellular Chlamydia and the 
others represent epithelial host cells that are infected with Chlamydia at dif-
ferent stages of the cycle. At its simplest, the compartments of infected cells 
can be represented by the three critical processes that occur intracellularly: en-
gulfed EBs converting to RBs, the replication of RBs, and the reorganisation 
of RBs back to EBs. We also consider a compartment to represent the cells 
that are rupturing to release newly formed EBs. It is the beginning and end 
of the cycle, when converting between the EB and RB forms and including the 
spectrum of forms between these extremes, that makes Chlamydia different from 
other organotrophic bacteria. We assume that the dynamics of the populations 
associated with these compartments take place in a system, such as the female 
reproductive tract. 
Chlamydia infections in vivo are often asymptomatic and can remain for a 
long period of time if left untreated. These latent infections that endure for a 
relatively long time may be caused by a lag in the cycle caused by the formation 
of a persistent state of chlamydiae. There is evidence to support the existence 
of a persistent phase leaking out of the cycle in which intracellular RBs are 
abnormal morphologically, are non-infectious, but central to long-term infection 
[17, 18, 19, 20]. Agents such as IFN-1 or nutrient deprivation induce this chronic 
form of chlamydiae in in vitro models [21]. The persistent state of RBs is char-
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acterised by abnormal infected cells. We model this persistent phase, suggesting 
that a certain proportion of cells containing replicating RBs will move into the 
persistent phase before possible feedback into the regular lytic cycle. 
We let C(t) be the concentration of extracellular chlamydia! particles in the 
system, A(t) the concentration of host cells that have chlamydia! particles at-
tached and been infected by chlamydia! particles, and E(t) the concentration 
of cells infected with EBs converting to RBs, at time t. We let R(t) be the 
total concentration of cells that are purely replicating. We also let <I>( t) be the 
concentration of cells in the persistent phase, and I(t) be the total concentration 
of host cells that contain particles that are replicating whilst other chlamydia! 
particles inside cells in this phase are converting back into infectious bodies. We 
let B(t) represent the concentration of host cells that are bursting. We assume 
that these cells do not contain significant numbers of replicating RBs, but con-
tain EBs predominantly. 
We define a parameter, r, which can be thought of as a time parameter 
over one generation, denoting the infected cell maturity through the cycle. The 
parameter, r, is more general than age and represents maturity of an infected cell. 
Here, we track an infected cell and associate the infected cell's maturity with the 
chlamydia! development in it's internal inclusion. Equations for species that are 
modelled discretely, independent of r, are formulated by considering that the 
rate of change of the species concentration includes a source from the previous 
phase and a sink as the cell progresses into the next phase in the developmental 
cycle. However, for equations describing species characterised by the continuous 
variable, r, we derive an age-structured model. An immune response may act 
differently at each age of the phase. We let p(r, t) be the concentration of host 
cells at time t that contain purely replicating RBs, at stage of maturity between 
r and r + b..r through this replication phase. Then the total number of cells 
containing purely replicating chlamydia! particles is given by 
1rl R(t) = p(r, t)dr . ro 
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Also, the number of cells containing RBs converting back into EBs is given by 
1T2 I(t) = i(r, t)dr, Tl 
where i(r, t) represents the concentration of cells of maturity r in the cycle that 
contain RBs converting to EBs. Appendix A contains the development of the 
governing PDE, namely, 
op o 
ot + or (kp(r)p(r, t)) + f-L(r)p(r, t) = 0. (6.8) 
The rate of progression throughout the replicating phase, kp, must be a con-
tinuous function of r and is the probability of a progression in maturity of !:lr 
in time !:lt for a given maturity r. If r is strictly the time since the inclusion 
started then the transition rates are equal to unity for all r. The Von Foerster 
equation, equation (6.8) with kp = 1, is appropriate to model our continuous 
phases. However, here we generalise by considering maturity to be given not 
necessarily strictly by age. 
The time rate of change for each species to describe our model is given by 
dC Pk1B(t) - k2C(t) - >..C(t) (6.9) dt 
dA (1- e)k2C(t) - k3A(t) (6.10) dt 
dE k3A(t)- k4E(t) (6.11) dt 
op 0 (6.12) 
ot 
-or (kp(r)p(r, t))- f-L(r)p(r, t) ' r1 ::::; r ::::; r2 
d<I> 
akp(r2)p(r2, t)- f3<I>(t)- 6<I>(t) (6.13) dt 
oi 
- :r (ki(r)i(r, t))- f-L(r)i(r, t) , 
ot 
r2 ::::; r ::::; r3 (6.14) 
dB k5i(r3, t)- k1B(t) . (6.15) dt 
Here, the k/s are rate constants indicating the speed of progression through 
that part of the developmental cycle, and >.. is the loss of free Chlamydia due to 
natural death. The parameter, e, represents the effect of attachment blocking 
caused by antibodies, 0 ::; e ::::; 1 where e = 1 represents complete blocking of 
attachment and infection. The parameter, a, represents the proportion of cells 
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that move into the quiescent phase from p(r2 ), where 0 ~ a~ 1. The average 
number of EBs that are released from a bursting cell is modelled using the 
parameter P. Feedback from the persistent phase to the lytic cycle is modelled 
with the parameter (3, and 6 represents the natural death rate of persistent cells. 
We let the cytotoxic immunological attack terms be represented by f.-l(r). 
6.4.1 Cytotoxic Thl term 
It is reasonable to assume that loss of infected cells is governed by first order 
interaction between immune cells and the presentation of peptides. However, we 
assume that Chlamydia peptides are presented to immune cells in proportion to 
the number of RBs within the infected cell's inclusion. We let the population of 
immune cells responding against a Chlamydia-infected cell at timet be denoted 
by T(t) and assume the population of immune cells is changing according to 
dT (1~ 1~ )  = Ps-brT(t)+krT(t) Rs(r)p(r, t)dr + Rs(r)i(r, t)dr . (6.16) 
t Tl T2 
Here, Ps denotes a constant source of immune cells, 5r is their natural death 
rate and kr is the rate of activation ofT cells by presented peptides. However, 
over the time frame of investigation, we assume that kr is small and so T(t) is 
approximately constant since prior to infection, T = P8 /5r. We are assuming 
that the immune system does not respond quickly to the presence of RBs. Here, 
the immune cell population is fixed but in a later section we indirectly model 
change in the immune cell population with a rising secondary response, but we 
leave the modelling of changing immune cell populations to future work. 
Then, the cytotoxic effect of the immune system against an infected cell of 
maturity r is proportional to the number of intracellular RBs. Thus, we take 
this factor to be 
f.-l(r) = rJRs(r) (6.17) 
where rJ is the rate of immune response per intracellular RB and the population 
of RBs is given by equation (6.3). 
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6.5 Closed-form Solution 
6.5.1 Basic Reproduction Ratio 
The basic reproduction ratio is a fundamental concept in epidemiology and micro-
epidemiology [22, 23]. We define the basic reproduction ratio as the expected 
number of secondary cases produced, in a completely susceptible population, by 
one typical infected individual/cell during its entire period of infectiousness. 
The ratio is evaluated when abundance of uninfected cells is at pre-infection 
level. We obtain the following expression for the basic reproductive ratio of sec-
ondary chlamydia! particles produced per particle from our continuous Chlamy-
dia model: 
This result is consistent with equation ( 6.34), our non-trivial equilibrium crite-
rion in Appendix B. 
6.5.2 Solution to the Governing Equation for the Age-
Structured Model 
We would like to understand how the immune response, t-L(r), affects the growth 
of the chlamydia! population with time. Boundary conditions for p and i are 
given by 
p(O, t) 
di(r2, t) 
dt 
k4E(t) 
(1- a)kp(r2)p(r2 , t) + {3if!(t) . 
(6.19) 
(6.20) 
Initially, we assume that there are no cells infected with Chlamydia particles. 
At time t = 0 there is a small inoculum of EBs, of concentration C0 , introduced 
into the system. Then, the initial conditions are 
C(O) = C0 , A(O) = E(O) = R(O) = I(O) = B(O) = 0. 
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We solve equation (6.12) for the concentration of replicating cells at each 
maturation level, using the method of characteristics, to obtain 
kp(ro) ( 1r J-L(() ) 
p(r, t) = k4E(to) kp(r) exp - ro kp(() d( , (6.21) 
1r 1 where to= t- r kp(() d(, the time to progress to maturity r. 
specifically, with %P = 1, 
However, more 
(6.22) 
As expected, this solution shows that increasing the immune response, J-L, will 
decrease the number of host cells progressing through the replicating phase in 
an exponential manner. The limits of integration indicate the history property 
of a cell's maturity. The concentration at a particular maturity is influenced 
by the flow through the entire replicating phase since the time that the current 
cycle of infection began in the phase. The concentration of replicating cells is 
damped due to the immune response and transition rate throughout the phase, 
otherwise the solution for our continuous species, p, would be purely a travelling 
wave (a function of t - r). 
We obtain a similar solution and implications for the concentration of cells 
containing RBs converting to EBs, namely, 
(6.23) 
6.5.3 Parameter Estimation 
Average duration times of each phase within one developmental cycle are ap-
proximated from experiments [2] from which we obtain our transition rates. 
They are shown in Table 6.1 together with other model parameter values. 
6.6 Numerical Solution of the Model Equations 
When the system is solved numerically the critical behaviour depends on the 
basic reproduction ratio. If the basic reproduction ratio is greater than unity 
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then all species will increase without bound with time (what we term active 
disease). However, if the basic reproduction ratio is less than unity then the 
infection will be cleared for large times as the population levels tend to zero. If 
the basic reproduction ratio is equal to one, an equilibrium is set up, whereby 
the average source of infected cells into each phase is the same as the number 
that leave the phase and the developmental cycle continues, but all infected cell 
concentrations and Chlamydia numbers stay fixed. We define this equilibrium 
condition as controlled infection. In reality this generally will not occur because 
it requires precise conditions that will not occur for a fixed immune population. 
Mathematically, this situation will occur for a set of parameter values of measure 
zero. However, once varying populations of immune cells and host cells are in-
troduced one would expect a steady state corresponding to controlled infection. 
We solve for the three possible occurrences by altering the value of the immune 
response parameter, 7]. When R0 = 1 a threshold is defined, where we have con-
trolled infection, distinguishing between the other two occurrences. Figures 6.4 
and 6.5 illustrate the numerical solutions for our system. Behaviour of solutions 
where active disease occurs is illustrated in Figure 6.4. Figure 6.5 illustrates the 
numerical solutions when there is clearance of infection. We note that extracel-
lular chlamydial load is significantly smaller than the load of Chlamydia that is 
found intracellularly. 
6.7 Secondary Memory-Induced Thl Immune 
Response 
The immune system recognises and responds to subtle chemical differences that 
distinguish one foreign pathogen from another. Once an antigen has been recog-
nised, the immune system enlists the participation of a variety of cells and 
molecules to amount an appropriate response, called an effector response, to 
eliminate or neutrolise the organism. Later exposure to the same foreign organ-
ism induces a memory response, characterised by more rapid and heightened 
immune reaction that serves to eliminate the pathogen and prevent disease. 
When an antigen interacts with and activates mature, antigenically committed 
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Figure 6.4: Plots of populations of extracellular Chlamydia and the various phases of infected 
cells with time, for the case where Ro > 1, indicating active disease. Here, a = 0.5, e = 0.1, 
A = 0.2 and 77 = 0.000266. 
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Figure 6.5: Plots of populations of extracellular Chlamydia and the various phases of infected 
cells with time, for the case where Ro < 1, indicating clearance. Here, a = 0.5, e = 0.1, 
A = 0.2 and fJ = 0.000533. 
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T lymphocytes (and B lymphocytes) it brings about proliferation of the popu-
lation of cells. The antigen stimulates the cell to divide repeatedly into a clone 
of cells with the same antigenic specificity as the original parent cell. 
Thus, we consider that the strength of the maximum Th1 response will 
increase in effectiveness with time. We assume a similar form for our immune 
response, p,(r), over the phases of replicating inclusions and inclusions containing 
forms converting from RBs to EBs but consider the maximum immune response, 
denoted by the parameter ry, to be increasing with time, thus influencing the 
effect at every point of maturity. This is a straightforward way of modelling the 
secondary immune response. However, we capture basic general behaviour and 
leave the modelling of dynamically changing immune cell populations for future 
work. An appropriate form for ry, the response rate is 
( ) fJmaxt rJ = rJ t = t1;2 + t + rJo ' 
where f}o is the naive lymphocyte strength prior to infection, fJmax is the max-
imum increase of strength from the primary to secondary response and t 1; 2 is 
the time it takes for an increase of half the maximal increase in strength after 
primary contact with the antigen. The function, ry, as it changes with time is 
plotted in Figure 6.6. 
The basic reproduction ratio is typically defined as the growth per generation 
in a naive host. However, here we now consider the growth per generation in 
a host at any stage of infection and let the altered basic reproduction ratio 
expression be a function of the cell-mediated immune response rate, ry. That 
is, R0 = R0 (ry). The increased immune effectiveness and memory property is 
induced by clonal expansion and there are three possible cases for pathogenesis, 
ignoring precise conditions for the theoretical non-trivial equilibrium: 
1. Initially infection is under control (R0 (ry0 ) < 1) and then the immune 
system increases its control (Ro = Ro(rJo + fJmax) < 1). 
2. Initially infection is increasing (R0 (ry0 ) > 1) and despite a heightened im-
mune attack, the infection remains dominant ( R0 > 1), that is, the con-
centration of Chlamydia continues to increase and we have active disease. 
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3. Initially infection is increasing (Ro(rJo) > 1), however, the heightened im-
mune attack reverses the situation and eventually controls the infection 
(Ro < 1). 
We assume that case 3 occurs in most infections and it is the case of interest to 
us. Figure 6. 7 shows plots of species concentrations versus time for case 3. This 
occurrence will become more meaningful to experimentalists as data is obtained 
and fitted to the model. 
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Figure 6. 7: Plots of concentrations of extracellular Chlamydia and the various phases of in-
fected cells with time, for the case where R0 > 1 initially, indicating infection dominance but 
is overcome by an increasing immune action forcing Ro < 1. We assume that the amplitude of 
the oscillations is due to synchronization in the times EBs infect host cells for every generation. 
However, in reality, we would expect a distribution of infection starting times and oscillations 
would be less pronounced. 
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6.8 Discussion and Conclusions 
We have developed a model of the Chlamydia developmental cycle with empha-
sis on exploring the Thl immune impact against Chlamydia-infected cells over 
the developmental cycle. We developed an age-structured PDE as the tool to in-
vestigate the infected cell maturation and corresponding immune action against 
a cell of given maturity. Our model incorporates age-structured components 
and we generalise to maturation not necessarily time. The assumed form for 
the immune response, over the developmental cycle is derived by considering 
the presentation of peptides proportional to the number of replicating particles 
inside the host cell. We also investigated the secondary Thl immune response 
capturing basic behaviour of this response and leave the modelling of the dy-
namic interactions between immune cells to future work. However, we arrived 
at three outcomes for the long term behaviour of an infected individual or cell 
culture under secondary Thl immune attack. 
Parameters of our system were estimated and the system of equations was 
solved verifying our analysis and displaying plots of the various outcomes that 
our model indicates. Solution to our model equations demonstrated that increas-
ing immune response decreases the number of host cells progressing through the 
replicating phase at an exponential rate. The solution also demonstrated a mem-
ory property of cell maturity and cell dependence on its history. 
We have also obtained an expression for the reproduction ratio, namely, 
(6.24) 
This expression is obtained from the steady state analysis in Appendix B. We 
can interpret the factors in the expression for the reproduction ratio, outlining 
what is critical to disease progression. Firstly, the number of secondary cases 
produced depends on P, the average burst size of one lysing infected cell, which 
. . k2(1- e) . 
IS obvwus. Secondly, R0 depends on A wh1ch depends only on extracel-k2 + 
lular Chlamydia activity. The ratio depends on e, representing attachment of 
antibodies to EBs, and A, representing natural death and wash out of EBs. In-
creasing the parameter e will decrease the reproduction ratio, that is, decreasing 
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attachment to host cells by stronger blocking with antibodies. Also, increasing 
A, the clearance of extracellular Chlamydia due to wash out and natural death, 
k 
will improve clearance or control of the disease. Thirdly, -k 5 is a factor of 
5+77 
R0 • We consider this term to represent maximum Th1 effectiveness. Fourthly, 
the persistent phase may have an influence on overall disease progression, as 
(3 + 5- a5 
represented by the factor, (3 + 5 . The parameter, a, represents the pro-
portion of cells that move into the persistent phase from the purely replicating 
. . (3 + 5- a5 . phase. If the proportwn IS low, then (3 + 5 ~ 1 and the persistent phase 
has negligible effect on the overall progression of disease. However, if a¢ 0 then 
the factor, 1-~ , suggests that the rate of feedback into the normal lytic 
1+8 
cycle from the quiescent phase, (3, becomes important and should be decreased 
to assist in reducing secondary infections. Basically this is because if cells stay 
in the persistent form they are not sourcing the production of more infectious 
particles to commence new cycles. Eventually cells in persistent form will die 
naturally. However, adverse effects of persistent Chlamydia must be investi-
gated. This modelling suggests that inducing abnormal persistent infectious 
forms, by nutrient deprivation or increase of IFN-1 production, will decrease 
the chance of long term disease. Finally, the factor of most interest to us in the 
reproduction ratio, exp ( -1r2 ~~~~), reflects how the Th1 immune response 
effects the developmental cycfe and secondary infections. It is of interest that 
the immune response has an exponential effect on secondary infection numbers. 
This indicates the importance and strength of cell-mediated immunity relative 
to other factors in the system. Given the rate of extracellular chlamydia! clear-
ance and wash out rate, A, antibody blocking rate, e, and the proportion of cells 
that move into the persistent phase, a, along with the rate of feedback to the 
lytic cycle, (3, and natural death of persistent cells, 5, we can predict the critical 
immune response required to clear infection. 
Consider our general solution for the concentration of host cells containing 
replicating chlamydia! particles, equation (6.21), or the basic reproduction ra-
tio, equation (6.24), and the impact of changing the probabilistically inferred 
transition rate function, kp ( k). If the transition rate functions are reduced be-
low unity this implies that the inclusions are kept inside the cell for a longer 
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period of time. The longer the inclusion remains, the greater the opportunity 
for immunological attack and so the effectiveness of the Th1 response does not 
need to be as strong. This is verified by the impact on the exponential decay 
factor in equation (6.21). Decreasing kp will effectively boost the impact of the 
immune response function f.L· 
We suggest that maintaining inclusions for longer periods of time, slowing 
down the progression through the replicating phase will increase the chance 
of controlling infection. Different strains of Chlamydia have different lytic cycle 
times and it is interesting to note that one of the most virulent forms of Chlamy-
dia is the LGV biovar which has a relatively short cycle time which supports 
our findings. 
The modelling we have presented has commenced a within-host modelling 
approach to the study of Th1 action against infected cells, in particular, against 
Chlamydia trachomatis. It has outlined relationships between parameters, rep-
resenting the processes in the cycle, that determine the overall disease outcome 
of either clearance or disease. We have shown that the Th1 arm of the immune 
system is important and predicted how its effectiveness changes over the devel-
opmental cycle. It is possible to eliminate the bacteria with the Th1 response 
alone. We have provided a foundation upon which further modelling may be 
done to provide a complementary tool to interpret and extend experimental 
results. 
Appendix A: Derivation of the Governing Age-
Structured Model Equation 
We use a conservation law to derive the governing equation for the maturing 
species. Here, we discretise r and definer ---7 r + b.r as the interval to represent 
any r E [r, r + b.r). A replicating cell of maturity between r and r + b.r changes 
its density in the time interval [t, t + b.t) due to source from cells of maturity 
in the interval [r- b.r, r), loss due to maturity to the interval [r + b.r, r + 2b.r) 
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and a loss due to cytotoxic immune effects. This is represented by the following 
equation: 
p(r -t r + b..r, t + b..t)b..r- p(r -t r + b..r, t)b..r 
= kp(r- l:::,.r -t r)p(r -l:::,.r -t r, t)J:::,.r 
-kp(r -t r + b..r)p(r -t r + b..r, t)b..r 
-f-L(r -t r + b..r)p(r -t r + l:::,.r, t -t t + i:::,t)J:::,.rl:::,.t. 
Here, kp is a function representing the rate of transition through the phase. 
Dividing through by l:::,.r and i:::,t, subtracting and adding terms, and taking 
limits as l:::,.r -t 0 and i:::,t -t 0 , results in the following governing PDE, 
op 
ot 
opdr okp dr 
-k (r)--- p(r)--- f-L(r)p(r, t) p or dt or dt 
dr o 
- dt or (kp(r)p(r, t))- f-L(r)p(r, t) (6.25) 
Upon simplification, if r is seen to be chronological age of the cell, then ~: = 1 . 
Furthermore, if kp = 1 then 
op op 
ot + or = -f-L(r)p' (6.26) 
which is the Von Foerster equation. Then if f-L = 0, it reduces to a conservation 
equation which states simply that the species time rate of change is given by 
the rate at which the population gets older (matures), ~~ . 
Appendix B: Steady State Analysis 
From equations (6.9)-(6.11) we obtain the following steady state values: 
f3 = k2+>.. 0 (6.27) 
Pk1 
A (1- e)k2 0 
k3 
(6.28) 
E (1- B)k2 () 
k4 
(6.29) 
Since purely replicating cells and cells containing reticulate bodies converting 
back into infectious form are not only functions of time, t, but also of r, their 
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steady state values will depend on r. Equation (6.12) and the boundary condi-
tion, ,8(0) = k4E from (6.19), provide the means to find the steady state value 
for p(r) , namely, 
_ k2(1- B) ( lr Pl(~) ) -
p(r) = kp(r) exp - ro kp(~) d~ C' (6.30) 
Then, 
(6.31) 
Equation (6.14) can be used with boundary condition (6.20) to find I(r) , for 
r1 ::; r ::; r 2 , namely, 
Here, 
and 
Also, 
implying that either C = 0 or 
0 ::; r < r1 
r1 ::; r ::; r2 , 
0 ::; r < r1 
r1 ::; r ::; r2 . 
(6.33) 
Pk2k5(1-B)(f3+8-a8) exp ( -1~ ~~~~ d~) -(k2+l.)(k5+17)(f3+8) = 0. (6.34) 
If C = 0 then A = E = p(r) = <P = I(r) = B = 0 . This steady state is the 
disease-free trivial steady state. When condition (6.34) is satisfied, a non-trivial 
equilibrium is established theoretically and production of chlamydial particles 
is the same as that cleared during the developmental cycle. This indicates the 
critical level for infection or clearance, a threshold level. 
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Parameters and Constants 
k1 = rate of transition from B to C 
k2 = effective loss rate of C due to attachment 
k3 = rate of transition from A to E 
k4 = rate of transition from E to beginning of R 
k5 = rate of transition from end of R to <I> and beginning of I 
k6 = rate of transition from the end of I to B 
r 1 = length of R maturation 
r 2 = measure of maturity at end of I 
P = average number of EBs released upon bursting 
,\ = clearance and washing rate of extracellular EBs 
e = proportion of EBs blocked from attachment 
a = proportion of infected cells that move into the persistent phase 
TJ = rate of Th1 clearance of replicating infections per RB 
Values 
5 
4 (hours-
1) 
2 (hours-1) 
1 S (hours-1) 
1 
10 
(hours- 1) 
1 
6 
(hours-1) 
1 
16 
(hours-1) 
10 (hours) 
32 (hours) 
200 
varies (hours-1) 
varies (hours-1) 
Table 6.1: Parameter Values for Continuous Chlamydia Developmental Cycle Mathematical 
Model 
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Abstract: We develop a description of HIV mutations based upon a contin-
uum representation of the fitness of the virus, including the interaction of the 
virus with both specific Thl lymphocytes as well as cross-reactive cells. This 
deterministic model allows a straight forward measure of the diversity of viral 
population and reproduces the observed increase in diversity as the disease pro-
gresses in an untreated patient. We use the diversity threshold theory, extending 
the modelling to track mutations on a continuum. When the diversity threshold 
is exceeded, the host immune system collapses. 
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7.1 Introduction 
The development of AIDS is associated with the depletion of the most crucial 
cell type of the immune system, the CD4+ helper T lymphocyte. This occurs 
after a period of clinical latency varying in length from 1-2 years to more than 
15 years. The human immunodeficiency virus (HIV) and the immune system 
interact dynamically over the entire course of infection. HIV replicates in large 
numbers each day and also contributes to the destruction of cells of the immune 
system. This growth is usually balanced by a strong defensive response which 
keeps the virus in check. However, eventually the balance of power is transferred 
so that HIV gains the upper hand and causes this severe damage to the immune 
system. This defines the period of disease known as AIDS. 
As with all viruses, HIV cannot reproduce by itself. It relies on a host to 
assist reproduction. HIV targets CD4+ T cells which are the most abundant 
white blood cells of the immune system. Since CD4+ T cells play a key role in 
orchestrating both the humoral and the cellular immune response, the infection 
and destruction of this cell type by HIV has a devastating impact on the immune 
response. When HIV enters the body, it targets cells with CD4+ receptors. The 
gp120 protein on the viral particle binds to the CD4+ T cell receptors and the 
HIV particle injects its core. HIV, being a retrovirus carries a copy of its RNA, 
which is first transcribed into DNA. After the processes of reverse transcription, 
integration of viral DNA into cellular DNA, translation forming polypeptides 
and protease, and cleaving of polypeptides by protease into functional HIV pro-
teins, the infected cell is stimulated to produce copies of the virus, releasing 
hundreds, or even thousands, of free virus particles that can infect other CD4+ 
T-cells. We assume that peripheral blood CD4 counts (generally 1000/ p,L in 
healthy persons) are a good indicator of CD4 densities in the body. Since the 
CD4+ cells are depleted over time, strengthening cytotoxic responses cannot oc-
cur. The loss of immune competence enables normally controllable diseases to 
cause opportunistic infections. In addition to a reduced CD4 count, one of the 
reasons for the specific immune response dysfunction is that viral epitopes also 
change resulting in escape from immunological response. 
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Initially, the transformation of immune-sensitive to resistant genotypes oc-
curs by the generation of mutations primarily due to reverse transcriptase errors. 
HIV's RNA genome is reverse transcribed into DNA when the virus replicates. 
Amplification of mutant genotypes by selection, and then fixation of the resis-
tant population aids in the problem of resistance. These mutations are changes 
in DNA structure, and therefore changes in protein and phenotype. The mu-
tations we consider are caused by spontaneous errors during DNA replication 
(base substitutions), or frame shift mutation (addition or deletion of a base). 
They are heritable and may be beneficial, neutral or detrimental to an organism. 
In contrast to most other infectious agents, HIV combines a very high mutation 
rate with a very large production of virions. The extreme heterogeneity and 
diversity of HIV makes the design of effective vaccines extremely difficult [1]. A 
virus' biological fitness determines its survival. It is this phenomenon, of viral 
mutation, causing escape from immunological attack, that we address in this 
paper. 
The understanding of the dynamics of antigenic escape from immunological 
response has been that a mutation may enable the virus to have a selective ad-
vantage. Mansky and Temin found that the level of genetic variation of HIV is 
high relative to similar retroviruses, although not as high as earlier predicted. 
They were able to estimate the mutation rate for HIV (See below) [2]. 
There is measurable variation among the replication rates of HIV strains 
in CD4+ cells [3]. Mathematical models for the interaction of HIV and CD4+ 
suggest that evolutionary forces may drive selection for more virulent strains 
[4, 5, 6]. The observations that the apparent diversity of viral strains increases 
with time [7, 8] has eventually lead to the conclusion that evolutionary dynamics 
of HIV quasispecies is not a consequence but a cause of immunodeficiency [9]. 
In this paper, we suggest a novel approach to considering viral diversity and the 
progression of mutation towards diversity threshold at which time AIDS results. 
The number of immunologically different mutants appears to be very large. 
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Genetic variation is not uniform throughout the HIV genome. There is more 
variablility in the env gene than in the gag or pol genes. Within the env gene 
there are five hypervariable regions. Much attention has been paid to the third 
hypervariable region, the V3 loop because it has immunodominant properties. 
The combinatorial possibilities of the 19 variable amino acids in the V3 loop 
of the env protein is 1920 , and furthermore the shape of the loop can also be 
altered by mutations in other parts of the envelope protein [3]. For information 
on genetic and antigenic variation of the V3 loop refer to [10, 11, 12] 
The complexity of the retroviral lifecycle results in difficulty in estimating 
the rate of mutation. However, Mansky and Temin state that the error rate has 
been estimated as 3.4 x 10-5 per base per replication cycle. Since the average 
HIV genome has approximately 104 bases, the average changes per genome is 
approximately 0.34 per replication cycle [13]. In addition to the occurrence of 
large antigenic variation that occurs due to this probability, a very large num-
ber of virions are produced each day during the asymptomatic period of HIV 
progression before AIDS [14]. 
During early stages of infection the viral strains that are most prevalent in 
initial infection dominate the dynamics. As the immune response to HIV is 
initiated virus diversification results. This antigenic diversity makes it difficult 
for the immune system to control the different mutants simultaneously and the 
virus runs ahead of the immune response. This is also because there is an asym-
metric interaction between immunological specificity and viral diversity. Martin 
Nowak was the first to point out this asymmetry with the diversity threshold 
model (See [3, 15, 16, 17, 18]). That is, each viral strain can infect all immune 
cells with CD4+ protein, but individual strain-specific immune cells can only 
attack specific virus strains. The outcome of mutation is that each viral genome 
must be viewed as being different from any other but at the same time viral 
strains may be thought of as populations of closely related genomes. The im-
mune system is then persistently confronted with new antigen targets before it 
has built up a defence to antigen already present. 
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It has also been suggested that viral genetic diversity is caused by the host 
immune response. Findings by Lukashov, Kuiken and Goudsmit and Wolinsky 
et al. indicate that HIV undergoes adaptive evolution in vivo, in response to 
selective pressure exerted by the host immune system [19, 20]. Evidence for 
immune-response dependence of virus mutation can be observed by noting that 
viral genetic diversity is greatest in clinically healthy individuals and much less 
in persons with AIDS, where the immune response has become severely impaired. 
Many have mathematically modelled virus mutation in a discrete form in 
an attempt to understand this phenomenon (see, for example, [3, 5, 13, 21]). 
But since there are a large number of mutations and each is considered to be 
very closely related to its parent strain, it seems that a reasonable proposal is to 
model mutation in a continuous form. This gives rise to this novel continuous 
model. The model of Nowak et al. involving the tracking of many viral variants 
is extended here whereby antigenic diversity and immune response are consid-
ered as a continuum [3]. In our model, we assume that all possible mutants will 
exist at all times, even if at minute concentrations, and the viral distribution 
will change form or shift as mutation occurs. 
7.2 Modelling Viral Mutation 
In this section we present the essential mutation concepts for our mathemat-
ical model that explores antigenic drift of HIV. Mutations are assumed to in-
volve small changes in the gene sequence of a viral strain. These small se-
quence changes may alter the viral properties considerably. However, we con-
sider viruses associated with a neighborhood of sequences in sequence space 
around a given sequence to have very closely related properties. Here, we are 
assuming the existence of criteria for defining a neighborhood of gene sequences 
in sequence space such that all viruses containing sequences in this space have 
quantitative properties in a measurable neighborhood. The properties of a virus 
are influenced by many aspects associated with the complicated sequence. We 
suggest that all viral strains, influenced multi-dimensionally, can be ordered and 
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mapped onto a one-dimensional continuum. In reality amino acids are discrete 
and mutations are obviously not continuous. But for reasons of elegance we de-
velop a continuous mutation model. In our model, we let V(t) be the total virus 
population, and v(r, t) be the population of virus identified by parameter r at 
timet. The identifier for a viral strain, r, is an attribute measuring the strain's 
fitness. We regard the non-negative parameter r as a continuous variable. We 
refer to fitness as an ordered measure of competitive advantage. One way to 
define fitness is in terms of the the basic reproduction ratio of the population 
[22, 23, 24, 25, 26]. For mathematical convergence and to reduce our assump-
tions we define the domain of r to be finite, such that 0 ::; r ::; M. Thus defining 
fitness in terms of the standard reproduction ratio would not be appropriate in 
our model due to the consequent complexity. 
The total virus load at time t is given by 
V(t) =1M v(r, t)dr. (7.1) 
The time rate of change of viral strain r is given by 
~~ =,\1M k(r, r')v(r', t)dr'- ,\1M k(r', r)v(r, t)dr' + f-L(r, t) . (7.2) 
Here, ,\ is the replication rate per unit time and k(r, r') is the probability that 
viral strain r' mutates to viral strain r. We consider mutations to and away 
from viral strain r. The function, f-L(r, t), describes the net growth rate of the 
viral strain with fitness r. This function is described later. 
Since a virion's genome changes only slightly as it mutates, we assume that 
this affects the fitness parameter, r, incrementally. Here, we assume that small 
genome mutations influence small changes in the corresponding viral fitness 
properties although it is possible that this results in a large change in viral fit-
ness. Then for r' =/= r we assume the form, ae-f3(r-r') 2 , for the probability of 
mutation from strain r to strain r', where a and f3 are to be determined. 
However, for r = r', there is no mutation. Thus we include an atom P0 (r), 
for k(r, r), obtaining a quasi-continuous distribution. We have already resolved 
153 
that the probability that a genome will change in a replication cycle is 0.34. 
Then P0 = 0.66, independent of r. We obtain a probability distribution of the 
form 
k(r, r') = { 
Equation (7.2) becomes 
Po , 
-{3(r-r')2 ae , 
r = r' 
r f=- r' . 
fJv(r, t) 1M fJt =A 
0 
k(r, r')v(r', t)dr'- A (1- Po) v(r, t) + J-L(r, t) . (7.3) 
To determine a, we consider lim k(r, r') = a , and suggest a parameter e, 
r-+r1 
0 ~ e ~ 1 such that a = eP0 . If there is no mutation, v is independent of r, 
e = 0 and we set P0 = 1 . Then ~~ = J-L(r, t). If e = 1 the probability density 
function is continuous suggesting that the mutations occur readily from strain 
r, however, the mutations will be closely related to the parent strain in fitness 
properties. The smaller the parameter e takes, the more likely it is that a mu-
tant will have properties away from the parent strain. Mutation occurs during 
the reverse transcription process in an infected immune cell and then mutant 
virion will be released from the infected cell. Thus, we indirectly model muta-
tion amongst released virions by modelling species shifts in the viral population 
distribution. 
Since k is a probability density function, we require 
1M k(r, r')dr' + k(r, r) = 1 . 
Thus, (3 = (3(r) and 
e~o [;ii (erf(r~)- erf((r- M)~)) +Po -1 = 0. 
This equation allows the determination of the value of (3, given a value of 
r. The function, (3(r) will be symmetric about r = ~. A plot of (3 versus r is 
shown in Figure 7.1. It should be intuitive that (3 is a function of r as illustrated 
by plots of k(r, r') for fixed r in Figure 7.2. We choose values for the parameter 
e so that (3 > 0 for realism. If e is too low, (3 will become negative indicating 
higher likelihood of mutation to a fitness farther away from the parent strain. 
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7.3 Modelling Immune Interaction with Anti-
gen 
The immune system is capable of generating vast diversity in its recognition 
of foreign antigens and distinguishing subtle differences between them. Lym-
phocytes adapt to recognize a particular molecular configuration on cells to be 
attacked. Lymphocytes are generated with random receptors for antigen. A 
T-lymphocyte has of the order of 105 receptors each with an identical specificity 
for a particular antigen. Goldsby, Kindt, and Osbourne state there are of the 
order of 109 antigenic specificities in the immune system although this is later 
diminished through a selection process in the thymus ensuring that there are 
only non-self receptors [27]. Once an antigen with particular specificity is rec-
ognized by aT-lymphocyte, the lymphocytes become activated causing clonal 
expansion, so that a much higher proportion ofT-lymphocytes will be able to 
recognize any further infection, providing the basis of immunological memory. 
Since there is great diversity in the immune specificity, we consider s(r, t)dr to 
be the total number of T lymphocytes with specificity for viral antigen with 
fitness between r and r + dr at time t. 
Null cells, a type of lymphocyte that generally makes up about 5-10% of 
all lymphocytes in human blood [27], do not express the membrane molecules 
and receptors that distinguish T and B lymphocytes. They lack immunological 
memory and specificity but have shown cytotoxic behavior against a variety 
of antigens. In addition, when a mutation occurs, the viral epitope may be 
conserved so that a lymphocyte species with committed specificity may respond 
against multiple strains. Phagocytes, activated macrophages and other CD4+ 
cells that can mount immunological attack against different antigenic strains are 
known as cross-reactive cells. Here, we assume cross-reactive cells have negligible 
influence on our investigation of the evolution of mutation (see Nowak and May 
[28] for modelling with cross-reactive cells). In our model, the population of 
immune cells (majority T lymphocytes), T, at timet is given by 
T(t) =1M s(r, t) dr. 
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Many models distinguish between effector cells and target cells, generally 
CDS and CD4 cells, respectively. Since the population of effector cells are di-
rectly influenced by and signaled by target cells we combine the two immune 
cell types into the one population. Time rate parameters will incorporate the 
proportion of cells that are of each type. We assume that the change in the 
strain specific population is given by 
as(r, t) 
at = s1 + Ps(r, t) - 5ss(r, t) - k1 V(t)s(r, t) , (7.4) 
where s1, 5s and k1 are constants. The parameter s1 represent the source of 
immune cells originating in the thymus for the strain specific immune popula-
tion. Although there are various algebraic expressions that may be used for the 
source of immune cells, for simplification we take the source, s1, as constant. 
The parameter, 58 , represents the rates of natural death for immune cells. The 
constant, k1, represents the rate that the immune cells are infected with virus. 
The term Ps(r, t) represents the immune response of clonal expansion from exist-
ing cells (mainly memory cells), once activated. We assume activation occurs by 
interaction with virion. When an antigen binds to an antigenically committed 
T (or B) lymphocyte, the cell is stimulated to divide repeatedly into a clone of 
cells with the same antigenic specificity as the original parent cell. Specificity 
and immunological memory are consequences of clonal expansion. We assume 
that HIV-induced clonal expansion is limited by an immune cell-dependent re-
action and consequently is governed by a mass action term. We describe the 
proliferation as mass action saturated by the concentration of antigen presenting 
. ( ) P1 v(r, t)s(r, t) A . 
s1tes. Thus, we take P8 r, t = ( ) . sim1lar form has been used by 
c1 + v r, t 
Kirschner [29]. Here, p1 is constant and c1 is a saturation constant giving the 
concentration of antigenic sites at which the rate of proliferation is half-maximal. 
We denote the total population of immune cells that have become infected 
at timet by I(t) where 
I(t) = 1M i(r, t) dr , (7.5) 
with i(r, t) representing the population at time t of cells infected with virus of 
fitness r. We assume that these species populations are governed by 
ai(r, t) 0 0 0 
at = Si(t)v(r, t)- 5I%(r, t)- P21,(r, t)- Im(r, t)1,(r, t) . (7.6) 
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Here, Si(t) is a source rate denoting infection of a healthy immune cell and 51 
is a natural death rate. As infected cells are activated we assume they die, re-
leasing infectious virion. This occurs at a rate p2 , incorporating activation of 
the infected cell by a large range of cell types to release its virion. N virions 
are released and will become a source for the viral population of type 'r'. The 
function, Im(r, t), represents the rate of cytotoxic effect the immune system gen-
erates against virus-infected cells. 
Strains with greater fitness parameter values have a competitive advantage. 
We could consider many combinations of factors to influence the selective ad-
vantage of a viral strain. However, here we regard the immune response against 
an antigenic variant to be the influencing factor determining strain fitness in an 
attempt to model immune evasion by means of evolutionary drift. We assume 
that the cytotoxic immune response function is given by Im(r, t) = r;(r)s(r, t) . 
Here, we consider the immune response to be of the form given by the decreasing 
function r;(r) = r;or() , where r;0 , n and r0 are constants. The parameter TJo 
r0+rn 
is the maximum immune response against the strains of lowest fitness and r0 is 
the fitness value in which the immune response is half maximal. The parameter 
n is a shape factor. 
The total source rate of infected cells is given by 
Si(t) = V(t) 1M k1s(r, t)dr = k1T(t)V(t) = k1T(t) 1M v(r, t)dr , 
where k1 has been described above. Then, we take the source of cells that are 
infected with viral strain r to be k1T(t)v(r, t) . 
7.4 Model Terms for Change in Viral Popula-
tion 
We have seen that our model presents the total change in viral load by the term 
J0M f.L(r, t)dr. We now specify the components of M(r, t) to describe the aspects 
of the HIV lifecycle that effect its change in population. 
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We consider that the rate of change of virus concentration is influenced by 
a source of new virions released from activated infected cells and loss due to 
natural death. We assume the rate of change of viral strain 'r' to be given by 
~~ =..\1M k(r, r')v(r', t)dr'- ..\ (1- P0 ) v(r, t) + Np3i(r, t)- 8vv(r, t) . (7.7) 
Here the parameter 8v is the rate of natural death and N is the average 
number of virions that are released from an infected cell. Although variant 
strains are released at this stage of the viral lifecycle, since mutation occurs 
inside the host cell when reverse transcription errors arise, for simplicity we 
model mutation exterior to the host cell amongst the viral dynamics. 
7.5 Initial Conditions 
We assume that the initial inoculum of virus consists of one strain of Vo per mL 
and that the initial strain has the weakest fitness, which for convenience we have 
taken to be r = 0. Then, 
v(r, 0) = { Vo6~r' 0 ~ r ~ 8r 
r > 8r. 
Since we model on a continuum, immediately after inoculation all strains will 
exist, sourced from the initial strain, even if at minute concentrations. We as-
sume that initially there are no infected immune cells so i(r, 0) = 0 . 
Typically, a healthy person will have an average of 1000 CD4 + cells/ pL of 
blood and so we take T(O) = 1000. In the maturation process for lymphocytes 
the random gene rearrangements generate an enormous diversity of antigenic 
specificities before its contact with antigen. Since generation of specificity is 
random, before inoculation we assume a uniform distribution of strain specific 
cells and so s(r, 0) = T~). 
7.6 Measuring Diversity of Model HIV Strains 
To measure how genetic variation within the HIV quasispecies changes with time 
we consider the ecologist's Simpson Index [30]. A diversity index is a measure 
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of species diversity in a community. Diversity indices provide more information 
about community composition than simply species richness (i.e., the number of 
species present). They also take the relative abundances of different species into 
account. Simpson's Diversity Index, D, is a simple measure that characterizes 
species diversity in a community. In our case of continuous HIV strains, we take 
D - D (t)- [V(t)]2 
v- v - foM [v(r, t)]2 dr ' 
so that initially Dv(O) = Or ----> 0 for infinitesimal Or. We also track a diversity 
index for immune strain specific cells to indicate how the immune response is 
adapting to the presented antigen. Then, we let 
so that initially Ds(O) = M. Using our adapted Simpson's diversity index for the 
continuous case, we see that 0 ::; D ::; M where a small value of D corresponds 
to little diversity. 
Antigenic change is important to the success of the virus. We would expect 
to see antigenic change in our model and therefore see the value of Dv increase to 
resemble the high mutation rate. Over time, antigenic drift will occur whereby, 
in a practical sense, gradual mutation of the gene sequences for the glycoproteins 
will occur at a constantly slow rate and there will be a shift in the distribution 
of viral dominance. The value of Dv will reflect this shift. Accordingly, the 
strain specific immune cells will adapt to confront the presenting challenge of 
HIV strains. In effect, since most CD4 immune cells do not contribute to the 
destruction of the virus but are merely targets for the virus, because of the 
asymmetric dynamics, they, in fact, make a negative impact on the system as 
a whole. The distribution of strain specific cells will attempt to reflect the dis-
tribution of viral strains and the adapted Simpson's diversity index for immune 
diversity, D8 , will track the immune system's evolution. 
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7.7 Results 
Prior to infection we expect initial conditions to be the constant population 
levels for all species and therefore, from equation (7.4), 0 = s1 - 08 T0 . Thus, 
08 = ~ . The parameter values are shown in Table 7.1. Some parameter values 
may vary from individual to individual. The values of parameters are taken 
from other models [29, 31, 21]. Numerical simulations can now be carried out 
and the output is presented in Figures 7.3 - 7. 7. 
Parameters and Constants 
M =Upper range of domain of all measured fitness's 
Vo = Initial inoculation concentration of virus 
P0 = Probability that HIV genome will not mutate in a replication cycle 
e = Measure of amount of mutation 
a = Coefficient of mutation function 
,\ = Rate of mutation /replication cycle 
N = Average number of virions released upon bursting of infected cell 
fiv = Rate of natural death of HIV 
68 = Rate of natural death of strain specific immune cells 
61 = Rate of natural death of HIV-infected immune cells 
rto = Maximal rate of infected cell death due to cytotoxic immune cells 
r0 = Fitness value for which the immune response is half maximal 
n = Shape factor for the immune response function 
s1 = Total source of strain specific immune cells from the thymus 
p1 = Maximal proliferation rate constant (Strain-specific cells) 
p2 = Release of virion from infected cells rate constant 
c1 = Viral half-maximal saturation constant for proliferation 
k1 = Rate of HIV-infection of immune cells 
Table 7.1: Parameter Values for HIV Mathematical Model 
Values 
1 
10-3 
0.66 
o~e~1 
a =ePa 
0.38 
1000 
3.33 
0.01 
0.5 
0.001 
M 
2 
4 
10 
0.01 
0.001 
100 
0.001 
In our simulations in which immune cells are depleted we see an increasing 
antigenic diversity until a threshold level, a competitive reduction and then 
approximately constant diversity thereafter (Fig. 7.3). The rapid change in the 
dynamics of the virus diversity occurs prior to immune collapse. The immune 
distribution is not specifically targeted enough to handle the relatively peaked 
viral distribution. Towards the end of our simulation we observe a decrease in 
immune specificity to combat the virus but it is too little-too late. We suggest 
that to control the viral load, the immune diversity would need to be as small 
as the viral diversity (obviously evolved to specificity around the peak viral 
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distribution). Then, extraneous immune cells are not purely target cells for HIV 
but effector cells against the virus. 
CD 
0 
(_() 
::n • 
~o 
Ul 
L 
OJ 
> 
·~ ::l-
0· 
0 
ru 
0 
e-----
/ 
/ 
2 
I 
I 
I ' 
' I 
3 5 6 7 
time (~rs) 
8 
""' 
" \ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
" 
9 10 11 
Figure 7.3: Simulation showing change in Adapted Simpson's Diversity Index for viral pop-
ulation and specific immune cell population with time. D 8 (long dashed line), Dv (shorter 
dashed line) 
7.8 Discussion 
A key cause for HIV's devastating impact is the generation of mutants primarily 
due to reverse transcription errors enabling the virus to escape from immuno-
logical response. The level of genetic variation of HIV is high and the number 
of immunological mutants is very large. Immune resistance is thought to be 
induced by mutation and so has been the topic of much study. The mathemati-
cally modeling of a finite number of mutants in a discrete form has been carried 
out by other researchers (for example, May and Nowak). However, we consider 
mutations on a continuum to more accurately represent the antigenic diversity. 
162 
0 
lJ) 
-1 
lJ) 
ru 
-1 
0 
0 
-1 
0 
lJ) 
lJ) 
ru 
2.5 
time 
0 
0 
ro 
0 
0 
,.....(() 
.... 
._, 
1-
0 
0 
::1-
0 
0 
ru 
Figure 7.4: Simulation of model equations accounting for immunological memory. Resembles 
the typical course of infection in an untreated patient. (a) Total viral load with time. (b) 
Total immune cell population with time. 
m 
lJ) 
ru 
ru 
lJ) 
0 
2.5 5 
time 
7.5 10 
0 
0 
ro 
0 
0 
,.....(() 
.... 
._, 
1-
0 
0 
::1-
0 
0 
ru 
a~~~~~~~~~~~~~~ 
2.5 5 7.5 10 
time 
Figure 7.5: Simulation of the dynamics without mutation. (a) Total viral load with time. (b) 
Total Immune Cell Population with time. 
163 
0 
0 
n 0 ...; 0 00 ...; 0 00 0 0 0 00 0 If) . 
...; 0 
0 0 (!) ru 0 0 
,...,...; 
,...,(!) 0 ..... . 
.... .... ;::a 
'-" ....... 
>o 1- ci 
en 0 ::1-0 0 0 
::1- . 
0 0 
(!) 
0 ru 0 0 0 
0 ru . 
m 0 
0 0 \ 0 2 If- 2 If-
time time time 
Figure 7.6: Simulation of the dynamics with low effector immune response. (a) Total viral load 
with time. (b) Total Immune Cell Population with time. (c) Adapted Simpson's Diversity 
Index with time. 
1.() 
0 ::1-0 
0 0 0 0 
...; 1.() 
m 
::1- . 
0 0 
0 
m 0 0 
co . 
0 
m 1.() ru 0 0 . 0 0 0 
..... ,...,(!) ..... 
.... 
.... +'fU 
'-" '-" DO > 1-ru 
0 0 1.() . 0 ...; 0 ::1- . 
0 
...; 
...; . 
0 0 0 
. 0 
0 ru 1.() 
0 
. 
0 
o\ 0 0 5 10 5 10 5 10 
time time time 
Figure 7.7: Simulation of the dynamics with low rate of infection of immune cells. (a) Total 
viral load with time. (b) Total Immune Cell Population with time. (c) Adapted Simpson's 
Diversity Index with time (see text for description) 
164 
Our model adequately represents the natural course of HIV in a typical un-
treated patient (See Figure 7.4). We have varied parameters to identify key 
aspects leading to AIDS. Our model suggests a number of conclusions about the 
dynamics of HIV as it interacts with the immune system and the evolutionary 
drift of the virus frequency to evade the immune response, eventually resulting 
in AIDS. 
Nowak and colleagues have proposed the existence of an antigenic diversity 
threshold, in which the genetic diversity of HIV is ever-expanding and eventually 
exhausts the immune system's capacity to respond, resulting in immune collapse 
[3, 32, 33]. Although a well-presented theory, direct support for this theory has 
been elusive. Our model incorporates the assumptions of the diversity threshold 
theory and consequently our numerical solutions show this. We suggest that if 
mutation is rapid, which we assume it is in vivo, then the virus will run ahead 
of the immune system's capacity to withhold the virus' impact. We measure 
diversity with an adapted Simpson's index. We suggest that to control the viral 
load, the immune diversity would need to be as small as the viral diversity. 
Without mutation the immune system can control the impact of HIV in-
fection and the level of immune cells remains at a steady value, although at a 
compromised level in comparison with the pre-infection level, as illustrated in 
Figure 7.5. Thus, our model leads us to conclude that mutation is important 
to the pathogenesis of disease. If mutation occurs readily and there is a high 
probability that mutant strains are closely related to the parent strain in re-
gards to fitness, then evolutionary drift to escape immune response will occur 
but it will occur quite slowly. In fact, in this case large antigenic drift will not 
occur because there are high levels of strains in a local area which actually forces 
immune evolutionary drift through proliferation. Proliferation, regardless of its 
extent, will not be adequate to prevent immune collapse. However, if mutation 
from a strain has a high likelihood of obtaining a significantly different fitness, 
then evolutionary drift will occur rapidly. It will occur at a rate which is too 
rapid for the immune system to adapt and the virus will eventually dominate 
the system, resulting in AIDS. Here, the rate of immune depletion is noticeable 
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immediately and immune cell levels continue decreasing steadily, as opposed to 
most situations in which there is a slower decrease in immune cells during the 
majority of the dynamics before a rapid decrease. 
Proliferation of naive cells to stimulate memory cells is crucial in the im-
mune defence. Our model suggests that if the proliferation of immune cells is 
high, then, despite the increased proliferation enabling immune control over the 
antigenic drift in fitness of antigens for a prolonged time, the immune response 
will never be strong enough to contain the virus and AIDS will result. Here we 
observe immune specificity frequencies drift with the antigenic drift yet it is still 
not adequate to withhold the virus. If the proliferation of immune cells is low 
then viral dominance occurs early in infection and immune cell depletion will 
occur quickly. 
If the effector immune response is low then there is not a strong drive in the 
evolutionary drift of HIV frequencies. However, the killing of infected cells is 
reduced enabling the virus to replicate quite freely. Because the cytotoxic effect 
of the immune system is low the virus maintains control and depletes immune 
levels. It does this despite only a small drift in diversity (see Figure 7.6). In con-
trast, if the effector immune response is high then there is a greater evolutionary 
drive to evade the response but less virus replication due to killing of infection. 
For a very large effector response our model suggests it is theoretically possible 
to eliminate the virus. Here there is a strong drive for drift of HIV frequencies 
to higher fitness but the high fitness values are still able to be controlled by the 
high effector response. In practice, we suggest that immune cytotoxic levels can 
not be driven this high, but we suggest that it is possible to eliminate disease 
with a high rate of clearance of infected cells. 
Our model also suggests that if infection of target cells occurs rapidly then 
immune cell levels are depleted early and the virus soon dominates the dynam-
ics, and does so without full antigenic drift. However, if the rate of infection is 
small then large antigenic diversity will result, with viral frequencies drifting to 
high fitness values, but the virus levels may be contained and, in fact, cleared 
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by the immune system (shown in Figure 7. 7). If infection of target cells can 
be reduced, the virus will not have its devastating impact. In practice, drugs 
such as protease inhibitors have shown these effects. However, over an extended 
period of time, protease inhibitors will not completely eliminate the virus. 
We suggest that under normal circumstances all of the factors we have pre-
sented that hinder immune control of HIV will exist in a typically infected in-
dividual. Our model suggest that building immune defence to remove HIV by 
strengthening T cell proliferation is not a viable strategy for preventing the on-
set of AIDS. However, diminishing the rate of infection of target cells by HIV, 
or highly increasing clearance of infected cells can lead to HIV eradication the-
oretically. Our model suggests that mutation of HIV is a crucial aspect of its 
dominance over the immune system. We support the antigenic diversity thresh-
old theory. Our continuous model for antigenic drift gives rise to this threshold, 
leading to the onset of AIDS. 
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Abstract: Chlamydia is an important pathogen which possesses a unique devel-
opmental cycle. We used real-time PCR technology to measure gene transcript 
levels in Chlamydia trachomatis strain 12. By measuring 168 rRNA transcript 
levels, and developing a mathematical model of the chlamydia! developmental 
cycle fitting the data, we predict an average generation time of approximately 
2.6 hours. Additionally, potentially this modelling also provides the foundation 
for the application of emerging micro-array technology in which identification of 
the gene signals that trigger a chlamydia! body to start replicating or transform 
to its infectious form can be made possible. 
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8.1 Introduction 
Infection with Chlamydia is common around the world where human chlamydial 
infections are predominantly caused by Chlamydia trachomatis and Chlamydia 
pneumonia. C. trachomatis infection leads to trachoma, the highest cause of 
preventable blindness, and is also the most common human sexually transmit-
ted disease. C. pneumoniae causes a broad spectrum of respiratory disease, 
including pneumonia and is associated as an etiological agent for atherosclero-
sis. Although chlamydial infections can be effectively treated with antibiotics, 
many infections are asymptomatic resulting in worsening disease when left un-
diagnosed and untreated. 
Chlamydiae are obligate intracellular parasites with a unique developmen-
tal cycle characterised by the inter-conversion between morphologically differ-
ent forms (see Figure 8.1). Development commences when the infectious and 
metabolically inert chlamydial cell, termed the elementary body (EB), attaches 
and enters a susceptible host cell where it remains in the host-derived vacuole 
known as the inclusion. The EB reorganises its outer membrane and DNA 
structure during the first 6-8 hours post-infection (PI) prior to developing into 
a replicative reticulate body (RB). The metamorphosis of EB to RB includes 
passage via an intermediate body (IB), and although this form of chlamydiae is 
not part of the classic developmental cycle it is relevant to our investigations. 
The RBs subsequently divide by binary fission until approximately 12-18 hours 
PI when chlamydial development becomes asynchronous with some RBs con-
verting to EBs and others still replicating. The re-organisation of RB to EB 
involves an IB that can not be classified as either EB or RB. As development 
continues into the late phase of the cycle more RBs are committed to becom-
ing EBs and the proportion of EBs in the inclusion increases. The end of the 
developmental cycle is characterised by the release of infectious EBs from the 
host cell, the whole process taking approximately 40-72 hours for C. trachomatis. 
Current estimates for RB doubling times range from 2 hours (McClarty, 1994) 
to 3 hours (Mathews et al., 1999). Additionally, the rate of RB commitment 
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Figure 8.1: Schematic representation of the developmental cycle of Chlamydia. The different 
stages of chlamydia! development are illustrated commencing when the EB attaches to the 
host cell (I) and is endocytosed within the first 2 hours PI and remains within the inclusion 
(II). From 2-8 hours PI the EB commences transformation via an IB (III) to become a RB 
(IV). The RBs multiply within the inclusion (V) before some RBs convert to EBs and some 
RBs continue to divide after 12 hours PI (IV). RBs that have committed to become EBs are 
classified as IBs. Late development (VII) is identified when RB multiplication has slowed 
down and RB to EB conversion is at the highest rate (24-48 hours PI). 
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to EBs is not known apart from relatively simple modelling by Mathews et al. 
based on two general term sequences although this lacks a firm biological basis. 
Because chlamydia! development is asynchronous it is difficult to determine the 
number of chlamydia! bodies and progression of infection. Here, mathematical 
modelling can be utilised to track and predict the population of each type of 
chlamydia! body throughout the developmental cycle. We use recently developed 
quantitative real-time Polymerase Chain Reaction (PCR) technology to measure 
gene transcript levels (RNA) of the chlamydia! 168 rRNA gene. PCR increases 
the number of Complimentary DNA (eDNA) copies generated from the RNA. 
We obtain more real-time PCR data than has been obtained previously and 
we develop a mathematical model to fit the data in order to obtain a better 
approximation for the RB doubling time, and the rate of RB to EB commitment. 
We predict, based on our data, that for C. trachomatis 12 the doubling time is 
between 2.56 hours and 2.63 hours (95% confidence) with a best fitting doubling 
time of 2.59 hours. 
8.2 PCR Experiment Materials and Methods 
Despite the importance of chlamydia! disease, the developmental expression of 
relatively few genes has been determined. The major difficulties in quantitative 
analysis of chlamydia! gene expression are the inability to culture Chlamydia 
in a host-free environment, the asynchronous nature of chlamydia! development, 
measuring the low level transcripts within the host cell background and difficulty 
in standardising for the number of chlamydiae within an inclusion. Although 
many studies have been significant in reporting quantitative gene expression, 
most have not been standardised for the number of chlamydia! particles to pro-
vide a measurement of gene expression. Consequently, the presence of increased 
mRN A or protein levels may be associated with increased chlamydiae per host 
cell. Nevertheless, the relative developmental expression profiles of several genes 
have been determined with euo being described as an early gene (Zhang et al, 
1998), omcB, hctA and hctB as late genes (Koehler et al, 1990; Hackstadt et al, 
1991; Perara et al, 1992) and many genes expressed constitutively, including the 
168 rRNA gene (Engel and Ganem, 1987) and the groE8L operon (Lundemose 
177 
et al, 1990). More recent investigations have increased the repertoire of known 
developmental-stage-specific expression using quantitative RT-PCR (Shaw et al, 
2000) and micro-arrays (Nicholson et al, 2003). The first global stage-specific 
gene expression analysis of C. trachomatis using microarray analysis divided the 
chlamydial genome into seven differential expression profiles (Nicholson et al, 
2003). The presence of constitutively expressed genes allows them to be used to 
standardise for the number of chlamydial particles during normal development. 
The emergence of real-time PCR technology has allowed the development of 
an assay to accurately determine the level of relative gene transcripts (RNA) 
during chlamydial development (Mathews et al., 1999). Since the number of 
chlamydial particles increases per host cell during development and the 16S 
rRNA gene is constitutive, the 16S rRNA was chosen as a reference to stan-
dardise for the number of chlamydia! particles. The study involved generating 
eDNA of the 16S rRNA by random-priming and confirmed that random prim-
ing of total RNA (isolated from C. trachomatis infected HEp-2 cells) generated 
eDNA representative of the RNA levels. In the same study, Mathews et al. de-
termined the relative mRN A level of the late-stage-specific omcB gene and the 
three RNA polymerase O" factor genes. The details of the experimental setup, 
method of data collection, and data used in the model are given in the Appendix. 
8.3 Mathematical model 
8.3.1 Observed Data 
eDNA is a DNA copy of RNA and its amount has been shown to be a good 
approximation to the amount of RNA in the culture. The ratio of RNA to DNA 
differs between EBs and RBs. Every chlamydial particle has one copy of DNA. 
RBs have a RNA to DNA ratio of approximately 4:1 and EBs have a ratio of 
approximately 1:1. We assume that on average, IBs have a RNA to DNA ratio 
of 5:2. The omcB transcript levels reflect the number of RBs committed to 
become EBs because this gene product is only found in the outer membrane of 
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EBs and thus indicates the number of IBs. The previous data of Mathews et al. 
shows the levels of omcB eDNA and DNA over the developmental cycle. Since 
the data does not directly give the number of EBs, IBs and RBs we assume that 
in terms of EBs, IBs and RBs, the total DNA at timet is given by 
(8.1) 
the total eDNA at timet is given by 
cDN A(t) = k2 (2EB(t) + 5h(t) + 8RB(t)) , (8.2) 
and the total omcB at time t is given by 
omcB(t) = k3IB(t) , (8.3) 
where k1 , k2 and k3 are unknown constants. 
8.3.2 Theoretical Simulation 
Previous mathematical modelling of the biology of the chlamydia! developmental 
cycle has involved equations for the different stages of the cycle (Wilson et al., 
2003). However, the triggers within the inclusion that cause the end of one stage 
and the commencement of another stage are unknown. For example, it is not 
known how RBs that are purely dividing are prompted to commit to transform 
back to EBs. We postulate that the transition between different stages are 
continuous and are nutrient dependent since chlamydiae require access to the 
nutrient-rich cytoplasm of a host cell in order to construct the macromolecules 
(protein, DNA, RNA, lipids, lipopolysaccaride (LPS) and murein) that make up 
a chlamydia! particle. Although RBs are purely dividing initially and the rate 
of commitment to IBs is zero, we assume that there is an increasing, yet small 
rate of transformation. Thus, we model the dynamics of all chlamydia! bodies 
over the entire developmental cycle. We assume that nutrients are consumed 
by chlamydia! particles. We let N(t) be the concentration of nutrients at time 
t. The parameter t is a time parameter over one developmental cycle. We let 
I 1 ( t), R( t), I 2 ( t), E ( t) represent the concentration at time t of chlamydia! bodies 
at the different stages, namely, IBs transforming from EBs to RBs, RBs, IBs 
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transforming from RBs to EBs, and EBs respectively. Assuming that nutrient 
consumption is governed by a mass-action law, we obtain 
dN dt =- [c1J1(t) + c2R(t) + c3h(t) + c4E(t)] N(t) , (8.4) 
where c1, c2 , c3 and c4 are rate parameters representing the level of nutrient 
consumption by each type of chlamydial body. Here, since we are modelling an 
in vitro experiment we do not include a source of nutrients. A model of the in 
vivo developmental cycle would include a nutrient source. We assume that the 
chlamydial concentrations are changing according to the following model system 
equations: 
dJl 
-krl1(t), (8.5) dt 
dR ln 2 ( N0 - N(t)) n (8.6) 
dt kr11(t) + d;R(t)- k No+ N(t) R(t), 
dh (No-N(t))n (8.7) - k No+ N(t) R(t) - krl2(t) , dt 
dE 
= krl2(t) . (8.8) dt 
Here, kr is the average rate of transformation of an IB as it progresses from an 
EB to a RB, dt is the average doubling time of RBs, k is a rate parameter for 
RBs committing to IBs to become EBs, and N0 is the initial nutrient level. We 
assume that the average time for an EB to transform to a RB is the same as 
the average time for aRB to transform to an EB, represented by the parameter 
kr in equations (8.5) and (8.8). The loss term in equation (8.6) represents the 
rate of RBs committing to EBs and is governed by nutrient deprivation (Timms 
& Mathews, 2002). Initially, the rate is very small but as the supply of nutri-
ents decreases the rate of commitment increases to a maximal commitment rate. 
The parameter, n, is a shape factor. There is no data available to estimate the 
nutrient consumption of each chlamydial type and is an area for future inves-
tigation. However, nutrient uptake is most certainly higher for RBs than EBs 
because RBs are metabolically active while EBs are not. Additionally, RBs are 
seen in electron microscopy to be close to the inclusion membrane where they 
can gain access to host cell nutrients but EBs are mostly seen in the lumen of 
the inclusion where host cell nutrients are not as accessible (Rockey & Mat-
sumoto, 1999). Then, to investigate nutrient depletion we look at three cases: 
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(i) only RBs deplete host cell nutrients (c1 = c3 = c4 = 0); (ii) RBs deplete 
host cell nutrients twice as readily as IBs do (c1 = c3 = 1/2 c2 , c4 = 0); (iii) 
all chlamydial particles contribute equally to the depletion of host cell nutrients 
(c1 = c2 = c3 = c4). We suspect that case (ii) is most realistic, although the 
exact contribution of nutrient depletion by each chlamydial body is unknown. 
We nondimensionalise the system by introducing the variables 
N(t) = ~2 , T(t) = 1~:) , R(t) = ~:) , 
i(t) = I2 (t) E(t) = E(t) i = c t 
To' To' 2, 
kT ln2 k 
a1 = - , a2 = -d , a3 = - ' 
c2 c2t c2 
where T0 is the concentration of IBs at time t = 0. We obtain 
dT 
-a1T(t), (8.9) dt 
dR (1- N(t)) n (8.10) dt a1T(t) + a2R(t) - a3 1 + N(t) R(t) , 
dJ (1-N(t))n (8.11) = a3 1 + N(t) R(t) - a 1I(t) , dt 
dE 
a1I(t) , (8.12) dt 
dN { -R(t)N(t) , case (i) 
dt - [1/2 T(t) + R(t) + 1/2 J(t)] N(t) , case (ii) (8.13) 
- [T(t) + R(t) + I(t) + E(t)] N(t) , case (iii) 
where we have dropped the hat notation for convenience. The initial conditions 
are N(O) = 1, T(O) = 1, R(O) = 0, I(O) = 0, E(O) = 0. 
8.4 A Simplified Model 
Preliminary study with the full modelled to the conclusion that n needed to be 
large to fit experimental data irrespective of the assumptions used for nutrient 
depletion. We know that biologically there is an intracellular trigger causing 
the commencement of RB commitment to become EBs, thus it is plausible that 
n is large in equation (8.10), effectively causing the rate of commitment to be 
expressed mathematically as a Heaviside function. Furthermore, the rate of RB 
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. (1- N(r))n 
commitment, o 3 1 + N(r) , can be expressed as 
03 (~ ~ ~~~~) n = o 3exp [nln(1- N)- nln(1 + N)] , (8.14) 
but since ln(1- N) = -N + O(N2) and ln(1 + N) = N + O(N2), 
(
1- N(r))n 
03 1 + N(r) ~ 03 exp ( -2nN) , (8.15) 
and thus the rate of commitment becomes significant only if N ~ ~. Conse-
n 
quently, we reduce our model equations to the study of early dynamics and late 
dynamics of the developmental cycle, before and after the switching on of the RB 
commitment term. In addition, if n is large, the choice of parameters c1, c2, c3 
and c4 , cases (i), (ii), and (iii), and indeed any other choice also leads to similar 
predictions because, prior to the rate of commitment term becoming significant, 
the only variable with significant dynamics is R( t). This follows since in the first 
part of the developmental cycle RBs are replicating by binary fission and this is 
the only significant event occurring. 
8.4.1 Case 1: Early Dynamics 
The intracellular dynamics prior to the commitment of RBs to become IBs can 
be expressed by the following approximate system: 
dT 
dt 
dR 
dt 
-o1T(t), 
o1T(t) + o2R(t) , 
with solution T(t) = e-o:1 t and R(t) = 01 (eo:2t- e-o:1t) . 
ol +o2 
(8.16) 
(8.17) 
In nondimensionalising the simple model, we have put t = tjt* where the bar 
has been dropped for convenience and t* is the time for one developmental cycle. 
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8.4.2 Case 2: Late Dynamics 
The intracellular dynamics following the trigger for RBs to become IBs can be 
approximated by the following system: 
dR 
-(a3- a2)R(t) (8.18) dt 
dJ 
a3R(t) - a1I(t) (8.19) dt 
dE 
a1I(t) . (8.20) dt 
Here, we assume that the population of IBs converting to RBs is negligible 
because this process has already occurred. Assuming that the transition from 
early to late dynamics occurs quickly and that the trigger is at timet= t0 , the 
solution to the late dynamics model equations is given by 
R(t) = 
I(t) 
E(t) 
al ( ea2to - e-alto) e-(a3-0<2)(t-to) 
a1 + a2 
a 1a 3 (ea2to _ e-a1to) (e-(as-a2)(t-to) _ e-a1(t-to)) 
(a1 + a2- a3)(a1 + a2) 
CYl a3 ( ea2to _ e-a1to) 
(a1 + a2)(a3- a2) 
( 1 
- ( CY3 _ a 2)e( -ai(t-to)) _ a 1e(-(a3-a2)(t-to))) 
a3 - a 2 - a 1 
(8.21) 
(8.22) 
. (8.23) 
Our simplified model also has four parameters to be determined but has the 
advantage that simple closed form solutions are available and the dependence of 
RB loss on nutrient availability is removed. Thus, the assumptions of cases (i), 
(ii) and (iii) in the full model of the contribution each chlamydia! body makes 
to nutrient consumption is eliminated. It could be suggested that the simplified 
model supports the hypothesis of chlamydia! development due to a developmen-
tal time clock (Ward, 2003). That is, a specific point in time during the cycle 
triggers the activation of the next stage in development. 
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8.5 Solution and Results 
We fit our mathematical model to the eDNA data and from equation (8.2) take 
the parameter, k2 , to be 
cDNA(O) 6 k2 = 2EB(O) + 51B(O) + 8RB(O) = 0.2 cDNA(O) = 2.759 x 10 . (8.24) 
There are various methods that may be employed to fit parameters to the 
model equations. Additionally, an appropriate choice for the error function to be 
minimized must be made of which various choices can be made. Once estimates 
are made for the parameters, the uncertainty of these estimates is also impor-
tant, and it would be ideal if a probabilistic density function for each quantity 
that is being estimated is computed. When carrying out parameter estimation 
of non-linear models, a least squares or total least squares algorithm is very 
likely to give biased results in that the approach assumes independent, normally 
distributed (IND) forecast errors and nonlinear models will not yield IND errors 
even if the noise is IND (McSharry and Smith, 1999). A maximum likelihood 
approach would be adequate. However, since experiments have been performed 
in triplicate, we have some degree of confidence in the accuracy of our data and 
we use the sample variances as weights in non-linear weighted least squares and 
then employ a quasi-likelihood estimation technique to determine a profile likeli-
hood for each of our estimated parameters. The best fitting set of parameters to 
the weighted least squares algorithm is consistent with the solution determined 
by a maximum likelihood algorithm if cDNA(t) is of the exponential family of 
distributions. Finally, we establish a 95% confidence interval for each estimated 
parameter. 
A numerical algorithm minimized the weighted sum of squared residuals 
generated by 
g(a) = L cDNA(t)- cDNA(_g, t) [ --- ]2 
- var eDNA t ' 
t=experiment time pts. ( ( ) ) 
(8.25) 
where _g is a vector containing the set of parameters to be determined ( a 1 , a 2 , a3 
and n for the full system and a 1 , a 2 , a 3 and t0 for the simplified system). In the 
error function, cDNA(t) is the experimental level of eDNA data, var(cDNA(t)) is 
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--the sample variance, and eDNA is the predicted eDNA level from our mathemat-
ical model. A fourth order Runge-Kutta method was used to solve the full model 
system of coupled first order initial value equations, and the closed form solu-
tions was used in fitting for the simplified model. A steepest descent algorithm 
was used to obtain a search direction in parameter space for a better sequence 
of parameters until appropriate convergence of parameters was achieved. Var-
ious high, low and intermediate values were chosen as initial values for each 
parameter in order to obtain confidence that the final best fitting set of param-
eters gave rise to not just a local, but the global minimum of the error function g. 
Our data fitting algorithm for the full model system was performed using a 
range of values of n whilst ensuring physically realistic results arise. Throughout 
each data fitting procedure n is kept fixed and optimal values for other parame-
ters were determined. It was determined numerically that the integer parameter 
n, must be large (0(103 )) for a reasonable fit to the experimental data. The 
parameter, n, is large reflecting the triggering that occurs biologically as REs 
commit to transform. Thus, it seems reasonable to use the simplified model. 
As stated earlier, there are various ways of fitting the model to the data. 
Other methods, such as a relative least squares technique, provides a fit that 
appears to be a better fit. However, we do not have as much confidence in this 
fit because the mean experimental data is not reliable enough. We note that the 
sample variance tends to increase with time over the developmental cycle. Then, 
we do not have as much confidence in predictions of late dynamics. However, the 
variance is relatively small over early dynamics and it is over this period we may 
have increased assurance of our predictions. The eDNA data and curve fitting 
using the best fitting parameter set for the simplified model are illustrated in 
Figure 8.2. The simplified model yields profiles for each chlamydia! population 
and eDNA levels that are in good agreement with simulations of the full model 
(full model simulation not shown). Apart from the obvious advantage of ob-
taining a closed form solution to the model system of equation, the simplified 
equations also provides considerable computational advantage when finding the 
best fitting parameter set. 
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Figure 8.2: The eDNA data from our real-time PCR experiments, with standard error bars, 
and the best fitting curve for the simplified model. The plot shows log( eDNA) versus time. 
8.5.1 Confidence intervals for parameter estimates 
The confidence intervals are based on the ideas of profile likelihood (see, for 
example, Cox & Hinkley, 1974). Here, we assume for a given choice of a single 
(scalar) parameter,¢, with the remainder given by (vector) :E_, that the likelihood 
is given by L(¢,:E_). For fixed¢ we maximize L(¢,:£) giving'!}_(¢) as the solution 
for p_. The profile likelihood method gives a 95% confidence interval as those 
values of ¢ satisfying 
(8.26) 
with l( ¢, '!£) = log L( ¢, :£) and K the upper 5% of xi. To provide an estimated 
95% confidence interval for each parameter value we plot g(a1, az, c£3, t~) versus 
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a 1 where the hat denotes the converged parameter value. Then, the two so-
lutions of g(a1, c£2 , c£3 , t~) = 9min + K, give the bounds on the 95% confidence 
interval. We apply a similar technique for each parameter. The results obtained 
using this technique are given below for an extended model. 
However, the statistical model fitted is not adequate to explain all the lack 
of fit. From Fig. 8.2 it is obvious there is additional error to that from the 
replication of the experimental points for each value of t. As an aside, if the 
experiments were repeated in triplicate and the model were "true" then one 
would expect, for each of the 3 sets of points, for given t, each point randomly 
lying above or below the mean. Instead, for each t, the 3 values all lie below or 
above the mean (fitted curve) except fort= 1.0. We need to extend the model 
to take account of this extra level of error and the implied extra uncertainty. 
For each t we assume the experimental cDNA(t) values (average of 3) measure 
a value of the mean eDNA level at time t,f-l(t), without bias. However, these 
!-l(t) are distributed about the true (model) values m(t) with error with standard 
deviation a. Writing s(t) for the (estimated) standard deviation of experimental 
values (average of 3) for each t and m(t) is given by cDNA(g_, t), we extend 
the criterion (8.25) to include the parameter a 2 . The quantity is given by -2 
loglikelihood for this extended model assuming normal errors at each level and 
we take 
( ) ="'"" [cDNA(t) - cDNA(g_, t)l
2 
"'"" 1 ( ( )2 2) g Q, a ~ ( )2 2 + ~ og s t + a t st +a (8.27) 
The previous profile likelihood procedure is followed by extending the set of pa-
rameters to include a. It will make the confidence intervals wider. Also, as it 
stands, the t = 0.2 point is fitted too precisely because var(cDNA(t=0.2)) '""'0. 
This new statistical model will allow for more error at t = 0.2 and might give a 
better overall fit. 
When we incorporate the additional parameter, a, to account for the error in 
the model, and use the error function given in equation (8.27) the best fitting set 
of parameters are a 1 = 2.06, a 2 = 12.80, a 3 = 13.45, t0 = 0.49 and a= 2.68x 107 . 
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The mean RB doubling time, dt, is evaluated as 
ln(2)t* 
dt = = 2.59, approximately. 
0:2 
(8.28) 
We apply the technique described above, and illustrated in Figure 8.3, to ob-
tain 95% confidence intervals of a 1 E (1.89, 2.23), a 2 E (12.63, 12.97), a 3 E 
(12.04, 15.49), t0 E (0.48, 0.51), and dt E (2.56, 2.63). 
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Figure 8.3: (a) g(a1 ,&2,&3 ,t~,G-) versus a 1 (b) g(a1 ,a2 ,&3 ,t~,G-) versus a 2 (c) 
g(al,a2,a3,t~,G-) versus as (d) g(a1 ,&2 ,&s,t0 ,<7) versus t0. Here, the hat denotes the con-
verged parameter value. The line segments denote the bounds on 95% confidence intervals. 
8.6 Summary and Conclusions 
Chlamydia is a very difficult organism to propagate and determining the gene 
expression per chlamydia! particle has been elusive until recently. We have used 
real-time PCR methodology to quantitatively measure gene transcript levels in 
C. trachomatis L2, obtaining 168 rRNA eDNA levels (a measure of the RNA) 
for more developmental time-points than previously reported. 168 rRNA is an 
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essential component of the protein synthesis in bacterial cells and the levels 
are a good measure of the number of chlamydial particles. We have developed 
a mathematical model of chlamydial intracellular replication and fitted it to 
the eDNA data. The model more naturally represents the processes within a 
chlamydial host cell inclusion than previous models of chlamydial development. 
We employed a numerical algorithm to obtain parameters of best fit. As a re-
sult, the eDNA data we obtained gives rise to our prediction of a mean RB 
doubling time of 2.59 with 95% confidence interval (2.56, 2.63). Our mathemat-
ical model allows the definition of specific stages of chlamydial development, 
monitoring progression of disease in a more precise manner than classical de-
velopmental cycle descriptions. Consequently, our modelling of the number of 
each type of chlamydial particle in the inclusion during development will also 
assist understanding of immune response since chlamydial peptides presented to 
the cellular arm of the immune system depends on the number of chlamydial 
particles within each inclusion. In addition, an understanding of the population 
of chlamydial particles within the inclusion may allow development of more spe-
cific chemotherapeutic agents. 
Potentially, our modelling can be extended to identify triggers causing EBs to 
commit to IBs converting to RBs as well as the reverse process. This modelling 
would be an application to the emerging micro-array technology which has the 
potential to provide developmental expression for every chlamydial gene. The 
modelling of development will allow us to determine what genes are expressed 
at each specific stage of development, including the intermediate phases. We 
could potentially answer questions like "expression of what gene signals the 
committment of an RB to become an EB?" which would reveal clearly defined 
targets for microbiologists in drug and vaccine development. 
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Appendix: Experimental Setup and Method of 
Data Collection 
The real-time PCR data used for this modelling was obtained using eDNA gen-
erated from C.trachomatis 12/434/Bu grown in HEp-2 cell monolayer cultures 
(as described in Mathews et al., 1999) consisting of 2.5 x 107 cells. Monolayer 
cultures were infected with C. trachomatis and triplicate samples (5 x 106 cells) 
harvested at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32 and 48 hours PI by 
replacement of growth medium with 5 ml of Tri Reagent (Sigma) to allow for 
RNA isolation (according to the manufacturer's instructions). Genomic DNA 
was removed from the RNA by treatment with 20 U RNase-free DNase (Roche) 
and precipitation using 0.1 volume of 7.5 M ammonium-acetate and 2.5 vol-
umes of 100% ethanol precipitation before three 75% ethanol washes. eDNA 
was generated using the "Expand Reverse Transcriptase" kit (Roche) and 2 p,g 
ofrandom hexamers with 50 p,g of total RNA (denatured at 75°C for 10 minutes 
and quenced on ice), 1 U RN ase inhibitor (Roche) and 1 U reverse transcrip-
tase in a 12 p,L reaction incubated at 42°C for 1 hour. RNA was removed from 
the eDNA with the addition of 1 U DNase-free RNase I (Roche) in 0.1 volume 
0.2 M EDTA before precipitation with 0.1 volume 3.5 M sodium acetate and 
precipitated with 3 volumes of 100% ethanol prior to suspension in 100 p,L of 
Tris-Buffer (pH 7). 
The 16S rRNA PCR primers (ct16s-F and ct16sR) and DNA standards used 
for the real-time PCR are previously described (Mathews et al., 1999). The 
real-time PCR assays were done in triplicate for each developmental time-point 
using 50ng of eDNA (or 108 , 106 , 104 and 102 copies of the 16S DNA standard), 
1x Perkin-Elmer SYBR Green Mastermix (PE Biosystems) in a 15 p,L reaction 
volume containing 1 p,M of each primer. Amplification was done with the Ro-
torgene 2000 (Corbett Research, Sydney, Australia) using cycling parameters 
of: 1 cycle 95°C for 3 minutes 45 cycles of 94°C for 10 seconds/52°C for 10 
seconds/72°C for 10 seconds with fluorescent acquisition at 74°C. Melt curve 
parameters and data acquisition was set to range from 55°C to 90°C with a 
ramp rate of 10°C per 5 seconds. Quantitation and melt curve data analy-
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sis was performed on Rotorgene 2000 (Revision 4.4) software using melt curve 
analysis to verify correct target amplification. The copy number for each gene 
was compared to the copy number of 16S rRNA for the equivalent sample and 
a relative level of transcripts to chlamydia! particles calculated. The real-time 
PCR eDNA data is shown in Table 8.1. 
Time eDNA Sample Time eDNA Sample 
(hrs p.i.) level Var. (hrs p.i.) level Var. 
0 1.38 X 101 1.35 X 101:-l 14 1.80 X 10tj 3.18 X 1014 
2 2.64 X 107 3.88 X 1013 16 1.51 X 108 3.24 X 1014 
4 2.52 X 107 1.44 X 1012 20 5.78 X 108 6.55 X 1015 
6 1.50 X 107 1.54 X 1011 24 2.01 X 109 1.43 X 1016 
8 2.21 X 107 1.08 X 1013 28 2.31 X 109 5.76 X 1016 
10 5.69 X 107 1.60 X 1011 32 6.15 X 109 3.73 X 1017 
12 5.72 X 107 3.10 X 1012 48 5.98 X 109 3.63 X 1018 
Table 8.1: Real-time PCR eDNA data 
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Abstract: The medically significant, genus Chlamydia is a class of obligate in-
tracellular pathogens that replicate within vacuoles termed inclusions. Through-
out development Chlamydia's replicative form, the reticulate body (RB), is sig-
nalled to differentiate into the infectious form, the elementary body (EB). In 
this paper we present a hypothesis for the triggering of chlamydia! development 
involving intimate contact between the RB and the inclusion membrane. We 
use data and develop a mathematical model investigating this hypothesis. If the 
hypothesis proves to be accurate, then reducing the number of projections on 
the surface the RB will significantly reduce the burst size of infectious chlamy-
dia! particles. The full implications of the hypothesis as predicted by the model 
need to be tested further experimentally for verification. 
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9.1 Introduction 
Chlamydia is an obligate intracellular bacterium responsible for significant dis-
ease in humans and animals. Infection with Chlamydia is common in all coun-
tries, with human chlamydia! infections predominantly caused by Chlamydia 
trachomatis and Chlamydia pneumoniae. Ocular infections with C. trachomatis 
can be severe and are a major cause of conjunctivitis and trachoma leading to 
blindness in developing countries [24]. C. trachomatis is also one of the most 
common sexually transmitted diseases and is responsible for non-gonococcal 
urethritis in men and endometritis, salpingitis and pelvic inflammatory disease 
(PID) leading to infertility in women [2]. C. pneumoniae is recognized as a 
common cause of respiratory disease and is known to be involved in bronchi-
tis and pneumonia [1]. Given the pervasive nature and high incidence rates of 
chlamydia! infections, these bacteria are arguably among the most ubiquitous 
of the human pathogens. Currently there are no human vaccines for any of the 
chlamydia! species and the organism is only susceptible to broad range antibi-
otics. 
Chlamydia has a unique two-stage developmental cycle. Approximately two 
hours post infection of a host cell, vesicles containing endocytosed elementary 
bodies (EBs), the infectious form of Chlamydia, enter through the cell cytoplasm 
into a vacuole. Like several other gram negative bacterial pathogens, Chlamydia 
spp. have a complex protein secretion system named type III. It is hypothesized 
that the Chlamydia type III secretion (TTS) mechanism is involved in inject-
ing effector molecules into the host cell which, in turn, modify various host cell 
pathways [3, 4, 5]. A number of type III secretion injectisomes (that we will 
refer to as projections) that interact with the host cell protrude from the sur-
face of chlamydia! particles. In other bacteria the TTS system functions as a 
'molecular syringe', enabling the bacteria to inject virulence-related proteins into 
the cytoplasm of host cells [6]. Electron microscopic observations of Chlamydia 
have revealed the presence of surface projections on chlamydia! particles and a 
direct connection between the chlamydia! particles and the inclusion membrane 
by means of the projections [7]. Additionally, the projections are not uniformly 
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spaced but arranged such that they are on part of the surface close to the inclu-
sion membrane [8]. It has been suggested that chlamydia! replication depends 
on contact with the inclusion membrane and that contact is mediated by TTS 
[9, 10]. Since the EB enters into a tightly enclosing vacuole, there is close contact 
between the chlamydiae and the inclusion membrane from the onset of infection. 
It is known that upon infection of a eukaryotic cell (in vivo and in vitro), 
chlamydia! EBs differentiate into Chlamydia's replicative form, the reticulate 
body (RB), and the RBs double their DNA content every 2-3 hours (C. tra-
chomatis), with DNA synthesis beginning between 2 and 4 hours after infection 
[23]. Chlamydiae, in their RB form, develop independently within individual 
inclusions, replicating by binary fission. Inclusions fuse together approximately 
10-12 hours post infection [25, 26]. Whilst it is often assumed that one inclusion 
is formed, there is now ample evidence demonstrating that certain strains, such 
as C. pneumoniae or many veterinary isolates, consistently produce multiple 
inclusions (see, for example [27, 10]). Approximately 18 hours post infection, 
RBs begin to convert back to EBs, and these accumulate in the lumen of the 
inclusion. Late in the chlamydia! developmental cycle the majority of RBs are 
differentiating into the EB form until the host cell lyses, releasing the infectious 
chlamydia! particles for subsequent rounds of infection. Obviously, if the trigger 
causing RBs to convert to EBs was known, we would have a target for drug 
design and considerable research is being undertaken in gene analysis and other 
microbiological techniques to determine the triggering mechanism. 
We are proposing a hypothesis to explain the mid-to-late cycle transitions 
of Chlamydia that is intimately involved with physical contact of the RBs with 
the inclusion membrane and triggering of TTS activated events. A schematic 
diagram of the hypothesis is illustrated in Figure 9.1. We assume that there 
must be receptors on the inclusion membrane to which EB projections attach, 
and if the projections are 'loaded' as suggested by Hackstadt [19], their load is 
immediately released causing a signal transduction cascade and the EB differen-
tiates into the RB. The RB remains in contact with the inclusion membrane and 
contact induces TTS up-regulation as in other systems [6]. It is often observed 
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by electron microscopy that replicating chlamydiae appear to be in contact or 
close proximity to the inner surface of the inclusion membrane. We hypothesize 
that RBs replicate predominantly via physical contact between the RB and the 
inclusion membrane on the surface of the inclusion membrane. This might indi-
cate that contact-dependent activation of the TTS is a requisite trigger for the 
binary fission of RBs. We assume that the membrane grows with the number 
of RBs until some limiting point because of restrictions due to the size of the 
host cell. However, the RBs attached to the surface of the inclusion membrane 
continue to replicate at the same rate and thus some are physically squeezed 
out of contact with the surface. This coincides with the onset of expression of 
CopN, a TTS-secreted down-regulator of TTS. It is further hypothesized that 
TTS inactivation is a possible trigger for differentiation from the RB to EB 
[19, 20]. Although a preliminary study suggested that some components of the 
TTS system are either at middle or late in the developmental cycle providing 
some evidence for this hypothesis [21], there has been little supporting evidence. 
Our hypothesis is consistent with independent studies by Folkman who hypoth-
esizes 'anchorage dependence', describing the inability of normal cells to grow 
unless attached to a substratum and that appropriate cell shape is critical for 
DNA synthesis by normal cells [11, 12, 13, 14]. 
Another key aspect to the contact-driven hypothesis involves the number 
of projections present on the surface of RBs and EBs. The number of projec-
tions (which may be directly or indirectly related to the level of TTS activity) 
has been measured as it changes with time during the developmental cycle and 
thus the amount of physical contact between the RB and the inclusion mem-
brane can be inferred. We hypothesize that RBs will detach when there is a 
decrease in attachment strength associated with reduced contact area with the 
surface membrane. In summary, we hypothesize that TTS mediates chlamydia! 
development and growth by controlling (a) inclusion fusogenicity, (b) physical 
contact of the replicating RB with the inclusion membrane, and (c) coincidental 
down-regulation of TTS activity and onset of late differentiation. In this paper 
we present data and develop a mathematical model investigating this hypothesis. 
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Figure 9.1: A schematic diagram of the contact-dependent chlamydial development hypothesis 
presented in this paper. 
An alternate hypothesis to the contact-driven mechanism, involves assuming 
that key nutrient levels are sensed by the Chlamydia and when the level drops 
below a critical level, RBs are activated to transform to EBs [22]. If the trigger is 
nutrient-dependent, it would require all the RBs to be in close proximity to the 
cytosol. Alternatively, we suggest that RBs have certain transporters that ob-
tain freely diffusible nutrients from inside the inclusion. Moreover, RBs require 
some nutrients after they are detached to energize differentiation to EBs. The 
contact-dependent trigger also explains why chlamydia! development, initially 
almost synchronous, becomes asynchronous in the mature inclusion (late in the 
developmental cycle) as EBs differentiate from RBs [10]. 
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9.2 Mathematical Model 
We assume that, upon infection, the size of the host cell's inclusion is the size of 
the initial infecting EB and grows with the chlamydia! body as it becomes an RB. 
The inclusion grows to fill the cytosol of the infected cell as chlamydia! replication 
occurs. The growth of the volume enclosed by the inclusion membrane is limited 
to the size of approximately the volume of the cell less the nucleus and free space 
to account for mitochondria, etc., which we estimate at 30% of the cell volume. 
We let N be the number of inclusions within a host cell (assumed fixed) and we 
assume that there is the same chlamydia! development within each inclusion. 
We let R~ax. be the maximum number of RBs that can physically fit on the 
membrane surface of each inclusion (where there are N inclusions). We let R(t) 
be the number of RBs attached to the surface of each inclusion membrane at 
time t. Then, we model the change in the number of RBs attached to the 
inclusion membrane surface by the equation 
dR ( R ) 
- = koR 1 - - - b(t)R dt RN ' max 
(9.1) 
where k0 is a parameter denoting the constant rate of replication, and b(t) is the 
rate of detachment from the membrane surface due to decreased contact area 
as the number of protruding projections decreases. Here, we model the change 
in the number of attached RBs with a logistic growth term. We assume that 
RBs attached to the surface replicate at a constant rate but may be squeezed 
off the surface due to spatial restrictions. The RBs continue to replicate at the 
constant rate even when the surface is 'full', forcing new RBs to accumulate in 
the lumen of the inclusion. We let J(t) and E(t) be the total number of RBs 
that have detached from the inclusion membrane surfaces and the number of 
EBs within the lumens respectively. Although chlamydia! particles detached 
from the membrane may appear morphologically similar to replicating RBs, we 
assume they are unable to replicate further whilst not connected to the surface, 
but are triggered to start differentiating back to the infectious EB form. Thus, 
we refer to them as intermediate bodies (IBs). Then, the change in the number 
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of these chlamydia! particles is given by 
dJ 
( koR ) NR R~ax + b(t) - k1I (9.2) 
(9.3) 
where k1 is the rate of transformation of an IB to become an EB. Here, the 
source of IBs given by the term, koN R2 / R~ax' represents the RBs that could 
not attach to the membrane surface because of space limitations. We note that 
it can be seen from equations (9.1), (9.2) and (9.3) that the total change in the 
number of chlamydia! particles is given by 
d ( R + I + E) = k R 
dt 0 ' (9.4) 
to model the constant replication of RBs that are attached to the inclusion 
membrane surface. 
9.2.1 The evolution of the number of surface projections 
We assume the rate of detachment from the inclusion membrane, b(t), decreases 
linearly with the strength of attachment (which we assume is directly propor-
tional to the number of projections on the chlamydia! particle). Matsumoto was 
the first to discover and investigate the detailed structure of chlamydia! parti-
cles, including surface projections [15, 16, 17, 18]. We use his findings to infer 
attachment strength with time over the developmental cycle. Amongst other 
observations, Matsumoto determined that the projections are approximately 20 
to 40 nm in diameter [16], cylindrical and 10 to 25 nm in length [18] and pro-
jections are arranged with an approximate centre to centre spacing between the 
projections of 50 nm and the projections are in the centre of an 8 or 9 subunit 
"flower" rosette [17]. The number of projections on the surface of samples of 
chlamydia! particles was measured by Matsumoto [28]. The samples were taken 
at 10, 15, 20 and 48 hours post infection. Here, we fit the data of Matsumoto 
to known statistical distributions and also attempt to determine a relationship 
between distribution parameters with time. This is carried out so that an estima-
tion of the distribution of surface projections at any time during the chlamydia! 
developmental cycle can be interpolated. We then use the mean of the evolving 
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distribution in our deterministic model. 
After attempting to fit Matsumoto's data [28] to the negative binomial, nor-
mal, Laplace, exponential, Pareto, gamma, Weibull, inverse Gauss, and Poisson 
distributions, it was determined that the inverse Gauss distribution and the 
gamma distribution comparably stood out from the other chosen distributions 
as being distributions of best fit for each sample time point. The log likelihood 
was used as a measure of fit. We chose to continue investigation with the gamma 
distribution and explore how the distribution evolves with time. The use of a 
continuous distribution to describe discrete data is justified since the data values 
are relatively large. The standard gamma distribution has two parameters, a 
and f3, where the gamma( a, (3) distribution has the probability density function 
(~ y~-l exp( -xj (3) 
F(x; a, (3) = (3f(a) , (9.5) 
where X> 0, a> 0, f3 > 0 and r(z) = fooo t(z-llexp( -t)dt. The gamma distribu-
tion parameters are related to the mean, f.L, and the variance, CJ2 , by the following 
relationships, namely, f.L = af3 and CJ2 = af32 • To estimate the evolution of the 
distribution of projections with time, we first determined relationships for the 
mean and variance of the samples with time to provide us with relationships for 
a and f3 with time, using the method of moments. In Figure 9.2a we illustrate 
the linear fit of log of the variance with time (as an indicator of fit we obtained 
a Multiple R2 value of 99.3%). In Figure 9.2b we illustrate the linear fit of the 
inverse product of the mean and standard deviation with time (as an indicator 
of fit we obtained a Multiple R2 value of 99.8%). Then, for any given time, we 
estimate the mean and variance to determine a and (3. Because of the very good 
fit, we suggest that our estimate distribution interpolations are reasonable. In 
Figure 9.3 we plot the data of Matsumoto against our estimated gamma distri-
butions, and in Figure 9.4 we plot the distribution of projections on the surface 
of the chlamydia! particles at various times, and we also plot the evolving mean 
number of projections with time during the developmental cycle. 
The data presented gives us a good indication for the number of projections 
from 10 hours post infection. We do not have data prior to this point in the 
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developmental cycle. However, prior to this point the chlamydial growth is 
synchronous, the inclusion is expanding and RBs are undergoing pure binary 
fission. Thus, we assume that the number of projections early in the cycle, 
prior to 10 hours post infection, is approximately constant. This is based on 
the statement from Matsumoto that the number of projections is maximal at 10 
hours. Alternatively, we could assume the number of projections is increasing 
from the number on the EB surface at infection until approximately 2 hours post 
infection when the EB has converted to an RB and then assume the number 
of projections is approximately constant until 10 hours post infection. Since 
we assume that the number of projections is initially close to maximum (and 
remains almost constant for a period of time) and then decreases towards a 
limiting number, we may approximate the mean number of projections with 
time, for purposes of mathematical analysis, by assuming the change in the 
number of projections with time, f(t), is governed by 
df 
dt = -k2 (J - fmin) (!max - f) , (9.6) 
where !max and !min are the upper and lower limiting number of projections per 
RB. 
Given the number of projections on the RB as it changes with time, j(t), 
we estimate the rate of detachment of RBs from the surface of the inclusion 
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membrane with the following expression, namely, 
b(t) = k3 (!max- J(t)) , (9.7) 
where k3 is a positive rate parameter. Here, the rate of detachment, b( t), can be 
interpreted as being proportional to the decrease in the number of projections 
on the RB. Using the solution for f(t) from equation (9.6) we can estimate the 
rate of detachment, b(t), as 
b(t) = k3 Umax - fo) Umax -/min) , (9.S) 
Umax- !a)+ Uo- !min) exp ( -k2Umax- !min)t) 
where fo is the number of projections at time t = 0, a value slightly less than -
!max· Then, 
(9.9) 
where r 1 and r 2 are given by 
= ek3(fmax-fmin)t Jmax- JO JO- min e 
(
f ++(+ j )-k2(/max-fmin)t)ks/k2 
fmax- /min (9.10) 
kRo (+ ++(+ j )e-k2(fmax-fmin)t)k3/k2 
_o_eko(ek3(fmax-fmin)(t-() Jmax- JO JO- min (9.11) 
R~ax !max- Jo + (fo- /min)e-k2(fmax-fmin)( 
We use the data of Matsumoto and our fitting of the mean number of projections 
with time to estimate the parameters, !max and /min and use a least squares 
algorithm to determine the best fitting values for k2 and / 0 • 
9.2.2 Simplified Model Equations 
The model can be simplified by considering early and late dynamics. Early in the 
developmental cycle, the rate of detachment b(t) ~ 0 and R << R~ax leading 
to purely exponential growth of RBs. Late in the developmental cycle, the rate 
of detachment is approximately maximal and we let b = b = k3 Umax- /min) , 
which we assume is greater than k0 and so R << R~ax· Then, the model 
equations may be simplified to the following: 
• During early dynamics: 
dR dt = koR, (9.12) 
206 
• During late dynamics: 
dR 
dt 
di 
dt 
dE 
dt 
-(b- ko)R, (9.13) 
(9.14) 
(9.15) 
However, the full model is appropriate in the intermediate period between the 
early and late dynamics. During early dynamics the solution for the number of 
RBs within an inclusion at time, t, is given by 
R(t) = Roekot ' (9.16) 
and during late dynamics the solution for the number of RBs, IBs and EBs at 
time, t, is given by 
R(t) 
I(t) 
E(t) = 
(9.17) 
(9.18) 
(9.19) 
where RL, handEL are dependent on the time point during the developmental 
cycle when the late dynamics equations are considered appropriate. For the 
remainder of our study we use our early dynamics equation for t < 10 hours 
post infection and the full system for t 2:: 10 hours post infection. 
9.2.3 Geometrical Argument to Establish R~ax 
The host cell for Chlamydia is typically an epithelial cell (of the mucous mem-
brane of the female reproductive tract for urogenital strains, for example). Al-
though, epithelial cells are often classified into four distinct shapes, namely, 
squamous, cuboidal, columnar, and transitional, generally EBs will infect cil-
iated columnar epithelial cells that are cylindrical in shape. Chlamydia! EBs 
enter the host cell within a tightly encompassing endosomal membrane [29]. 
As the bacterial population grows, the enveloping membrane enlarges so that a 
fluid-filled vesicle, or inclusion, forms. Inclusions may undergo great distortions 
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of shape and fill the host cell[30]. However, it is reasonable to assume the inclu-
sions are approximately ellipsoid in shape [31, 32, 33]. 
In cells infected with C. trachomatis, a single mature inclusion has a surface 
area, A8 , of approximately 500 pm2 [33, 30]. The size of epithelial cells varies, 
but as an order of magnitude study, the height of a typical cell is approximately 
30pm and the width is approximately lOpm. Given that the cell nucleus and 
mitochondria etc. occupy approximately 30% of the cell, the nucleus of an in-
fected cell is displaced to the side as the inclusion grows, and the inclusion has 
little effect on the shape of the host cell [32], we assume that the space available 
to the inclusion is bounded by a cylinder 21pm in height and lOpm in width. 
Then, the ellipsoid that can fit inside this space has a surface area of 560 pm2 , 
approximately, which is consistent with the magnitude of the area found from ex-
perimental observation. Since an average RB has a radius, r, of approximately 
0.5pm [34], the final surface area of the inclusion is large relative to the RB. 
Therefore, we can assume that the inclusion surface is approximately planar. 
We let ARB be the cross-sectional area of a typical RB, and let 'TJ be the average 
packing density of the RB cross-sectional discs. Then the maximum number of 
RBs that can attach to the inclusion membrane is approximately 'T]As/ARB· We 
assume the discs are arranged according to the compact square lattice, which 
has a packing density of 'TJ = 1r /4 ~ 0. 785 [35] (The packing density is the 
fraction of area/space filled by given shapes/solids). Then, for the RB radius 
0.5pm < r < 0.6pm, we estimate the maximum number of RBs on the surface of 
the inclusion to be 389 < Rillax < 560, which is consistent with observations [33]. 
We extend our model to consider the case of multiple inclusions. We assume 
that the inclusions each occupy the same volume within the cell and that the 
inclusions are positioned as illustrated in Figure 9.5. For our estimates we also 
let the radius of the RB cross section to be 0.55pm. Table 9.llists the magnitude 
estimates for the maximum number of RBs attached to the inclusion membrane 
against the number of inclusions within the host cell. We note that order of 
magnitude approximations are all that we require because of the uncertainties 
involved. 
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Figure 9.5: Assumed position of multiple inclusions within a host cell for the purposes of our 
order of magnitude estimates. 
N RJV max N x R~ax 
1 462 462 
2 268 536 
3 209 627 
4 182 728 
Table 9.1: The maximum number of RBs that can attach to the surface of the inclusion 
membrane simultaneously when considering multiple inclusions within an infected cell. 
9.3 Results 
The overall lytic developmental cycle for Chlamydia is well understood but there 
are also many details which need to be further elucidated. We have outlined a 
hypothesis for the trigger of RB to EB transformation involving the detach-
ment of RBs from the inclusion membrane via being physically squeezed out 
and decreased strength in attachment because of decreased expression of surface 
projections. Additionally, RBs replicate by binary fission, and detached RBs 
(IBs) convert to EBs. In a mathematical model it is possible to incorporate 
all these effects, but more importantly we can separate them, and study how 
they interact. In this section we give results of simulations which examine the 
individual effects of each component in our model. We begin by determining a 
reference simulation. 
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Since the doubling time of Chlamydia RBs is approximately 2 hours [36], 
we let k0 = ln (2) /2 hrs-1 . Assuming a transformation time of 3 hours for a 
committed RB (IB) becoming an EB, we let k1 = 1/3 hrs-1. We have chosen a 
value for the dimensionless detachment rate parameter, k3 = 0.18, that provides 
simulated time courses that are indicative of realistic time courses for the num-
ber of RBs and EBs over the developmental cycle. A numerical simulation of 
the time-course for the populations of RBs and EBs is illustrated in Figure 9.6. 
We use this time course as a reference simulation and we carry out sensitivity 
analysis on other components of our model. 
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Figure 9.6: A reference simulation time course. (a) The number ofRBs attached to the surface 
of the inclusion membrane with time, (b) The number of EBs within the lumen of the inclusion 
with time. 
We use our model to investigate multiple inclusions. In Figure 9.7 we il-
lustrate simulations of an infected cell with 1, 2, 3 and 4 inclusions. Because 
inclusions do not interfere or interact with each other early (prior to the de-
crease in the number of projections) there is not significant change in the RB 
time course. However, as anticipated, increasing the number of inclusions in-
creases the number of infectious EBs released upon lysis of an infected cell. 
We suggest that increased control of infection will be obtained if inclusions are 
forced to fuse together. Thus, a drug that promotes the fusing of inclusions 
will be beneficial, but not sufficient to clear an infection. The concept that the 
trigger for RBs to reconvert to EBs is dependent on the space on the surface of 
the inclusion membrane suggests that a decrease in the space available for the 
inclusion to expand will decrease the number of infectious EBs released from the 
infected cell. In order to study a decrease in available space, we assume that the 
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available space for inclusions remains cylindrical and the ratio of the cylinder 
radius to height remains fixed. In Figure 9.8 we plot the reference time course 
and the time course when the available space is reduced by 50%. However, this 
results in only a slight reduction in the number of EBs produced. 
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Figure 9.7: Simulated time courses of the number of (a) attached RBs (b) EBs. In (a), the 
curves of increasing magnitude refer to 4, 3, 2, and 1 inclusions, respectively. In (b), the curves 
of increasing magnitude refer to 1, 2, 3, and 4 inclusions, respectively. 
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Figure 9.8: Simulated time courses of the number of (a) attached RBs (b) EBs. In (a) and (b), 
the curves of increasing magnitude refer to the case of available space for inclusion reduced 
by 50% and the reference time course respectively. 
Our hypothesis suggests that the detachment of RBs from the inclusion mem-
brane surface is critical in the regulation of chlamydial development. We have 
assumed that the rate of detachment increases as the number of surface projec-
tions attaching to the membrane decreases. Here we consider the effect of an 
increased or decreased rate of detachment. In Figure 9.9 we illustrate the time 
courses of the number of RBs and EBs for a 2-fold increase and 1/2-fold de-
crease rate of detachment, relative to our reference simulation. A 2-fold rate of 
detachment of RBs implies a decreased population of replicating RBs and thus 
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a decreased level of EBs. However, a 2-fold decrease in the rate of detachment 
of RBs implies an increased level of replicating RBs. In fact, the number of RBs 
saturates to a maximal level dependent on the rate of detachment and spatial 
aspects of the size of the inclusion. There is a constant (high) level of RBs on the 
membrane surface continually producing new RBs. However, because the inclu-
sion membrane cannot grow larger to accommodate the new RBs, some RBs are 
squeezed out of contact with the membrane surface and start converting to EBs 
leading to the production of a greater number of EBs. Therefore, we predict the 
counter-intuitive result that increasing the rate of detachment of RBs from the 
surface of the inclusion membrane will be effective in reducing the virulence of 
infection. 
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Figure 9.9: Simulated time courses of the number of (a) attached RBs (b) EBs. In both 
(a) and (b), the curves of increasing magnitude refer to decreasing rate of detachment, k3 = 
0.016, k3 = 0.008 and k3 = 0.004, respectively. 
The study of changes in the magnitude of the rate of detachment leads us 
to consider changes in the profile of the rate of detachment with time. Here, 
we consider two cases, namely, a constant level of projections throughout the 
developmental cycle at (i) the maximum number of projections on RBs and (ii) 
the number of projections on EBs. We present simulations of these cases in Fig-
ure 9.10. From the simulations it is evident that, according to our hypothesis, 
the number of projections is of crucial importance in determining the virulence 
of infection. For instance, if our hypothesis is correct and a drug is developed 
to prevent the development and presentation of more projections so that the 
number of projections on the chlamydia! particles remains at the level on the 
EB surface over the duration of the developmental cycle, then significant control 
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of chlamydial infection will be obtained, if not complete clearance. 
We also consider shifts in time of the profile of projections, that is, an in-
creased or reduced time delay before the decrease in projections on the RB 
surface. We present simulations of a reduced and increased time delay in the 
RB projection profile in Figure 9.11. Then, it is demonstrated that more effec-
tive control of infection will be obtained if the number of projections on RBs 
can be reduced towards the number of projections on EBs faster than in normal 
development. 
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Figure 9.10: Simulated time courses of the number of (a,c) attached RBs and (b,d) EBs. In 
(a) and (b) the rate of detachment of RBs is minimal corresponding to a constant number of 
projections consistent with the maximal number of projections that appear on the surface of 
RBs. In (c) and (d) the rate of detachment of RBs is maximal corresponding to the constant 
number of projections as the number on EBs. 
In addition, we investigate the effect of the rate RBs replicate on the surface 
of the inclusion membrane. In Figure 9.12 we illustrate time courses for RBs 
and EBs over one developmental cycle for three different rates of replication. It 
can be seen that if RBs replicate more quickly, then, as expected, the RB and 
EB populations are significantly higher. According to our hypothesis, once an 
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Figure 9.11: Simulated time courses of the number of (a) attached RBs and (b) EBs, resulting 
from the profile of the number of projections shifted in time. In (a) and (b), the curves of 
increasing magnitude refer to cases where the number of projections on RBs decrease T hours 
earlier, decrease according to our reference, and decrease T hours later, respectively. Here, 
the curves of increasing magnitude refer to F(t) = f(t + T), F(t) = f(t), and F(t) = f(t- T) 
respectively, where F is the new profile of the number of projections with time, f is the 
reference profile of the number of projections with time, and T = 5 hours is the delay used in 
our simulations. 
RB has detached from the surface of the inclusion membrane it is committed 
to transform (via the intermediate forms, IBs) to become an EB. In Figure 9.13 
we illustrate time courses for the number of EBs for different rates of RB to 
EB transformation. There is no significant difference in the resultant number of 
EBs for different IB transformation rates. 
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Figure 9.12: Simulated time courses of the number of (a) attached RBs (b) EBs. In (a) and 
(b), the curves of increasing magnitude refer to aRB doubling time of 2.5 hours, 2 hours and 
1.5 hours respectively. 
214 
500 
400 
300 
E(t)200 
100 
0 10 20 30 40 
time (hours) 
Figure 9.13: Simulated time courses of the number of EBs. The curves of increasing magnitude 
refer to k3 = 1/5, k3 = 1/3 and k3 = 1. 
9.4 Discussion 
The genus Chlamydia encompasses a class of obligate intracellular parasites of 
humans, birds and many mammals, responsible for significant disease. Given the 
pervasive nature and high incidence rates of chlamydial infections, these bacte-
ria are arguably among the most ubiquitous of the human pathogens. One of 
the most important questions to microbiologists studying chlamydiae is "What 
is the mechanism that triggers the replicative form of Chlamydia, the RB, to 
convert to the infectious form, the EB?". In this paper we present a hypothesis 
for the triggering of chlamydial development that involves a contact-dependent 
mechanism between the replicating Chlamydia and the host cell inclusion mem-
brane. The contact is mediated by a Type Three Secretion system. We present 
data and develop a mathematical model investigating this hypothesis. 
We can precisely describe all aspects of the hypothesis in a mathematical 
model, but more importantly the model allows us to separate them, study how 
they interact and determine implications of each aspect. We performed a sen-
sitivity analysis on each component in the model and obtained the following 
conclusions based on our hypothesis: 
• if RBs replicate more quickly, then, as expected, the RB and EB popula-
tions are significantly higher; 
• there is no significant difference in the resultant number of EBs for different 
IB transformation rates; 
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• increasing the number of inclusions per host cell significantly increases the 
number of infectious EBs released upon lysis of an infected cell. Increased 
control of infection will be obtained if inclusions are forced to fuse together; 
• decreasing the available space for inclusions does not have a significant 
impact on the number of EBs produced; 
• changing the rate of detachment of RBs from the inclusion membrane 
surface affects the development significantly. We predict, perhaps counter-
intuitively, that increasing the rate of detachment of RBs from the surface 
of the inclusion membrane will be effective in reducing the number of 
infectious EBs released from an infected cell. This can be done by reducing 
the number of projections on the surface of the RB; 
• more effective control of infection will be obtained if the number of pro-
jections on RBs can be reduced earlier in the developmental cycle; 
• the number of projections is of crucial importance in determining the viru-
lence of infection. If the development and presentation of more projections 
is prevented in the differentiation of EB to RB, then significant control of 
chlamydia! infection will be obtained, if not complete clearance. 
The full implications of the hypothesis as presented by the model needs to 
be tested further experimentally for verification. If the presented hypothesis 
proves to be accurate, then a considerable breakthrough may have been made 
in defining an important trigger for chlamydia! development. Consequently, a 
target for drug development may have been identified, that involves reducing 
the number of projections on the surface of Chlamydia's reticulate body. 
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Chapter 10 
General discussion 
There is a need to understand the mechanisms of infectious disease pathogene-
sis and to answer many of the questions that are quantitative in nature if there 
are to be improvements in disease control. Mathematical models can be used 
to inexpensively explore newly proposed processes. Modelling is inexpensive 
compared with the materials and resources required for experiments to be per-
formed. Although modelling will not replace experimental work, it may help 
guide experimental work or provide insights that can then be validated experi-
mentally. Development of such models requires novel, high-level mathematical 
and numerical techniques. Additionally, precise mathematical modelling is a 
way to formulate hypotheses in a framework that allows their full implications 
to be identified, adding an important dimension that cannot be carried out in 
other disciplines. In this thesis, a series of papers have been presented that per-
tain to the mathematical modelling of the cellular dynamics of human infectious 
diseases. 
We introduced the modelling by considering a simple overview of the interac-
tion between an infectious agent and the human immune system, and suggested 
that broadly there are three areas of investigation: humoral immunity, cell-
mediated immunity, and intracellular dynamics of the infectious agent. The 
remainder of the thesis investigated various aspects of each of the three areas. 
To investigate humoral immunity this thesis commenced by presenting a 
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short note suggesting that the concentration of antibodies is of greater impor-
tance than the specific affinity of the antibody-receptor interaction, in effecting 
a binding reaction. However, the theoretical problems associated with the bind-
ing of multivalent ligands centre around predicting the aggregate size distribu-
tion, and a complete description requires a very large set of coupled differential 
equations. The work in this thesis formulates a theoretical result enabling the 
aggregate size distribution to be determined by the solution of just one diffusion 
equation. This theoretical result greatly improves on the methods previously 
used that either involve the solution of an extremely large system of ordinary 
differential equations. Humoral immunity necessitates the physical binding of 
antibody fragments to cell/infectious agent receptors. Steric factors must be 
considered for a complete understanding of neutralization. The work in this 
thesis explored, in depth, the physical aspects of antibody Fab (fragment anti-
gen binding) fragments neutralizing a pathogen with a large number of binding 
sites. A theory was developed for binding of two receptors to a ligand with a 
large number of binding sites. This was done to describe the size distribution of 
aggregates of two receptor species, antibody Fabs and host epithelial cell recep-
tors, forming on the surface of a chlamydial particle. This theory is used within 
the development of a model for the in-host population dynamics of a chlamy-
dial infection. It makes a significant contribution to the field of modelling steric 
effects on adsorption reactions, and assists in the understanding of humoral im-
munity to chlamydial infection. 
This thesis presented two investigations of cell-mediated immunity. Firstly, 
since it is assumed that the number of peptides recognized by the cytotoxic arm 
of the cell-mediated immune response is proportional to the number of replicat-
ing forms of chlamydial particles, a mathematical model predicted the change 
in the numbers of intracellular chlamydial particles. Thus, we investigated a 
changing immune response over an infected cell's life-cycle. This was carried 
out with an age-structured model. The work also considered a secondary im-
mune response with changing levels of immune cells. This work on Chlamydia 
represents the first mathematical modelling of this important human infectious 
disease. We obtained an expression for the basic reproduction ratio, R0 , and 
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interpreted it in terms of factors critical to disease progression. The modelling 
predicts the effectiveness of the cell-mediated response over the life time of an 
infected cell and introduces the modelling of the important persistent state of 
chlamydial infection. It provides a firm foundation for future mathematical 
modelling of chlamydial development (both in this thesis and beyond). 
Many infectious agents evolve to become resistant to the immune defence. 
The immune system will often evolve with the mutating pathogen to control 
the infection. However, HIV is successful in eluding immunological attack and 
eventually will be the causal agent of death for many who are infected. HIV 
infection is used as an application for our second study of the cell-mediated im-
mune system, that investigates the evolutionary drift of immune specificity as it 
follows the diversity of strains of HIV. This involved a novel model of mutations 
and should lead to a new way of thinking about the diversity threshold (the 
criterion for the escape of the infection from the immune response). As far as 
we are aware it is the first time a diversity index of immune strain specific cells 
of this form is presented and helps demonstrate immune collapse. 
The attention of microbiological research of infectious diseases tends to be 
focussed on the mechanisms and gene expression of the infectious agent within in-
fected cells. To investigate intracellular dynamics (referring to dynamics within 
a cell infected by an infectious agent), in this thesis, the Chlamydia pathogen 
was chosen for investigation. Experimental micro-array data has measured gene 
transcript levels for a chlamydial gene, 168, that can be used to standardize for 
the amount of chlamydial DNA over the chlamydial developmental cycle. In this 
thesis we modelled the intracellular dynamics of the chlamydial developmental 
cycle to predict the average generation time. This modelling is a foundation 
for the analysis of the vast array of gene expression data that is emerging be-
cause of advances in experimental technology. Potentially, the modelling can 
be extended to identify triggers for chlamydial development to answer questions 
like "expression of what gene signals the commitment of an RB to become an 
EB?" which would reveal clearly defined targets for microbiologists in drug and 
vaccine development. 
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It is unknown what the important triggers are in the chlamydia! developmen-
tal cycle for commencement of the next stage of development. It is hypothesized 
that contact-dependent activation of Type Three Secretion is a requisite trigger 
for chlamydia! replication. In this thesis we present and investigate this hypoth-
esis and its implications. The hypothesis is at the cutting edge of Chlamydia 
research. Whilst the modelling provides some support of the hypothesis, the 
full implications of the hypothesis as presented by the model needs to be tested 
further experimentally for verification. If the presented hypothesis proves to be 
accurate, then a considerable breakthrough may have been made in defining an 
important trigger for chlamydia! development, clearly identifying a target for 
drug development. 
Infectious diseases give rise to mutually exclusive states of populations at an 
epidemiological level (immune, infective and susceptible). During the last cen-
tury, the application of mathematical models to infectious disease has consisted 
of describing their spread through human populations. This enables the quan-
tification of the transmission dynamics of infectious diseases in mathematical 
models, using known data on patterns of human contact and the characteristics 
of the organism. Mathematical modelling is used to forecast disease epidemics, 
trends in disease transmission, and is relevant to plan vaccination programs and 
health policies. 
More recently, advances in molecular techniques have generated information 
on how microbes develop within infected hosts, how they change their structure, 
and the ways in which they interact with the immune system. This biological 
data has led to a new type of mathematical epidemiology that deals with the 
complex dynamics of infectious agents within infected individuals. Future de-
velopments in this field will see increasing efforts to understand the population 
dynamics of infectious agents. Mathematical models present clear concepts and 
guidelines for further collection and analysis of data. Additionally, mathemati-
cal models of the complex interaction between infectious agents and the immune 
system will allow immunologists to employ more quantitative approaches to their 
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data. 
As in the epidemiological case, infectious diseases give rise to mutually ex-
clusive states of interacting populations at a micro-epidemiological level, in vivo 
(e.g. healthy cells, infected cells, immune cells). This enables the quantification 
of the infection and control dynamics using known characteristics of the organ-
ism and immunology. Mathematical modelling is a tool to develop strategies for 
communicable disease control and gives a dynamic picture of disease transmis-
sion and infection, whilst assisting in gaining understanding of, and predicting 
progression of, infection and the outcome of different control strategies. 
There are many areas for future research in this field. Some of these areas 
have already been discussed in this thesis. Here, we make specific mention of a 
few directions for future work: 
• The theory established in Chapter 4 is a framework for the investigation 
of competition between antibodies. This will be useful in conjunction 
with relevant data, for the analysis of the effectiveness of potential vac-
cines. Theoretical studies of receptor-ligand aggregation can now also be 
extended with much more ease. 
• In Chapter 5 an expression for the valence is developed for a ligand bound 
by large receptors where steric hindrance effects are considered. The ex-
pression was used in a population dynamics model as an example, but can 
be applied to any pathogen. 
• A persistent phase associated with Chlamydia development has been de-
fined and involves the transition of dividing RBs to abnormal or aberrant 
bodies (ABs) which remain metabolically active but are morphologically 
different to RBs. This phase is thought to be an important factor in the 
development of serious disease. The mechanisms inducing persistence and 
the consequences of persistent Chlamydia is a topic for future work. 
• The theory presented in this thesis to describe how HIV eludes the immune 
defence can be extended to other topics of importance in the literature, 
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such as how HIV becomes resistant to combination antiretroviral therapies 
(ART) and imperfect vaccines. 
• Recently, due to technological advancements, vast amounts of gene expres-
sion data have become available for analysis. The mathematical modelling 
presented in this thesis can be extended to fit this data in order to pre-
dict how Chlamydia regulates control of gene expression during its unique 
developmental cycle and what associated mechanisms are involved in de-
velopment. 
• Most of the severe sequelae of chlamydial infection, such as conjuncti-
val scarring (trachoma) and damage to fallopian tube function follow-
ing chlamydia! pelvic inflammatory disease occur as a result of long-term 
(chronic) inflammation leading to fibrosis and scarring. The mechanisms 
causing scarring due to chlamydial infection is an area of importance and 
is awaiting investigation. 
Mathematical modelling is increasingly being applied to interpret and predict 
the dynamics and control of infectious diseases. In this thesis, mathematical 
modelling of various aspects of infectious disease interaction with the immune 
system has been presented. The modelling has been applied to the study of 
Chlamydia and HIV, although much may be more generally applicable to other 
infectious agents. An interdisciplinary approach in the fight against human 
infectious diseases, including mathematical modelling as presented in this thesis, 
is required if the long-term goal of a vaccine and/ or cure is to eventuate for many 
of the infectious diseases that currently exist or will emerge, to endanger human 
populations. 
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Appendix A 
Opportunistic Infections and HIV 
The pattern of disease progression in HIV infection can be subdivided into three 
phases: (i) the first few weeks after inoculation with virus marks the acute phase 
of the infection, (ii) the majority of the time of infection marks the asymptomatic 
(or chronic) phase, and (iii) the last 2-3 years of an infected person's life is the 
period known as AIDS. During the early acute phase, patients usually develop 
high virus loads and show some symptoms often described as being similar to 
the common cold. In this phase, the virus is distributed to many different or-
gans of the body. The level of CD4 cells fall temporarily and then return to 
almost normal levels of approximately 1000 per p,l. At the end of the acute 
phase, virus load falls and the clinical symptoms subside. The second stage of 
HIV disease is largely asymptomatic, but the virus continues to replicate and 
CD4 cells continue to fall. In some patients the population of CD4 cells declines 
rapidly whilst in other patients the population decreases more slowly. There 
is large heterogeneity in the length of the asymptomatic phase ranging from a 
few months to many years. The average length of the asymptomatic period is 
approximately 10 years. Stage 3, the final phase of the disease is characterized 
by the development of AIDS. This phase is defined, amongst other criteria, to 
be when the level of CD4 cells have fallen to below 200 per p,l, and opportunistic 
infections begin to appear. The impaired immune system can no longer fight off 
infections that would normally pose no problem. Patients die from opportunistic 
infections. 
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Nowak and May's basic model of virus dynamics (presented in Chapter 2) 
has three variables, namely the population sizes of uninfected susceptible cells, 
T; infected cells, I; and free virus particles, V. The cells targeted by HIV are 
CD4 immune cells. This property distinguishes HIV from other viruses because 
the cells orchestrating the body's defence are the same cells that are under threat 
of infection. The three variables can either denote the total abundance in a host, 
or the abundance in a given volume of blood or tissue. Free virus particles infect 
uninfected cells at a rate proportional to the product of their abundances, ryTV. 
The rate constant, ry, describes the efficacy of this process, including the rate at 
which virus particles find uninfected cells, the rate of virus entry, and the rate 
and probability of successful infection. It is assumed that infected cells produce 
free virus at a rate proportional to their abundance, f-Ll. Infected cells die at 
a rate wi, and therefore the average life-time of an infected cell is 1/w. The 
amount of virus particles produced from one infected cell, the 'burst size', is 
f-L/W. As an extension to the basic model of virus dynamics, here it is assumed 
that free virus particles are removed due to an immune response proportional 
to the number of uninfected immune cells, at a rate proportional to the product 
of their abundances, r;TV. The presence of the variable, T, is specific to HIV 
dynamics. In addition to the dynamics describing virus infection, we specify 
the dynamics of the uninfected cell population. The simplest assumption is 
that uninfected cells are produced at a constant rate, a, and die at a rate f3T. 
The average life-time of an uninfected cell is therefore 1//3. Here, the following 
arguments are made: 
• the load of infectious agent is an important determinant of disease; 
• cytotoxic T lymphocytes ( CTLs) limit the infectious agent load; and 
• therefore, variation in CTL responsiveness may account for much variation 
in the outcome of disease. 
Then, the change in the population of our three quantities can be expressed 
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by the following equations: 
dT 
dt 
dJ 
dt 
dV 
dt 
a- f3T(t) - 1T(t)V(t) (A.1) 
1T(t)V(t)- wl (A.2) 
p,I(t) - 'flT(t)V(t) . (A.3) 
Prior to an inoculum of HIV, I= 0, V = 0, and uninfected cells are at equi-
librium, T = a/ {3. If infection occurs with a certain number of virus particles, 
V0 , the initial conditions are T0 =a/ /3,10 = 0, and V0 . Whether or not the virus 
can grow and establish an infection depends on the basic reproductive ratio, R0 , 
which, as defined in Chapter 2, is the number of newly infected cells that arise 
from the introduction of one infected cell when the system is at pre-inoculum 
levels. For our system, 
Ro = IP . 
W'fl 
(A.4) 
If R0 < 1 then the virus will not spread, since every infected cell will on average 
produce less than one other infected cell. However, if R0 > 1, then every infected 
cell will on average produce more than one infected cell. HIV has a basic ratio 
greater than unity and thus a chain reaction generates an increasing growth of 
virus levels. Subsequently, the immune cell population, represented here by T, 
will decrease. This will influence dynamics of other infections within a patient 
as the immune population is required to clear other infections. See Figure A.1 
for plots of the solutions to our HIV model equations. 
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Figure A.1: The time course of HIV infection using the basic model of virus dynamics. (a) CD4 
immune cell population (b) infected CD4 cell population (c) HIV viral load. The parameter 
values used to generate the plots are: a= 100,,8 = 0.1,w = 0.45,ry = O.OOOl,;u = 100,7] = 
0.005. 
Consider the introduction of an additional infection, such as Chlamydia. Let 
C(t) be the population of the infectious agent at timet. We let H(t) be the pop-
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ulation of targeted cells of the pathogen at time t, and we assume the target cells 
are in over-supply, so that we let H(t) = H0 , a constant. Extracellular pathogen 
particles infect uninfected host cells at a rate proportional to the product of 
their abundances, k1 C, where H0 is incorporated into the rate constant, k1 . We 
let Hi(t) be the population of pathogen-infected cells at time t. Cytotoxic T 
cells play an important role in protecting the host against infection by lysing 
pathogen-infected cells. Assuming their abundance is proportional to CD4 cells, 
we take the rate of infected cell clearance to be proportional to the product of 
their abundances, k2HiT. We assume infected cells die at a rate k0 Hi, with a 
burst size of P new infectious particles ( P > 1). Then, the change in the new 
pathogen and infected host populations can be expressed as 
dC 
dt 
dHi 
dt 
(A.5) 
(A.6) 
We let t0 be the time post HIV inoculation that the additional pathogen is in-
troduced, at concentration C0 so that C(t0 ) = C0 , Hi(t0 ) = 0. 
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Figure A.2: The time course of the population of an infectious pathogen. (a) Inoculum of 
pathogen introduced during the asymptomatic phase of HIV infection, after 8 years, where 
To= 831. (b) Inoculum of pathogen introduced during the AIDS period ofHIV infection, after 
10 years, where To = 106. For both simulations we take P = 200, k0 = 0.02, k1 = 0.05, kz = 
0.02. 
Since infection with HIV will last over the time scale of years whilst infection 
with other pathogens such as Chlamydia will occur over the time scale of days to 
weeks, we assume that over the period of investigation of the pathogen's infection 
the population of immune cells is approximately constant, T0 (although there will 
be clonal expansion as an antigen of the pathogen will stimulate immune cells 
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to divide repeatedly to establish a heightened defence specific for the antigen). 
The parameter, T0 , gives an indication of the average level of defence from the 
immune system. Then, the basic reproduction ratio for our secondary infection, 
R1 , is given by 
R _ Pko 1-
ko + kzTo 
(A.7) 
Thus, it can be seen that an infection in which R1 is typically less than unity 
can become an opportunistic infection, with R1 greater than unity, if T0 is re-
duced sufficiently. This phenomenon of disease (and death) due to opportunistic 
infection is illustrated in Figure A.2. Here, two cases are presented of pathogen 
infection by an infectious agent during different stages of HIV infection. Firstly, 
we consider infection with a pathogen during the asymptomatic phase of HIV 
(see Figure A.2a). Secondly, we consider infection with the same pathogen dur-
ing the final phase of HIV infection (See Figure A. 2b). 
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